<SEC-DOCUMENT>0001193125-12-009414.txt : 20120111
<SEC-HEADER>0001193125-12-009414.hdr.sgml : 20120111
<ACCEPTANCE-DATETIME>20120111172134
ACCESSION NUMBER:		0001193125-12-009414
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20120106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120111
DATE AS OF CHANGE:		20120111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOGENOMICS INC
		CENTRAL INDEX KEY:			0001077183
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		IRS NUMBER:				742897368
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54384
		FILM NUMBER:		12522691

	BUSINESS ADDRESS:	
		STREET 1:		1726 MEDICAL BOULEVARD, SUITE 201
		STREET 2:		SUITE 201
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34108
		BUSINESS PHONE:		9419231949

	MAIL ADDRESS:	
		STREET 1:		1726 MEDICAL BOULEVARD, SUITE 201
		STREET 2:		SUITE 201
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN COMMUNICATIONS ENTERPRISES INC
		DATE OF NAME CHANGE:	19990120
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d281487d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, DC 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section 13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>January&nbsp;6, 2012 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>NEOGENOMICS,
INC. </B><B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-54384</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>74-2897368</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12701 Commonwealth Drive, Suite 9, Fort Myers, Florida</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>33913</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(239) 768-0600 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;6, 2012, NeoGenomics Laboratories, Inc. (&#147;<U>NeoGenomics Laboratories</U>&#148;), a wholly-owned subsidiary of NeoGenomics, Inc. (the &#147;<U>Company</U>&#148;), and Health Discovery
Corporation, a Georgia corporation (&#147;<U>HDC</U>&#148;), entered into a Master License Agreement (the &#147;<U>License Agreement</U>&#148;). Pursuant to the terms of the License Agreement, NeoGenomics Laboratories and its affiliates were granted
an exclusive worldwide license to HDC&#146;s &#147;Licensed Patents&#148; and &#147;Licensed Know-How&#148; (as defined in the License Agreement) to, among other things, use, develop, make, have made, sell, offer to sell, modify, and commercially
exploit &#147;Licensed Uses&#148; (as defined in the License Agreement&#148;) and &#147;Licensed Products&#148; (as defined in the License Agreement), in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology
and digital image analysis (excluding non-pathology-related radiologic and photographic image analysis) relating to the development, marketing production or sale of any &#147;Laboratory Developed Tests&#148; or LDTs (as defined in the &#147;License
Agreement&#148;) or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer
(collectively with certain other qualifications as defined in the License Agreement, the &#147;Field&#148; or &#147;Field of Use&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The License Agreement allows NeoGenomics Laboratories, among other things, to develop and sell, without limitation, any gene, gene-product or protein-based LDTs using HDC&#146;s technology in the Field
and provides for sublicensing rights and the assignment of the License Agreement, in whole or in part, at the discretion of NeoGenomics Laboratories. The License Agreement further provides NeoGenomics Laboratories with access to certain HDC
personnel and consulting resources in the fields of mathematics and in genetic and molecular test development. The Licensed Know-How also includes, among other things, certain tests, algorithms and computer software which have already been developed
by HDC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics Laboratories has agreed to use its best efforts to commercialize certain products within one year of the
date of the License Agreement, subject to two one-year extensions per product if needed, including (and as defined in the License Agreement), a &#147;Plasma Prostate Cancer Test&#148;, a &#147;Pancreatic Cancer Test&#148;, a &#147;Colon Cancer
Test&#148;, a &#147;Cytogenetics Interpretation System&#148;, and a &#147;Flow Cytometry Interpretation System&#148; (collectively, the &#147;Initial Licensed Products&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If NeoGenomics Laboratories has not generated $5.0 million of net revenue from products, services and sublicensing arrangements pursuant to the License Agreement within five years of the effective date of
the License Agreement, HDC may, at its option, revoke the exclusivity with respect to any one or more of the Initial Licensed Products, subject to certain conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon execution of the License Agreement, NeoGenomics Laboratories paid HDC $1,000,000 in cash and the Company issued HDC 1,360,000 shares of the Company&#146;s common stock, par value $0.001 per share,
which had a market value of $1,945,000 using the closing price of $1.43 per share for the Company&#146;s common stock on the OTC Bulletin Board on January&nbsp;6, 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the License Agreement provides for milestone payments to HDC, in cash or stock,
based on sublicensing revenue and revenue generated from products developed as a result of the License Agreement. Milestone payments would be in increments of $500,000 for every $2,000,000 in GAAP revenue recognized by NeoGenomics Laboratories up to
a total of $5,000,000 in potential milestone payments. After $20,000,000 in cumulative GAAP revenue has been recognized by NeoGenomics Laboratories, HDC will receive a royalty of (i)&nbsp;6.5% (subject to adjustment under certain circumstances) on
Net Revenue (as defined in the License Agreement) generated from all Licensed Uses except for the Cytogenetics Interpretation System and the Flow Cytometry Interpretation System and (ii)&nbsp;a royalty of 50% of Net Revenue (after the recoupment of
certain development and commercialization costs) that NeoGenomics Laboratories derives from any sublicensing arrangements it may put in place for the Cytogenetics Interpretation System and the Flow Cytometry Interpretation System. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless sooner terminated pursuant to its terms, the License Agreement will remain in effect until the expiration of the last of the
patents licensed under the License Agreement and the license for certain products related to a specific patent will extend for an additional one year after the expiration of such patent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effectiveness of the License Agreement is contingent upon the execution of an employment or other agreement between NeoGenomics
Laboratories and Maher Albitar, M.D. and consulting agreements between NeoGenomics Laboratories and each of Dr.&nbsp;Stephen Barnhill, Dr.&nbsp;Herbert Fritsche, Dr.&nbsp;Isabelle Guyon, and Dr.&nbsp;Hong Zhang. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the press release announcing the execution of the License Agreement is attached hereto as Exhibit 99.1 and the License
Agreement is attached hereto as Exhibit 10.5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information set forth in Item&nbsp;5.02 below is hereby incorporated by
reference in this Item&nbsp;1.01. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description of the License Agreement does not purport to be complete and is
qualified in its entirety by reference to such document, a copy of which is filed as an exhibit to this Current Report on Form 8-K. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information set forth in Item&nbsp;1.01 above is hereby incorporated by reference in this
Item&nbsp;5.02. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D., age 56, has been appointed to the position of Chief Medical Officer and Director of
Research and Development. From 2008 to 2010, Dr.&nbsp;Albitar served as the Medical Director for Hematopathology and Oncology, Nichols Institute of Quest Diagnostics, and Chief R&amp;D Director for Hematopathology and Oncology for Quest Diagnostics,
a diagnostic testing, information and services company. From 2003 to 2008, Dr.&nbsp;Albitar served as the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Director of Hematopathology for the Nichols Institute of Quest Diagnostics. From 2005 to 2010, Dr.&nbsp;Albitar also served as a Board member of Associated Diagnostics Pathologists, Inc. From
1991 to 2003, Dr.&nbsp;Albitar held various faculty positions at The University of Texas MD Anderson Cancer Center. Dr.&nbsp;Albitar previously served as the Chief Medical Officer of HDC and is currently a member of the Board of Directors of HDC.
Dr.&nbsp;Albitar has also served as a consultant to multiple companies. Dr.&nbsp;Albitar received his medical degree in 1979 from Damascus Medical School in Damascus, Syria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;6, 2012, NeoGenomics Laboratories contracted for the services of Dr.&nbsp;Albitar on a full-time basis in connection with his appointment as Chief Medical Officer. As a result of the State
of California&#146;s regulations against the corporate practice of medicine, Dr.&nbsp;Albitar was engaged as an independent contractor through Albitar Oncology Consulting, LLC, a company previously formed by Dr.&nbsp;Albitar in which he is the sole
member and physician-employee (the &#147;<U>Medical Group</U>&#148;). On January&nbsp;6, 2012, NeoGenomics Laboratories and the Medical Group entered into a Medical Services Agreement (the &#147;<U>Services Agreement</U>&#148;) and Dr.&nbsp;Albitar
and NeoGenomics Laboratories entered into a letter agreement (the &#147;<U>Letter Agreement</U>&#148;) with respect to Dr.&nbsp;Albitar&#146;s appointment as Chief Medical Officer and Director of Research and Development. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Services Agreement provides, among other things, that NeoGenomics Laboratories will engage the Medical Group to provide and that
Medical Group will employ Dr.&nbsp;Albitar to provide certain specified services to NeoGenomics Laboratories on a full-time basis. The Services Agreement further provides that NeoGenomics Laboratories will perform administrative, non-physician
services for the daily support of the business operations of the Medical Group&#146;s practice including all billing and collection activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Services Agreement provides that Dr.&nbsp;Albitar&#146;s start date is January&nbsp;9, 2012 and that NeoGenomics Laboratories will pay cash compensation of $425,000 per annum to the Medical Group and
a bonus targeted at 25% of the base compensation if certain performance thresholds are met. Dr.&nbsp;Albitar is also entitled to participate in all medical benefits that NeoGenomics Laboratories&#146; offers to its independent contractors, receive
five weeks of paid time off, payment of his state licensing fees, and reimbursement for up to $5,000 annually for expenses associated with Dr.&nbsp;Albitar&#146;s continuing medical education. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Letter Agreement provides that Dr.&nbsp;Albitar will be granted an option (the &#147;<U>Option</U>&#148;) to purchase 250,000 shares
of the Company&#146;s common stock at an exercise price equivalent to the closing price per share at which the Company&#146;s stock was quoted on the OTC Bulletin Board on the last trading day prior to his start date. The Option has a five year term
and 25% of the Option vests on each one year anniversary of Dr.&nbsp;Albitar&#146;s start date. The Option will fully vest upon a change of control of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Letter Agreement also provides that Dr.&nbsp;Albitar will receive a warrant (the &#147;<U>Warrant</U>&#148;) to purchase up to 200,000 shares of the Company&#146;s common stock. The Warrant will have
an exercise price equal to the closing price per share at which the Company&#146;s stock was quoted on the OTC Bulletin Board on the last trading day prior to Dr.&nbsp;Albitar&#146;s start date, a five year term and will vest in accordance with
certain specified performance criteria. In </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
addition, in the event of a change of control of the Company in which the consideration payable to each common stockholder of the Company in connection with such change of control has a deemed
value of at least $4.00 per share then the Warrant would immediately vest in full. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;6, 2012, the Company and
Dr.&nbsp;Albitar also entered into a Confidentiality and Non-Competition Agreement (the &#147;<U>Non-Compete</U>&#148;) and a Confidentiality, Title to Work Product and Non-Solicitation Agreement (the &#147;<U>Non-Solicitation</U>&#148;).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the press release announcing the appointment of Dr.&nbsp;Albitar is attached hereto as Exhibit 99.2. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing descriptions of the Services Agreement, the Letter Agreement, the Warrant, the Option, the Non-Compete and the
Non-Solicitation do not purport to be complete and are qualified in their entirety by reference to such documents, copies of which are filed as exhibits to this Current Report on Form 8-K. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant Agreement dated January&nbsp;6, 2012 between NeoGenomics, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Stock Option Agreement between NeoGenomics, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medical Services Agreement dated January 6, 2012 between Albitar Oncology Consulting, LLC and NeoGenomics Laboratories, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement dated January 6, 2012 between NeoGenomics Laboratories, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality and Non-Competition Agreement dated January 6, 2012 between NeoGenomics Laboratories, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality, Title to Work Product and Non-Solicitation Agreement dated January 6, 2012 between NeoGenomics Laboratories, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Master License Agreement, dated January 6, 2012, between NeoGenomics Laboratories, Inc. and Health Discovery Corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of NeoGenomics, Inc. dated January 9, 2012 relating the License Agreement</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of NeoGenomics, Inc. dated January&nbsp;9, 2012 relating to the Appointment of Maher Albitar, M.D. as Chief Medical Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEOGENOMICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">George Cardoza</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">George Cardoza</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: January&nbsp;11, 2012 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit Index </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant Agreement dated January 6, 2012 between NeoGenomics, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Stock Option Agreement between NeoGenomics, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medical Services Agreement dated January 6, 2012 between Albitar Oncology Consulting, LLC and NeoGenomics Laboratories, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement dated January 6, 2012 between NeoGenomics Laboratories, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality and Non-Competition Agreement dated January 6, 2012 between NeoGenomics Laboratories, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality, Title to Work Product and Non-Solicitation Agreement dated January 6, 2012 between NeoGenomics Laboratories, Inc. and Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Master License Agreement, dated January 6, 2012, between NeoGenomics Laboratories, Inc. and Health Discovery Corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of NeoGenomics, Inc. dated January 9, 2012 relating the License Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of NeoGenomics, Inc. dated January 9, 2012 relating to the Appointment of Maher Albitar, M.D. as Chief Medical Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 8 -
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d281487dex41.htm
<DESCRIPTION>WARRANT AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Warrant Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 4.1 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Execution Copy </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES WHICH MAY BE ISSUED
UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES OR BLUE SKY LAWS. NO SALE OR DISTRIBUTION HEREOF OR THEREOF MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER APPLICABLE SECURITIES LAWS. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>WARRANT AGREEMENT </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS WARRANT AGREEMENT (this
&#147;Agreement&#148;) is dated this 6</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of January
2012, by and between NeoGenomics, Inc., a Nevada corporation (the &#147;Company&#148;), and Maher Albitar, M.D., an individual residing at 27165 Kiavo Drive, Valley Center, CA 92082 (the &#147;Warrant Holder&#148;). </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, as of the date hereof, the Company has entered into a Letter Agreement and a Medical Services Agreement with the Warrant Holder
pursuant to which the Warrant Holder has been retained as the Chief Medical Officer of the Company; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, in addition
to entering into the Letter Agreement and the Medical Services Agreement with the Warrant Holder, the Company desires to provide an additional incentive for the Warrant Holder to create shareholder value for the Company&#146;s shareholders and has
agreed to issue to the Warrant Holder a warrant (the &#147;Warrant&#148;) to purchase an aggregate of 200,000 shares of the Company&#146;s common stock, par value $0.001/share (&#147;Common Stock&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.
<U>Incorporation of Recitals</U>. The Recitals portion of this Agreement is hereby incorporated by this reference as though it were fully set forth and rewritten herein, and the affirmative statements therein contained shall be deemed to be
representations of the Company and the Warrant Holder, which are hereby confirmed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Warrant</U>. The Company hereby
grants to the Warrant Holder, subject to the terms set forth herein, the right to purchase, subject to the vesting schedule set forth in Section&nbsp;12 hereof, at any time during the term (the &#147;Warrant Exercise Term&#148;) commencing on the
date hereof and ending at 5:30 p.m., New York time on the fifth anniversary of the date of this Agreement (the &#147;Expiration Date&#148;) 200,000 shares of Common Stock (the &#147;Shares&#148;), at an exercise price of $1.43 per share (the
&#147;Exercise Price&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Exercise of Warrant</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Exercise</U>. The Warrant may be exercised by the Warrant Holder, in whole or in part, by delivering the Notice of Exercise
purchase form, attached as <U>Exhibit A</U> hereto (the </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
&#147;Notice of Exercise&#148;), duly executed by the Warrant Holder to the Company at its principal office, or at such other office as the Company may designate, accompanied by payment, in cash
or by wire transfer or check payable to the order of the Company, of the amount obtained by multiplying the number of Shares designated in the Notice of Exercise by the Exercise Price (the &#147;Purchase Price&#148;). The Purchase Price may also be
paid, in whole or in part, by delivery of such purchase form and of shares of Common Stock owned by the Warrant Holder having a Market Price (as defined in Section&nbsp;3.3 hereof) on the last business day ending the day immediately prior to the
Exercise Date (as defined below) equal to the portion of the aggregate Exercise Price being paid in such shares. In addition, the Warrant may be exercised, pursuant to a cashless exercise by providing irrevocable instructions to the Company, through
delivery of the Notice of Exercise with an appropriate reference to this Section&nbsp;3.1 to issue the number of shares of the Common Stock equal to the product of (a)&nbsp;the number of shares as to which the Warrant is being exercised multiplied
by (b)&nbsp;a fraction, the numerator of which is the Market Price of a share of the Common Stock on the last business day preceding the Exercise Date less the Exercise Price therefor and the denominator of which is such Market Price. For purposes
hereof, &#147;Exercise Date&#148; shall mean the date on which all deliveries required to be made to the Company upon exercise of the Warrant pursuant to this Section&nbsp;3.1 shall have been made. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Issuance of Certificates</U>. As soon as practicable after the exercise of the Warrant (in whole or in part) in accordance with
Section&nbsp;3.1 hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Warrant Holder (i)&nbsp;a certificate or certificates for the number of fully-paid and non-assessable Shares to which the Warrant
Holder shall be entitled upon such exercise and (if applicable) (ii)&nbsp;a new warrant agreement of like tenor to purchase all of the Shares that may be purchased pursuant to the portion, if any, of the Warrant not exercised by the Warrant Holder.
The Warrant Holder shall for all purposes be deemed to have become the holder of record of such Shares on the date on which the Notice of Exercise and payment of the Purchase Price in accordance with Section&nbsp;3.1 hereof were delivered and made,
respectively, irrespective of the date of delivery of such certificate or certificates, except that if the date of such delivery, notice and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to
have become the holder of record of such Shares at the close of business on the next succeeding date on which the stock transfer books are open. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Market Price</U>. The &#147;Market Price&#148; of a share of Common Stock means: the average of the daily closing price of shares of Common Stock on the principal market on which shares of the
Common Stock are traded for the five (5)&nbsp;trading days immediately preceding the date of the determination of the Market Price. If shares of Common Stock are not traded on any public market (e.g. NYSE, AMEX, NASDAQ, OTCBB or Pink Sheets), the
Market Price of the Common Stock shall be determined, in good faith, by the Board of Directors of the Company (the &#147;Board&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4. <U>Adjustments</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>Stock Splits, Stock Dividends and
Combinations</U>. If the Company at any time subdivides the outstanding shares of the Common Stock or issues a stock dividend (in Common Stock) on the outstanding shares of the Common Stock, the Exercise Price in effect immediately prior to such
subdivision or the issuance of such stock dividend shall be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
proportionately decreased, and the number of Shares subject hereto shall be proportionately increased, and if the Company at any time combines (by reverse stock split or otherwise) the
outstanding shares of Common Stock, the Exercise Price in effect immediately prior to such combination shall be proportionately increased, and the number of Shares subject hereto shall be proportionately decreased, effective at the close of business
on the date of such subdivision, stock dividend or combination, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>Merger or Consolidation</U>. In
the case of any consolidation of the Company with, or merger of the Company with or into another entity (other than a consolidation or merger which does not result in any reclassification or change of the outstanding capital stock of the Company),
the entity formed by such consolidation or merger shall execute and deliver to the Warrant Holder a supplemental warrant agreement providing that the Warrant Holder of the Warrant then outstanding or to be outstanding shall have the right thereafter
(until the expiration of such Warrant) to receive, upon exercise of such Warrant, the kind and amount of shares of capital stock and other securities and property receivable upon such consolidation or merger by a holder of the number of Shares for
which such Warrant might have been exercised immediately prior to such consolidation or merger. Such supplemental warrant agreement shall provide for adjustments which shall be identical to the adjustments provided in Section&nbsp;4.1 hereof and to
the provisions of Section&nbsp;11 hereof. This Section&nbsp;4.2 shall similarly apply to successive consolidations or mergers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Transfers</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Unregistered Securities</U>. Warrant Holder hereby acknowledges and agrees that the Warrant and the Shares have not been registered under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), and are &#147;restricted securities&#148; under the Securities Act inasmuch as they are being acquired in a transaction not involving a public offering, and the Warrant Holder agrees not to sell, pledge, distribute,
offer for sale, transfer or otherwise dispose of the Warrant or any Shares issued upon exercise of the Warrant in the absence of (a)&nbsp;an effective registration statement under the Securities Act as to the Warrant or such Shares and registration
and/or qualification of the Warrant or such Shares under any applicable Federal or state securities law then in effect or (b)&nbsp;an opinion of counsel, reasonably satisfactory to the Company, that such registration and qualification are not
required. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Transferability</U>. Until such time as the Shares are vested pursuant to Section&nbsp;12 hereof, the rights
under this Agreement with respect to such Shares shall not be transferrable. After all or any portion of the Shares have vested pursuant to Section&nbsp;12 hereof, then subject to the provisions of Section&nbsp;5.1 hereof, the rights under this
Agreement relating only to that portion of the Shares that are vested are freely transferable, in whole or in part, by the Warrant Holder, and such transferee shall have the same rights hereunder as the Warrant Holder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Warrant Register</U>. The Company will maintain a register containing the names and addresses of the Warrant Holders of the
Warrant. Until any transfer of Warrant in accordance with this Agreement is reflected in the warrant register, the Company may treat the Warrant Holder as the absolute owner hereof for all purposes. Any Warrant Holder may change such Warrant
Holder&#146;s address as shown on the warrant register by written notice to the Company requesting such change. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>No Fractional Shares</U>. Any adjustment in the number of Shares purchasable hereunder
shall be rounded to the nearest whole share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>Investment Representations</U>. The Warrant Holder agrees and acknowledges
that it is acquiring the Warrant and will be acquiring the Shares for his own account and not with a view to any resale or distribution other than in accordance with Federal and state securities laws. The Warrant Holder is an &#147;accredited
investor&#148; within the meaning of Rule 501(a) of Regulation D promulgated under the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <U>Covenants as to
the Shares</U>. The Company covenants and agrees that the shares of Common Stock issuable upon exercise of the Warrant, will, upon issuance in accordance with the terms hereof, be duly and validly issued and outstanding, fully-paid and
non-assessable, with no personal liability attaching to the ownership thereof. The Company further covenants and agrees that the Company will at all times have authorized and reserved a sufficient number of shares of Common Stock to provide for the
exercise of the rights represented under this Agreement. The Company will pay all documentary stamp taxes attributable to the initial issuance of Shares upon the exercise of the Warrant; <U>provided</U>, <U>however</U>, that the Company shall not be
required to pay any tax or taxes which may be payable in respect of any transfer involved in the issue of any certificates for Shares in a name other than that of the Warrant Holder, and the Company shall not be required to issue or deliver such
certificates unless or until the person or persons requesting the issuance thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. <U>Legend</U>. Any certificate evidencing the Shares issuable upon exercise hereof will bear a legend indicating that such securities
have not been registered under the Securities Act or under any state securities laws and may not be sold or offered for sale in the absence of an effective registration statement as to the securities under the Securities Act and any applicable state
securities law or an opinion of counsel reasonably satisfactory to the Company that such registration is not required. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.
<U>Rights Applicable to the Warrant Shares</U>. The parties hereby acknowledge and agree that the Shares, when issued in accordance with the terms hereof, shall be entitled to all of the same rights and privileges provided to the Company&#146;s
Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. <U>Dividends and Other Distributions</U>. In the event that the Company shall, at any time prior to the
exercise of all Warrants, declare a dividend (other than a dividend consisting solely of shares of Common Stock) or otherwise distribute to its stockholders any assets, properties, rights, evidence of indebtedness, securities (other than shares of
Common Stock), whether issued by the Company or by another, or any other thing of value, the Warrant Holder shall thereafter be entitled, in addition to the shares of Common Stock or other securities and property receivable upon the exercise
thereof, to receive, upon the exercise of such Warrant, the same assets, property, rights, evidences of indebtedness, securities or any other thing of value that the Warrant Holder would have been entitled to receive at the time of such dividend or
distribution as if the Warrant had been exercised immediately prior to such dividend or distribution. At the time of any such dividend or distribution, the Company shall make (and maintain) appropriate reserves to ensure the timely performance of
the provisions of this Section&nbsp;11. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <U>Vesting</U>. The Warrant shall only be exercisable in whole or in part, according to
the following vesting schedule: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000 of the Shares will vest upon the commercial launch of the Company&#146;s gene/gene
product-based plasma prostate cancer test licensed from Health Discovery Corporation (&#147;HDC&#148;) or similar test based on mutual written agreement with the Company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">40,000 of the Shares will vest upon the commercial launch of the Company&#146;s gene/gene product-based colon cancer test licensed from HDC or similar test based on mutual written agreement with the
Company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000 of the Shares will vest upon the commercial launch of the Company&#146;s gene/gene product-based pancreatic
cancer test licensed from HDC or similar test based on mutual written agreement with the Company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000 of the Shares will
vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the cytogenetics automated image analysis technology licensed from HDC or similar product or test based on mutual written agreement with
the Company. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000 of the Shares will vest upon successful consummation of a sublicensing agreement with an instrument
manufacturer to commercialize the flow cytometry automated image analysis technology licensed from HDC or similar product or test based on mutual written agreement with the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, in the event of a Change of Control (as defined below) of the Company in which the consideration payable to each common stockholder of the Company in connection with such
Change of Control has a Deemed Value (as defined below) of at least $4.00 per share (as adjusted for stock splits, stock dividends, reverse stock splits, and the like) then the Shares subject to the Warrant shall immediately vest in full.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of this Agreement, &#147;Change of Control&#148; means either: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without
limitation, any reorganization, merger or consolidation or stock transfer, but excluding any such transaction effected primarily for the purpose of changing the domicile of the Company), unless the Company&#146;s stockholders of record immediately
prior to such transaction or series of related transactions hold, immediately after such transaction or series of related transactions, at least 50% of the voting power of the surviving or acquiring entity (provided that the sale by the Company of
its securities for the purposes of raising additional funds shall not constitute a Change of Control hereunder); or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) a
sale of all or substantially all of the assets of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of this Agreement, &#147;Deemed Value&#148; shall mean the value of consideration payable to
each common stockholder of the Company in connection with a Change of Control as determined in good faith by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that the
Warrant Holder terminates the Medial Services Agreement with the Company at any time prior to the time when all Shares have vested pursuant to this Section&nbsp;12, then the rights under this Agreement with respect to the unvested portion of the
Shares as of the date of termination shall immediately terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13. <U>Miscellaneous</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1 <U>Waivers and Amendments</U>. This Agreement or any provisions hereof may be changed, waived, discharged or terminated only by a
statement in writing signed by the Company and by the Warrant Holder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 <U>Governing Law</U>. This Agreement shall be
governed by and construed and enforced in accordance with the laws of the State of Florida. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <U>Notices</U>. All notices
and other communications hereunder shall be in writing and shall be deemed to have been given when delivered by hand or by facsimile transmission, when telexed, or upon receipt when mailed by registered or certified mail (return receipt requested),
postage prepaid, to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to Company: </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics,
Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12701 Commonwealth Drive, Suite 5 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Fort Myers, FL 33913 </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="74%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phone:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(239) 768-0600</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(239) 768-1672</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to Warrant Holder, the address listed in the preamble to this Agreement </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.4 <U>Headings</U>. The headings in this Agreement are for convenience of reference only, and shall not limit or otherwise affect the terms hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5 <U>Closing of Books</U>. The Company will at no time close its transfer books against the transfer of any Shares issued or issuable
upon the exercise of the Warrant in a manner that interferes with the timely exercise of the Warrant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6 <U>No Rights or
Liabilities as a Stockholder</U>. This Agreement shall not entitle the Warrant Holder hereof to any voting rights or other rights as a stockholder of the Company with respect to the Shares prior to the exercise of the Warrant. No provision of this
Agreement, in the absence of affirmative action by the Warrant Holder to purchase the Shares, and no mere enumeration herein of the rights or privileges of the Warrant Holder, shall give rise to any liability of such Holder for the Exercise Price or
as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7 <U>Successors</U>. All the covenants and provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns and transferees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.8 <U>Severability</U>. If any provision of this Agreement shall be held to be invalid and unenforceable, such invalidity or
unenforceability shall not affect any other provision of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>[SIGNATURE PAGE FOLLOWS] </I></B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the date
first written above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEOGENOMICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Douglas M. VanOort</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Douglas M. VanOort</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WARRANT HOLDER</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar, M.D</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>EXHIBIT A </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>NOTICE OF EXERCISE </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(To be signed only on exercise of Warrant) </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To: NeoGenomics, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The undersigned, pursuant to the provisions set forth in the attached Warrant Agreement, hereby irrevocably elects to: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock covered by such Warrant Agreement and herewith
makes a cash payment of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing the full purchase price for such shares at the price per share provided for in such Warrant Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of Common Stock covered by such Warrant Agreement and herewith delivers &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock having a Market Price as of the last trading day preceding the date hereof
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing the full purchase price for such shares at the price per shares provided for in such Warrant Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> acquire in a cashless exercise
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock pursuant to the terms of Section&nbsp;3.1 of such Warrant Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Please issue a certificate or certificates representing such shares of Common Stock in the name of the undersigned or in such other name as is specified below. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="72%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name&nbsp;(print):</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title&nbsp;(if&nbsp;applicable):</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company&nbsp;(if&nbsp;applicable):</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>d281487dex42.htm
<DESCRIPTION>FORM OF STOCK OPTION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Form of Stock Option Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 4.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NEOGENOMICS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EQUITY INCENTIVE PLAN </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>STOCK OPTION AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to this Stock Option Agreement (&#147;Agreement&#148;), NeoGenomics, Inc. (the &#147;Company&#148;) has granted you an option (&#147;Stock Option&#148;) under its Amended and Restated Equity
Incentive Plan, dated March&nbsp;3, 2009 (the &#147;Plan&#148;) to purchase the number of shares of the Company&#146;s Common Stock at the exercise price and in accordance with the vesting schedule indicated herein. Defined terms not explicitly
defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The details of
your Stock Option are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Optionee (&#147;you&#148;):</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Address of Optionee:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">27165 Kiavo Dr.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valley Center, CA 92082</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Date of Grant:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 9, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Vesting Commencement Date:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 9, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Number of Shares Subject to the Stock Option:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exercise Price:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Per Share $ 1.43</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total $ 357,500</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Type of Grant:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Incentive Stock Option</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">XX<B>X&nbsp;&nbsp;</B>Non-Qualified Stock Option</FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Vesting&nbsp;Schedule:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your Stock Option shall vest based on the following schedule:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500&nbsp;on&nbsp;January&nbsp;9,&nbsp;2013</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500 on January&nbsp;9, 2014</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">62,500 on January&nbsp;9, 2015</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500 on January&nbsp;9, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Authorization for Grant</U></B><B>:</B> This Stock Option was granted to you pursuant to that certain letter
agreement between you and the Company dated January&nbsp;6, 2012 and accepted by you on January&nbsp;6, 2012 that created an exclusive medical services contractor relationship between the Company and you (the &#147;Offer Letter&#148;) and that
certain Medical Services Agreement, dated January&nbsp;6, 2012 (the &#147;Contractor Agreement&#148;) executed by you and the Company. This grant was authorized by the Board of Directors of the Company at a telephonic Board Meeting held on
January&nbsp;6, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Expiration Date</U></B><B>:</B> Unless sooner terminated in accordance with this Agreement or the terms of the
Plan, the Stock Option will terminate on the fifth anniversary of the Date of Grant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 1 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;1. <U>Grant of Stock Option</U></B><B>.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.1 </B><U>Type of Stock Option</U>. The type of Stock Option that you have been awarded is referenced above. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.2 </B><U>This Section Intentionally Left Blank</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>1.3 </B><U>Number of Shares and Exercise Price</U>. The number of shares of Common Stock subject to your Stock Option and the exercise price per share referenced above may be adjusted from time to time
for capitalization adjustments, as provided in Section&nbsp;22 of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;2. <U>Vesting</U>.</B> Subject to
the limitations, if any, provided in the Plan or contained herein, your Stock Option will vest as provided above. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;3. <U>Exercise of Stock Options</U>.</B> Except as otherwise provided herein, and subject to the provisions of the Plan
(including restrictions on the transferability of the Stock Option and special provisions relating to exercise or termination of the Stock Option following your termination, death or Disability, certain changes in capitalization of the Company or a
merger or asset sale), the Stock Option granted pursuant to this Agreement shall be subject to exercise as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)
</B>You may exercise the vested portion of your Stock Option during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Committee, or to such other person as the Committee may
designate, during regular business hours, together with such additional documents as the Company may then require. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)
</B>By exercising your Stock Option, you agree that, as a condition to any exercise of a Stock Option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the
Company arising by reason of (1)&nbsp;the exercise of your Stock Option, (2)&nbsp;the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (3)&nbsp;the disposition of shares of
Common Stock acquired upon such exercise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>If your Stock Option is an Incentive Stock Option, by exercising your
Stock Option, you agree to notify the Company in writing within 15 days after the date of any disposition of any of the shares of Common Stock issued upon exercise of your Stock Option that occurs within two years after the Date of Grant or within
one year after such shares of Common Stock are issued upon exercise of your Stock Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>By exercising your Stock
Option, you agree that the Company (or a representative of the underwriter(s)) may, in connection with the first underwritten registration of the offering of any securities of the Company under the Act, require that you not sell, dispose of, assign,
encumber, transfer, make any short sale of, grant any Stock Option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other securities of the Company held by
you, for a period of time specified by the underwriter(s) (not to exceed 180 days) following the effective date of the registration </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
statement of the Company filed under the Act. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are
consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such
period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;4. <U>Method of Payment</U>. </B>Payment of the exercise price is due in full upon exercise of all or any part of the
Stock Option. You may elect to make payment by one or a combination of the following methods: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>Cash, check or wire
transfer; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>In the Committee&#146;s sole discretion at the time your Stock Option is exercised and provided that at
the time of exercise the Common Stock is publicly traded and quoted regularly in <I>The Wall Street Journal, </I>pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board which, prior to the issuance of Common
Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds attributable to such Common Stock; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>Provided that at the time of exercise the Common Stock is publicly traded and quoted regularly in <I>The Wall Street Journal,
</I>by delivery of already-owned shares of Common Stock either that you have held for the period required to avoid a charge to the Company&#146;s reported earnings (generally six months) or that you did not acquire directly or indirectly from the
Company, that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. &#147;Delivery&#148; for these purposes, in the sole discretion of the Committee at
the time you exercise your Stock Option, shall include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Committee. Notwithstanding the foregoing, you may not exercise your Stock Option
by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;5. <U>Whole Shares</U>. </B>You may exercise your Stock Option only for whole shares of Common Stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;6. <U>Term of Stock Option</U>.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>6.1 </B><U>Commencement</U>. The term of your Stock Option commences on the Date of Grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>6.2 </B><U>Expiration</U>. Except as otherwise provided in Section&nbsp;35 of the Plan in the event of a merger or sale under certain circumstances, the term of your Stock Option expires upon the
earliest of the following: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>immediately upon the termination of your service with the Company or any Subsidiary,
whether as an employee, officer, director, adviser or consultant, for &#147;Cause&#148; (as such term is defined below) or upon the breach by you of any of the covenants set forth in Section&nbsp;9 below, except as otherwise provided in
Section&nbsp;9.3 below; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>three months after the termination of your services with the Company for any
reason other than death or Disability, provided that if during any part of such three month period your Stock Option is not exercisable solely because of the condition set forth in Section&nbsp;7 below relating to &#147;Securities Law
Compliance&#148;, your Stock Option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three months after the termination of your service with the Company; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>12 months after the termination of your service with the Company due to death or Disability; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) </B>the Expiration Date; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(e) </B>the fifth anniversary of the Date of Grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.3 </B><U>Cause</U>.
For purposes of this Agreement, the termination of your services with the Company for &#147;Cause&#148; shall mean termination due to any of the reasons listed in Section&nbsp;6 (b)&nbsp;of the Contractor Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.4</B> <U>Disability</U>. For purposes of this Agreement, &#147;Disability&#148; shall mean any mental or physical illness,
condition, disability or incapacity which prevents you from reasonably discharging your duties and responsibilities to the Company for a period of forty five (45)&nbsp;days in any ninety day period. In the event that any disagreement or dispute
shall arise between the Company and you as to whether you suffer from any Disability, then, in such event, you shall submit to the physical or mental examination of a physician licensed under the laws of the state in which you reside, who is
mutually agreeable to you and the Company, and such physician shall determine whether you suffer from any Disability. In the absence of fraud or bad faith, the determination of such physician shall be final and binding upon the Company and you.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.5 </B><U>Incentive Stock Option Employee Rule</U>. If your Stock Option is an Incentive Stock Option, note that to
obtain the federal income tax advantages associated with an &#147;Incentive Stock Option,&#148; the Code requires that at all times beginning on the Date of Grant of your Stock Option and ending on the day three months before the date of your Stock
Option&#146;s exercise, you must be an employee of the Company or a Subsidiary or Parent Company, except in the event of your death or Disability. The Company has provided for extended exercisability of your Stock Option under certain circumstances
for your benefit but cannot guarantee that your Stock Option will necessarily be treated as an &#147;Incentive Stock Option&#148; if you continue to provide services to the Company or a Subsidiary or Parent Company as a consultant, adviser or
director after your employment terminates or if you otherwise exercise your Stock Option more than three months after the date your employment terminates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;7. <U>Securities Law Requirements</U>. </B>Notwithstanding anything to the
contrary contained herein, you may not exercise your Stock Option unless the shares of Common Stock issuable upon such exercise are then registered under the Act or, if such shares of Common Stock are not then so registered, the Company has
determined that such exercise and issuance would be exempt from the registration requirements of the Act. The Company may request a legal opinion of your counsel, reasonably satisfactory to the Company, with respect to such exemption. The exercise
of your Stock Option must also comply with other applicable laws and regulations governing your Stock Option, and you may not exercise your Stock Option if the Company determines that such exercise would not be in material compliance with such laws
and regulations or would result in liability under Section&nbsp;16 of the Securities Exchange Act of 1934, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8. <U>Change of Control</U>.</B> Notwithstanding the provisions of Section&nbsp;2, in the event that a Change of Control
shall occur after the Date of Grant, all unvested portions of your Stock Option shall vest in full. For purposes of this Section&nbsp;8, &#147;Change of Control&#148; means the occurrence of any of the following events: (i)&nbsp;any
&#147;person&#148; or &#147;group&#148; (as defined in Section&nbsp;13(d) and 14(d) of the Exchange Act) together with their affiliates become the ultimate &#147;beneficial owner&#148; (as defined in Rule 13d-3 of the Exchange Act) of voting stock
of the Company representing more than 50% of the voting power of the total voting stock of the Company; (ii)&nbsp;the stockholders of the Company approve a merger or consolidation of the Company with any other corporation or entity regardless of
which entity is the survivor, other than a merger or a consolidation which would result in the voting stock of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or being converted into voting
securities of the surviving entity or the parent thereof) at least 50% of the combined voting power of the voting securities of the Company or such surviving entity or the parent thereof, outstanding immediately after such merger or consolidation;
or (iii)&nbsp;the stockholders of the Company approve a plan of complete liquidation or winding up of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#146;s assets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9. <U>Confidentiality and Non-Compete</U>. </B>In connection with and in consideration for the grant of this Stock Option
to you, the Company and you have executed a Confidentiality, Title to Work Product and Non-Solicitation Agreement, dated January&nbsp;6, 2012 (the &#147;Work Product Agreement&#148;) and a Confidentiality and Non-Compete Agreement, dated
January&nbsp;6, 2012 (the &#147;Non-Compete Agreement&#148;, and together with the Work Product Agreement, the &#147;Ancillary Agreements&#148;), which are incorporated into this Agreement by reference, and you hereby acknowledge your obligations
thereunder. You further agree that if you violate any provision of the Ancillary Agreements, you shall immediately forfeit any rights and benefits under your Stock Option, this Agreement and the Plan; provided, however, that any inadvertent
violations of the provisions set forth in the Ancillary Agreements that have not had or are not expected to have a material impact on the Company shall not result in the forfeiture of your rights and benefits under your Stock Option, so long as you
notify the Company upon becoming aware of such inadvertent violations and agree to rectify and/or cease such activities immediately. Nothing in this Section&nbsp;9 or the Ancillary Agreements will be deemed to limit, in any way, the remedies at law
or in equity of the Company for a breach by you of any of the provisions of this Section&nbsp;9 or the Ancillary Agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;10. <U>No Right to Continue Employment or Service</U>.</B> Nothing in this
Agreement, the Plan, or your Notice of Exercise shall confer upon you any right to continue to serve the Company or any Subsidiary in the capacity in effect at the time the Stock Option was granted or shall affect the right of the Company or any
Subsidiary to terminate (i)&nbsp;your employment, if you are an employee, with or without notice and with or without cause, (ii)&nbsp;your service as a consultant or adviser, if you are a consultant or adviser, pursuant to the terms of your
agreement with the Company or any Subsidiary or (iii)&nbsp;your service as a director, if you are a director, pursuant to the Bylaws of the Company or any Subsidiary and any applicable provisions of the corporate law of the state in which the
Company or any Subsidiary is incorporated, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;11. <U>Withholding of Taxes</U>.
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) </B>At the time you exercise your Stock Option, in whole or in part, or at any time thereafter as requested by the
Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#147;cashless exercise&#148; pursuant to a program developed under Regulation T
as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or a Subsidiary, if any, which arise in connection
with your Stock Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) </B>Upon your request and subject to approval by the Company, in its sole discretion, and
compliance with any applicable conditions or restrictions of law, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your Stock Option a number of whole shares of Common Stock having a
Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law. If the date of determination of any tax withholding obligation is deferred to a date later than the
date of exercise of your Stock Option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section&nbsp;83(b) of the Code, covering the aggregate number of shares of Common
Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your Stock Option. Notwithstanding the filing of such
election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your Stock Option that are otherwise issuable to you upon such exercise. Any adverse consequences to you
arising in connection with such share withholding procedure shall be your sole responsibility. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) </B>You may not
exercise your Stock Option unless the tax withholding obligations of the Company and/or any Subsidiary are satisfied. Accordingly, you may not be able to exercise your Stock Option when desired even though your Stock Option is vested, and the
Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein or under the Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;12. <U>Non-Assignability</U>.</B> Your Stock Option is not transferable,
except by will or by the laws of descent and distribution, and is exercisable during your life only by you. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third
party who, in the event of your death, shall thereafter be entitled to exercise your Stock Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, with the approval
of the Committee, you may transfer your Non-Qualified Stock Option for no consideration to or for the benefit of your Immediate Family (including, without limitation, to a trust for the benefit of your Immediate Family or to a partnership or limited
liability company for one or more members of your Immediate Family), subject to such limits as the Committee may establish, and the transferee shall remain subject to all the terms and conditions applicable to your Non-Qualified Stock Option prior
to such transfer. The term &#147;Immediate Family&#148; shall mean your spouse, parents, children, stepchildren, adoptive relationships, sisters, brothers and grandchildren (and, for this purpose, shall also include you). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At your request and subject to the approval of the Committee, Common Stock purchased upon exercise of your Non-Qualified Stock Option may
be issued or transferred into your name and the name of your spouse jointly with rights of survivorship. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;13.
<U>Notice</U>.</B> For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a)&nbsp;one business day following confirmed facsimile
transmission, (b)&nbsp;three business days after being delivered or mailed by United States registered mail, return receipt requested, postage prepaid, or (c)&nbsp;one business day after being sent via overnight delivery service, as follows:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>If to the Company</U>: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12701 Commonwealth Drive, Suite 5 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fort Myers, FL 33913 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attn: Chief Financial Officer or Director of Finance </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile No.:
(239)&nbsp;768-0711 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and, if to you, to the address shown on this Agreement, or to such other address as either party may have furnished to
the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;14. <U>Governing Plan Document</U>. </B>Your Stock Option granted pursuant to this Agreement is subject to the terms and
conditions set forth in the Plan, a copy of which is attached to this Agreement. All the terms and conditions of the Plan, as may be amended from time to time, and any rules, guidelines and procedures which may from time to time be promulgated and
adopted pursuant to the Plan, are hereby incorporated into this Agreement, without regard to whether such terms and conditions (including, for example, provisions relating to certain changes in capitalization of the Company) are not otherwise set
forth in this Agreement. In the event of any conflict between the provisions of this Agreement and of the Plan, the provisions of the Plan shall govern. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;15. <U>Governing Law</U>.</B> The Plan shall be construed in accordance with
the laws of the State of Nevada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signatures Appear on the Following Page.] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 8 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By signing below, the undersigned Optionee acknowledges receipt of, and understands and
agrees to, this Stock Option Agreement and the Plan. Optionee further acknowledges that as of the Date of Grant, the Stock Option Agreement and the Plan set forth the entire understanding between Optionee and the Company regarding the Stock Option
and the acquisition of Common Stock of the Company pursuant to the exercise thereof and supersede all prior oral and written agreements on that subject, with the exception of Stock Options previously granted and delivered to Optionee under the Plan.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NeoGenomics, Inc.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Optionee:</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven C. Jones</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar, M.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steven C. Jones</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice President, Finance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 9 -
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d281487dex101.htm
<DESCRIPTION>MEDICAL SERVICES AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Medical Services Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit 10.1 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Medical Services Agreement </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Medical Services Agreement (&#147;Agreement&#148;) is made and
entered into on January&nbsp;6th by and between ALBITAR ONCOLOGY CONSULTING, LLC, a Delaware limited liability corporation (&#147;Medical Group&#148;), with its mailing address at 27165 Kiavo Drive, Valley Center, CA 92082 and NEOGENOMICS
LABORATORIES, INC., a Florida Corporation (&#147;NeoGenomics&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>RECITALS </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> NeoGenomics operates a clinical laboratory, licensed in accordance with the California Business and Professions Code, Sections 1200
<I>et. seq</I>. and the regulations adopted pursuant thereto, and the Clinical laboratory Improvement Amendments of 1988 (42 U.S.C. &#167;263a) and the regulations adopted pursuant thereto (&#147;CLIA&#148;), located at 6 Morgan, Suite 150, Irvine,
California 92618 (the &#147;Laboratory&#148;), in which it performs the technical component of certain high-complexity pathology tests (&#147;Diagnostic Tests&#148;), and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>NeoGenomics requires the professional services of Medical Group and desires to engage Medical Group to render and perform the professional component of the Diagnostic Tests through the
services of one or more physicians who are licensed and legally authorized to render such professional services in the State of California, and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Medical Group employs MAHER ALBITAR, M.D., who is licensed and authorized to practice medicine in the State of California
(&#147;Physician&#148;) and is trained, experienced and board-certified in the field of pathology, and Medical Group is willing to provide the professional expertise and experience through its Physician in those areas required or desired by
NeoGenomics; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, Medical Group is solely owned by the Physician and is expected to be solely owned by the Physician during
the term of this Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> NeoGenomics desires to contract with Medical Group for the rendition and performance of the
professional component of the Diagnostic Tests, the management of certain new product development and clinical trial activities, and the provision of Medical Administrative Services, as more fully described in this Agreement, and Medical Group
agrees to render and perform such services on an independent contractor basis to NeoGenomics, on the terms and conditions set forth in this Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Medical Group desires to engage the services of NeoGenomics to provide management services in the manner hereinafter stated, and NeoGenomics agrees to provide such management services, on
the terms and conditions stated in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOW, THEREFORE,</B> in consideration of the foregoing recitals, which are hereby
incorporated into this Agreement as an integral part hereof, and the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, NeoGenomics and
Medical Group/Physician, intending to be legally bound, hereby agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. PROFESSIONAL COMPONENT AND MEDICAL ADMINISTRATIVE
SERVICES:</B> NeoGenomics shall engage Medical Group to provide and Medical Group shall employ Physician on a full-time basis to (a)&nbsp;perform the professional interpretation of the Diagnostic Tests performed by Laboratory (the &#147;Professional
Component&#148;), (b)&nbsp;provide new product development and clinical trials management services, and (c)&nbsp;to provide medical administrative services. Such new product development and clinical trials management services will include, but not
be limited to, providing general oversight and management direction to NeoGenomics with respect to launching new laboratory tests and conducting clinical trials (&#147;Management Services&#148;). Those medical administrative services will include,
but not be limited to, providing liaison services with health care providers and ordering physicians, reviewing and establishing protocols for testing, establishing clinical parameters for procedures, evaluating and making recommendations regarding
new diagnostic procedures, providing in-service education to the Laboratory staff, providing community education to medical service providers, and such other administrative </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 1 of 8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
functions as NeoGenomics may reasonably request (&#147;Medical Administrative Services&#148;, and together with the Professional Component services, and the Management Services, the
&#147;Services&#148;). Unless otherwise agreed upon between the parties in writing, Medical Group and its Physician shall perform all functions related to the Services at the Laboratory. Medical Group and Physician further agree that they will not
provide services under this Agreement at any location other than the Laboratory unless such location has obtained the appropriate California licensures and has been CLIA certified and that Physician shall provide the Services on a full-time basis on
behalf of NeoGenomics. Notwithstanding the foregoing, the term &#147;full-time&#148; shall not exclude the Physician from continuing his work as a Director on the Board of Directors and a Consultant to Health Discovery Corporation as long as this
work is not cancer or hematology-related, or such other work to third parties as may be mutually agreed upon. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. MANAGEMENT SERVICES AND
DUTIES: </B>Medical Group hereby engages NeoGenomics to perform administrative, non-physician services for the daily support of the business operations of Medical Group&#146;s practice (the &#147;Practice&#148;). These services shall include,
without limitation: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">transcribing reports, transmitting reports to referring physicians, all other technical support necessary to provide professional pathology services, non-medical staff
support, quality control, marketing, advertising, office space, furniture, fixtures, equipment, facility and equipment maintenance, utilities, maintenance, janitorial services, supplies, managed care contract administration (including, without
limitation, revenue recovery and member eligibility determination), accounting, bookkeeping, budgeting, record storage, preparation of financial reports, billing, accounts payable, accounts receivable, management information systems, facilities
management, liability insurance, workers compensation insurance, and property and casualty insurance in connection with the services provided by Medical Group to NeoGenomics pursuant to this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the term of this Agreement, NeoGenomics shall use its skills and efforts to the performance of, and to perform diligently on a timely basis, its duties.
NeoGenomics shall comply with all applicable laws, regulations and administrative procedures of federal and state government agencies and their agent in the billing and collection of services rendered on behalf of NeoGenomics by Medical Group.
NeoGenomics shall defend and indemnify Medical Group from any claim due or alleged to be due to false or fraudulent billing performed by NeoGenomics. Medical Group and its Physicians shall retain full control over, and NeoGenomics shall exert no
control over, the exercise of professional judgment and care in all tasks performed as a licensed physician and the administrative functions pertaining thereto. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>3. COMPENSATION </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment for Services: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">As consideration for the Services provided by the Physician and Medical Group hereunder, NeoGenomics shall pay to Medical Group a minimum annual amount (the &#147;Base
Compensation&#148;) equal to $425,000; in equal increments of $16,346, payable on a bi-weekly basis. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics agrees that included within this Base Compensation is a provision for up to five (5)&nbsp;weeks of paid time off per year for Physician,
which shall accrue and be earned on a pro rata basis through each year. Such period of paid time off shall cover all normal working days where Physician is not available to provide Services to NeoGenomics as a result of vacation, continuing
education classes or otherwise. Medical Group and Physician agree that that in the event that Physician provides Services for less than 47 weeks per year, such Base Compensation shall be prorated accordingly.&nbsp;Notwithstanding the forgoing,
NeoGenomics agrees that Physician will not be expected to provide Services on any legal holidays formally recognized by NeoGenomics. Physician and Medical Group agree that they will notify NeoGenomics in writing of any time that Physician will be
unavailable to provide services during normal working hours and, to the extent possible, at least four weeks in advance of any period in which </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 2 of 8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Physician will be unavailable to provide Services for longer than one day.&nbsp;Physician and Medical Group further agree that Physician will not take vacation or otherwise be unavailable to
provide services for a period of longer than two weeks at any given time while this Agreement is in effect without the prior written approval of NeoGenomics and that any unused paid time-off cannot be carried forward past December&nbsp;31</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of any given calendar year. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">As additional consideration for the Professional Component and the Medical Administrative Services, NeoGenomics will pay the Medical Group an amount, determined in the
Company&#146;s discretion, up to 25% of the Base Compensation paid by the Company during any of its fiscal years within sixty (60)&nbsp;days of the end of any such fiscal year, if Medical Group meets certain performance thresholds established for it
by the Company (the &#147;Incentive Compensation&#148;) and this Agreement has not otherwise been terminated prior to the time of each such payment. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Base Compensation and the Incentive Compensation shall be paid to the Medical Group without regard to the actual fees collected by NeoGenomics that may represent
the reimbursement for the Professional Component of the Diagnostic Tests performed. If such fees actually collected are not sufficient to cover the Base Compensation and the Professional Compensation, then NeoGenomics shall pay such difference from
its own resources, and such amounts shall not be subject to reimbursement, recoupment or offset from previously or subsequently collected Base Compensations and Professional Compensation. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics will also reimburse Medical Group for up to $5,000 annually for expenses associated with Physician&#146;s continuing medical education (&#147;CME&#148;)
credits. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics will also pay all states licensing fees for Physician. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Physician will be entitled to participate in all medical benefits that NeoGenomics offers to its independent contractors (reported on IRS Form 1099) in accordance with
the Company&#146;s policy for such benefits at any given time. In this regard, NeoGenomics will pay that portion of such benefits as it would normally pay for full-time employees of NeoGenomics. NeoGenomics reserves the right to modify its benefit
programs at any time in its sole discretion. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement has been negotiated on the basis of the Medical Group employing only the Physician. If Medical Group hires or retains additional Physician(s) during the
term of this Agreement, then this Agreement shall be renegotiated to account for the effect of that change in the status of the Practice. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics will bill for the technical component and the professional component of all Diagnostic Tests on a global basis, and all monies received by NeoGenomics for
the Diagnostic Tests that is in excess of the Base Compensation and Incentive Compensation will be retained by NeoGenomics as compensation for the Management Services provided in Section&nbsp;2(a) (the &#147;Management Fee&#148;). Medical Group and
Physician shall do such things and execute such documents as necessary to enable NeoGenomics to bill and collect for the professional services rendered by Physician pursuant to this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management Fee after Termination. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon any termination of this Agreement, NeoGenomics shall continue to bill and collect for all Diagnostic Tests rendered to the date of termination.
NeoGenomics will pay to Medical Group any sums due for Base Compensation and Incentive Compensation due with respect to services rendered by Medical Group through the date of termination. NeoGenomics shall be entitled to retain all additional sums
as post-termination </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 3 of 8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Management Fee. Medical Group shall have no right, title or interest to accounts receivable, proceeds from accounts receivable or other income from any source derived in whole or in part from
services rendered by Medical Group pursuant to this Agreement. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If NeoGenomics terminates this Agreement without cause (as hereinafter defined) and without the required 90-days&#146; written notice, then Medical Group shall be
entitled to be paid the Base Compensation during the 90 day notification period. NeoGenomics shall be entitled to the Management Fee during such period. The Base Compensation and Management Fee will be adjusted ratably depending upon when the
termination occurs during a calendar month. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. RELATIONSHIP OF THE PARTIES:</B> NeoGenomics, on the one hand, and Medical
Group and its Physician, on the other hand, shall act at all times under this Agreement as independent contractors. Nothing in this Agreement shall be construed or be deemed to create a relationship of employer and employee or principal and agent or
any relationship other than that of independent parties contracting with each other solely for the purpose of carrying out the purposes expressed in this Agreement. The Medical Group and Physicians shall exercise at all times independent medical
judgment with regard to the professional interpretation and diagnosis of Diagnostic Tests and the performance of Management Services and the Medical Administrative Services. NeoGenomics shall provide administrative and technical support services to
Medical Group pursuant to the terms of this Agreement and as required by the laws and regulations governing licensed and CLIA-certified clinical laboratories. Medical Group and Physicians shall be solely responsible for determining the manner in
which professional medical services are provided and shall ensure that such services are rendered in accordance with the applicable professional standard of care. Medical Group and Physicians shall at all times be governed and abide by all
applicable clinical licensure, certification, and accreditation laws, regulations, and standards, and the policies and procedures of NeoGenomics adopted to comply with such standards. The relationship of the parties is and shall remain that of
independent parties to a contractual relationship as specified in this Agreement. Each party shall be and remain responsible for all hiring and firing decisions relating to its personnel and for all costs associated with its personnel, including but
not limited to salaries, wages, other compensation, taxes, tax withholding and fringe benefits (if any). In the event the Internal Revenue Service or other government agency should challenge the independent contractor status of the parties, the
parties agree that each party shall have the right to participate in any discussions or negotiations associated therewith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. NO
CONNECTION TO REFERRALS:</B> The Parties agree and acknowledge that the services to be rendered by the Parties as contemplated by this Agreement shall constitute valuable and necessary services for the operation of NeoGenomic&#146;s clinical
laboratory, and that the amounts payable under Section&nbsp;3 of this Agreement represent the fair market value of the items and services to be rendered by each Party. The Parties further acknowledge that it is their intention that compensation
payable under this Agreement shall be for actual services rendered and shall not represent, and is not intended to represent remuneration, direct or indirect, in consideration for the referral of patients or business generated between the Parties.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. TERM AND TERMINATION </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of this Agreement shall commence on January&nbsp;9, 2012 or such other date as shall be mutually agreed upon between the parties (the &#147;Start Date&#148;),
and shall continue until terminated as hereinafter provided. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Cause: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics may terminate this Agreement at any time for &#147;Cause&#148; (as hereinafter defined), effective immediately upon written notice to
Medical Group. As used herein, the term &#147;Cause&#148; shall mean: (A)&nbsp;commission of a material breach of this Agreement, which breach is curable, in the judgment of NeoGenomics, and continues 30 days after receipt of notice which states
with particularity the nature of the breach; (B)&nbsp;Medical Group or any Physician is charged with a felony or misdemeanor involving moral turpitude; Medical Group or any Physician commits an act or omission that could subject Medical Group,
Physician or NeoGenomics to administrative sanctions, civil or criminal </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 4 of 8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
penalties, fines; or assessments (C)&nbsp;termination, restriction, suspension, exclusion or debarment of Medical Group&#146;s or Physician&#146;s participation in the Medicare, Medi-Cal,
Medicaid, or any other private, state or federal health benefit program; (D)&nbsp;Medical Group or any Physician is charged with a violation of any law pertaining to the performance or rendition of health care goods or services, health care fraud or
abuse, or insurance fraud; or (E)&nbsp;revocation, restriction, suspension or other loss of Physician&#146;s license to practice medicine in any jurisdiction. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medical Group also may terminate this Agreement at any time for &#147;Cause&#148; (as hereinafter defined), effective immediately upon written notice to NeoGenomics. As
used herein, the term &#147;Cause&#148; shall mean a material breach of this Agreement by NeoGenomics which breach continues after 30 days notice and opportunity to cure. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination Without Cause: NeoGenomics or Medical Group may terminate this Agreement without cause, and for any reason or no reason, at any time after giving written
notice of its intention to terminate to the other Party at least ninety (90)&nbsp;days prior to the intended date of termination; provided, however, that NeoGenomics, in its discretion, may make such termination effective immediately or on some date
prior to the expiration of such 90-day notice period, in which event NeoGenomics will pay Medical Group during such 90-day period, or the remainder of such 90-day period, as provided in Section&nbsp;3(c)(ii) above. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in Law: In the event there is a change or clarification in law, regulation, or policy by a court or governmental agency with regulatory jurisdiction over the
Parties such that any of the terms or provisions of this Agreement could be deemed to be in violation or contravention of applicable law or regulations, or either Party&#146;s right to compensation for its services will be affected materially and
adversely by such changes or clarifications, the Parties agree to take such actions as may be necessary to modify this Agreement and to do such other things as they deem prudent or necessary to bring the affected provisions or terms into compliance
while maintaining the Parties in substantially the same economic position. If the Parties are unable to mutually agree to amend the affected provisions of this Agreement after good faith negotiations, either Party may terminate the Agreement by
providing not less than thirty (30)&nbsp;days advance written notice to the other, it being the express intent of the Parties that this Agreement comply at all times with applicable federal and California laws and regulations. The negotiation period
shall be shortened as necessary to prevent either Party from operating in violation of applicable law. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. PROPRIETARY
CONFIDENTIAL INFORMATION AND TRADE SECRETS:</B> The agreements between the parties with respect to Confidential Information and Trade Secrets are set forth in that certain Confidentiality, Title to Work Product and Non-Solicitation Agreement between
the Physician and NeoGenomics, which is made a part hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ASSIGNMENT:</B> This Agreement shall not be assignable, in whole or in
part, by either party without the written consent of the other party, except that:<B> </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics, with prior notice to but without the consent of Medical Group, may assign its rights and delegate its obligations under this Agreement to an affiliate; or
to any unaffiliated corporation, firm or other business entity (i)&nbsp;with or into which NeoGenomics may merge or consolidate; or (ii)&nbsp;to which NeoGenomics may sell or transfer all or substantially all of its assets. After any such assignment
by NeoGenomics, NeoGenomics shall be discharged from all further obligations hereunder and such assignee shall thereafter be deemed to be &#147;NeoGenomics&#148; for the purposes of all provisions of this Agreement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medical Group, with prior notice to NeoGenomics, may assign its rights under this Agreement to an entity created by or affiliated with the Physician.
Upon receipt of such notice, NeoGenomics shall advise Medical Group whether it consents to the assignment, which consent shall not be unreasonably withheld. As a condition to the assignment, assignee shall agree to be bound by the terms of this
Agreement, Medical Group shall then be discharged from all further obligations </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 5 of 8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
hereunder, and such assignee shall thereafter be deemed to be &#147;Medical Group&#148; for the purposes of all provisions of this Agreement. This Agreement secures the professional medical
services of Medical Group and Physician based upon the professional training, experience and qualifications of Physician as required by NeoGenomics. Accordingly, Medical Group and Physician shall not delegate any duties, responsibilities or
obligations without the advance written consent of NeoGenomics. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. SURVIVAL AND REMEDIES:</B> Medical Group acknowledges and
agrees that Medical Group&#146;s covenants in this Agreement are reasonable and necessary in order to protect the legitimate interests of NeoGenomics, and that any violation thereof by Medical Group would result in irreparable injuries to
NeoGenomics. Therefore, Medical Group acknowledges and agrees that, in the event of a violation by Medical Group of any of those covenants, NeoGenomics shall be entitled to obtain, from any court of competent jurisdiction, temporary, preliminary and
permanent injunctive relief to prevent a threatened breach or to obtain a halt to an actual breach by Medical Group of any of Medical Group&#146;s covenants contained in this Agreement, in addition to any other rights or remedies to which
NeoGenomics may be entitled at law or in equity by reason of any such breach or threatened breach of this Agreement<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ACCESS TO
RECORDS:</B> The Parties agree to comply with the federal privacy and security laws and regulations enacted pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;). Accordingly, Physician agrees to execute a
Business Associate Agreement contemporaneously with the execution of this Agreement or upon request. Each Party shall document all services rendered in the clinical laboratory records of NeoGenomics during the term hereof in accordance with the
policies and procedures of NeoGenomics. Medical Group shall ensure that each Physician shall prepare and submit such interpretive reports, forms, and documents as reasonably requested by NeoGenomics to document the services rendered pursuant to this
Agreement. Medical Group and Physicians may retain copies of all interpretive reports prepared by Physicians in connection with the Diagnostic Tests. NeoGenomics shall maintain and retain the interpretive reports, as required by Section&nbsp;1220 of
the California Business and Professions Code and 45 C.F.R. &#167;164.530(j)(2) of HIPAA. Medical Group and each Physician shall have access to and may copy, at its own expense, interpretive reports rendered by such Physician at all times throughout
the term of this Agreement and for the applicable retention period thereafter. The Parties shall comply with all laws and regulations relating to the confidentiality and security of clinical laboratory records. Unless required by service of process,
Medical Group and Physician shall not provide access to or copies of records to any person other than on behalf of and at the request of NeoGenomics. Medical Group and Physician shall promptly advise NeoGenomics upon receipt of any request for
records. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding any other provision of this Agreement, in the event the access to records provisions of 42 U.S.C.
&#167;1395x(V)(I) are applicable to this Agreement, until the expiration of four (4)&nbsp;years after the termination of this Agreement, each party shall make available, upon written request to the Secretary of the United States Department of Health
and Human Services, or upon request to the Controller General of the United States General Accounting Office, or any of his or her duly authorized representatives, a copy of this Agreement and such books, documents, or records as are necessary to
certify the nature and extent of the costs of the services provided by each party under this Agreement. In connection with the foregoing, (a)&nbsp;the parties acknowledge and agree that any privileges for documents or information under applicable
attorney-client, accountant-client, or other legal privilege, if any, are not waived by this Section&nbsp;10, or by any other provision of this Agreement; (b)&nbsp;subject to the other provisions of this Agreement regarding confidentiality, any
party may examine the records of the other party and make copies of those records at the expense of the party seeking the copies (the records are to be available during normal business hours at the principal place of business of the party owning the
records); and (c)&nbsp;the provisions of this Section&nbsp;10 shall survive the termination of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.
SEVERABILITY:</B> If any provision of this Agreement is held to be invalid, illegal or unenforceable, then that provision shall be reformed to the maximum extent permitted to preserve the parties&#146; original intent as agreed by the parties;
failing which, such provision shall be severed from this Agreement with the balance of the Agreement continuing in full force and effect. Such occurrence shall not have the effect of rendering the provision in question invalid in any other
jurisdiction, case or circumstance, or of rendering invalid any other provisions of this Agreement to the extent that such other provisions are not themselves actually in conflict with any applicable law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 6 of 8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. COSTS OF ENFORCEMENT: </B>In any dispute arising under or relating to this Agreement, the prevailing
party shall be entitled to recover reasonable attorneys&#146; and paralegals&#146; fees and expenses incurred. For this purpose, the term &#147;prevailing party&#148; shall mean the party whose position is substantially sustained in the settlement
or in the final judgment rendered in any litigation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. HEADINGS:</B> The headings appearing in this Agreement are for convenience and
reference only and shall not be deemed to govern, limit, modify or in any manner affect the scope, meaning or intent of the provisions of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>14. COUNTERPARTS:</B> This Agreement may be executed in any number of counterparts or by facsimile or Adobe Acrobat PDF file, and by each of the undersigned on separate counterparts, and each such
counterpart shall be deemed to be an original, but all such counterparts put together shall constitute but one and the same Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.
NOTICE: </B>Any and all notices required, or permitted, to be given under this Agreement will be sufficient if furnished in writing and shall be effective immediately upon personal delivery, or the following day if sent by facsimile transmission
with confirmation of receipt, or two days after being deposited in the U.S. Postal Service, postage prepaid, registered or return receipt requested, or two days after being deposited with a commercial overnight courier (<U>e.g.</U>, Federal Express,
DHL, Sonic, <U>etc.</U>), return receipt or confirmation of delivery requested, to the address set forth herein or to such other address of record furnished by either Party to the other in accordance with this Section&nbsp;15 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>[<I>Rest of Page Intentionally Left Blank, Signature Page Follows</I>]<I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 7 of 8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AGREED TO AND ACCEPTED</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NeoGenomics:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Medical Group/Physician:</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEOGENOMICS LABORATORIES, INC.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ALBITAR ONCOLOGY CONSULTING, LLC</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Douglas M. VanOort</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar, M.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Douglas M. VanOort</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned contracted physician hereby individually joins in this Agreement for the purpose of agreeing to comply
with the provisions of the Agreement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By:</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/ Maher Albitar, M.D.</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 8 of 8
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>d281487dex102.htm
<DESCRIPTION>LETTER AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Letter Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit 10.2 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g281487ex10_2-pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;6, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Maher Albitar, M.D. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">27165 Kiavo Dr </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valley Center, CA&nbsp;92082 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear
Dr.&nbsp;Albitar, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I am delighted to offer you the position of Chief Medical Officer and Director of Research and Development for NeoGenomics
Laboratories based in our Irvine, California facility. In this new role, you will be responsible for leading our Medical team, providing Medical leadership for the company&#146;s research and development efforts, and for providing the Medical vision
to help NeoGenomics become America&#146;s premier cancer testing laboratory. We are excited to have you be a key member of our team. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
keeping with California&#146;s law about the corporate practice of medicine, we are making this offer in writing through a Medical Services Agreement (the &#147;Agreement&#148;), a copy of which is attached hereto, between NeoGenomics Laboratories,
Inc. a Florida Corporation (&#147;NeoGenomics&#148; or the &#147;Company&#148;) and Albitar Oncology Consulting, LLC, a Delaware limited liability corporation (&#147;Medical Group&#148;), a corporation previously formed by you in which you are the
sole shareholder and physician-employee. As an inducement for your causing Medical Group to enter into the Agreement, NeoGenomics hereby agrees to provide you with the following benefits as an independent contractor: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Start Date:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;9, 2012 or such other date as is mutually agreed upon (the &#147;Start Date&#148;)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$425,000 per annum, payable bi-weekly</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bonus:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Targeted at 25% of the Base Compensation amount paid by NeoGenomics during any of its fiscal years within sixty (60) days of the end of any such fiscal year, if you meet certain
performance thresholds established for you by the Company (the &#147;Incentive Compensation&#148;).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Benefits:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will be entitled to participate in all medical benefits that NeoGenomics offers to its independent contractors (reported on IRS Form 1099) in accordance with the Company&#146;s
policy for such benefits at any given time. In this regard, NeoGenomics will pay that portion of such benefits as it would normally pay for full-time employees of NeoGenomics. A summary of the current policies with respect to benefits is attached.
The Company reserves the right to modify its benefit programs at any time in its sole discretion.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Paid&nbsp;Time&nbsp;Off:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Included in the Compensation outlined above is a provision for five weeks of paid time off per year for periods in which you are unavailable to provide services to the Company
during normal business hours.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CME&nbsp;Expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics will also reimburse Medical Group for up to $5,000 annually for expenses associated with your continuing medical education (&#147;CME&#148;) credits.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Licensing Fees:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics will also pay all states licensing fees for you.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Options:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the Start Date, you will be granted non-qualified stock options to purchase up to 250,000 shares of NeoGenomics&#146; common stock at an exercise price equivalent to the
closing price per share at which NeoGenomics stock was quoted on the NASDAQ Bulletin Board on the last trading day prior to your Start Date. The grant of such options will be made pursuant to the Company&#146;s stock option plan and will be
evidenced by a separate Option Agreement, which the Company will execute with you within 60 days of receiving a copy of the Company&#146;s Confidentiality, Non-Solicitation, and Non-Competition Agreement which has been executed by you. As long as
the Agreement remains in effect, such options will have a five-year term from the Start Date and will vest according to the following schedule; provided, however, all of such options will vest upon a Change of Control of
NeoGenomics:</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500 on the one year anniversary of your Start Date</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500 on the second anniversary of your Start Date</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500 on the third anniversary of your Start Date</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500 on the fourth anniversary of your Start Date</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If for any reason the Agreement is terminated prior to the first anniversary of the Start Date (before the initial vesting occurs), all such options will be forfeited. Furthermore,
if the Agreement remains in effect on and after the first anniversary, then you understand that the Company&#146;s stock option plan requires that any vested options must be exercised within three (3) months after the date that the Agreement
terminates.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">You agree that the Company will have no obligation to issue a Stock Option Agreement granting the above options unless and until the Company receives an executed copies of the (i)
Confidentiality, Title to Work Product and Non-solicitation Agreement and the (ii) Confidentiality and Non-Compete Agreement from you.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock&nbsp;Warrants:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the Start Date, you will also be granted warrants to purchase up to 200,000 shares of NeoGenomics&#146; common stock. Such warrants will have an exercise price equal to the
closing price per share at which NeoGenomics stock was quoted on the NASDAQ Bulletin Board on the last trading day prior to your Start Date, a five year term and will vest in the following performance criteria are accomplished:</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-3.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000 will vest upon the commercial launch of the Company&#146;s gene-based plasma <U>prostate</U> cancer test licensed from
Health Discovery Corp (&#147;HDC&#148;) or similar test based on our mutual agreement.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-3.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000 will vest upon the commercial launch of the Company&#146;s gene-based <U>colon</U> cancer test licensed from HDC or
similar test based on our mutual agreement.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-3.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000 will vest upon the commercial launch of the Company&#146;s gene-based <U>pancreatic</U> cancer test licensed from HDC or
similar test based on our mutual agreement.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-3.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2</B>0,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize
the cytogenetics automated image analysis technology licenses from HDC</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-3.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2</B>0,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize
the flow cytometry automated image analysis technology licenses from HDC</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, in the event of a Change of Control of the Company in which the consideration payable to each common stockholder of the Company in connection with
such Change of Control has a deemed value of at least $4.00 per share (as adjusted for stock splits, stock dividends, reverse stock splits, and the like) then the Shares subject to the warrant shall immediately vest in full.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are in agreement with the above terms, please countersign this letter below and we will provide final copies of
the various agreements referred to above. We are very much looking forward to working with you. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Douglas M. VanOort</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman and Chief Executive Officer</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Agreed and Accepted:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>6
<FILENAME>d281487dex103.htm
<DESCRIPTION>CONFIDENTIALITY AND NON-COMPETITION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Confidentiality and Non-Competition Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.3 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONFIDENTIALITY AND NON-COMPETITION AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Confidentiality and
Non-Solicitation Agreement (the &#147;<B><U>Agreement</U></B>&#148;) dated this 6th day of January, 2012 is entered into by and between Maher Albitar, M.D., an individual who resides at the address set forth on the signature page hereof
(&#147;<B><U>Contractor</U></B>&#148;) and NeoGenomics Laboratories, Inc., a Florida corporation (&#147;<B><U>NeoGenomics</U></B>&#148; and collectively with NeoGenomics, Inc, a Nevada corporation, the NeoGenomics&#146; parent corporation, the
&#147;<B><U>Company</U></B>&#148;). Hereinafter, each of the Contractor or the Company maybe referred to as a &#147;<B><U>Party</U></B>&#148; and together be referred to as the &#147;<B><U>Parties</U></B>&#148;. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RECITALS: </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Contractor is a member of the Board of Directors of Health Discovery Corporation, a Georgia corporation, which
specializes, among other things, in the field of discovering new proprietary methods for genetic and molecular laboratory testing; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Health Discovery Corporation licensed its technology to NeoGenomics to commercialize certain cancer-related genetic and molecular testing products and services pursuant to a licensing
agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, pursuant to such licensing agreement, Contractor agreed to provide full-time services to
NeoGenomics in order to assist with such commercialization activities; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> NeoGenomics has appointed
Contractor as its Chief Medical Officer; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, NeoGenomics and Albitar Oncology Consulting, LLC, a Delaware
limited liability corporation solely owned by Contractor (&#147;Medical Professional Corporation&#148; or &#147;MPC&#148;), have entered into that certain Medical Services Agreement of even date herewith, which specifies how NeoGenomics will work
with MPC and Contractor, on a full-time basis to pursue business opportunities in the cancer-related genetic and molecular testing market (the &#147;<B><U>Medical Services Agreement</U></B>&#148;) and that certain Confidentiality, Title To Work
Product and Non-Solicit Agreement of even date herewith (the &#147;<B><U>Work Product Agreement</U></B>&#148;); and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Contractor will provide professional services to NeoGenomics through MPC and derive economic benefit from NeoGenomics
through MPC; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, Contractor has also been awarded non-qualified stock options and warrants of the Company as
part of the overall business relationship with the Company; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, the Company will be providing MPC and
Contractor with access to certain confidential and competitive information about NeoGenomics&#146; new product development plans, business and clients as part of the business arrangement with MPC; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> the Company desires to protect and preserve its Confidential Information and its legitimate business interests by having
the Contractor enter into this Agreement as part of the Medical Services Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, Contractor
acknowledges that Company will disclose certain Company confidential and proprietary information, trade secrets and customer and supplier relationships and desires to establish and maintain a business relationship with the Company and as part of
such business relationship desires to enter into this Agreement with the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Now, therefore, in consideration of the mutual promises set forth herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Contractor, the Parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.
<U>Term</U>. The parties agree</B> that the term of this agreement is effective upon execution and shall survive and continue to be in force and effect for two years following the earlier of a) the termination of any employment or independent
contractor relationship between the Contractor and the MPC, whether termination is by the MPC with or without cause, wrongful discharge, or for any other reason whatsoever, or by the Contractor, b) the date on which the Contractor ceases to be an
equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the Company or any entity that is wholly or partially owned by the Company (all of such entities being hereinafter referred to as
&#147;<B><U>Affiliated Entities</U></B>&#148;). The aforementioned period during which this Agreement will remain in effect shall hereinafter be referred to as the &#147;<B><U>Term</U></B>&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Definitions. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. The
term &#147;<B><U>Confidential Information</U></B>&#148; as used herein shall include all business practices, methods, techniques, or processes that: (i)&nbsp;derives independent economic value, actual or potential, from not being generally known to,
and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (ii)&nbsp;is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Confidential
Information also includes, but is not limited to, files, letters, memoranda, reports, records, computer disks or other computer storage medium, data, models or any photographic or other tangible materials containing such information, Customer lists
and names and other information, Customer contracts, other corporate contracts, computer programs, proprietary technical information and or strategies, sales, promotional or marketing plans or strategies, programs, techniques, practices, any
expansion plans (including existing and entry into new geographic and/or product markets), pricing information, product or service offering specifications or plans thereof, business plans, financial information and other financial plans, data
pertaining to the Company&#146;s operating performance, employee lists, salary information, Personal Information, Protected Health Information, all information the Company receives from customers or other third parties that is not generally known to
the public or is subject to a confidentiality agreement, training manuals, and other materials and business information of a similar nature, including information about the Company itself or any Affiliated Entity, which Contractor acknowledges and
agrees has been compiled by the Company&#146;s expenditure of a great amount of time, money and effort, and that contains detailed information that could not be created independently from public sources. Further, all data, spreadsheets, reports,
records, know-how, verbal communication, proprietary and technical information and/or other confidential materials of similar kind transmitted by the Company or any Affiliated Entity to Contractor or developed by the Contractor on behalf of the
Company or any Affiliate Entity as Work Product (as defined in Paragraph 7) are expressly included within the definition of &#147;Confidential Information.&#148; The Parties further agree that the fact the Company or any Affiliated Entity may be
seeking to complete a business transaction is &#147;Confidential Information&#148; within the meaning of this Agreement, as well as all notes, analysis, work product or other material derived from Confidential Information. Notwithstanding anything
contained herein to the contrary, Confidential Information does not include any information which is generally known to third parties in the industry. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">b. The term <B>&#147;<U>Personal Information</U>&#148; (&#147;<U>PI</U>&#148;)</B> is Confidential Information and includes, but is not limited to, an individual&#146;s first name and last name or first
initial and last name in combination with any of the following: an individual&#146;s social security number, tax I.D. number, social insurance number, driver&#146;s license number, state issued identification card number, financial information,
healthcare information, or credit or debit card number. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. The term <B>&#147;<U>Protected Health Information</U>&#148;
(&#147;<U>PHI</U>&#148;)</B> is Confidential Information and includes information that is created, received, and/or maintained by the Company related to an individual&#146;s health care (or payment related to health care) that directly or indirectly
identifies the individual. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">d. The term &#147;<B><U>Customer</U></B>&#148; shall mean any person or entity, the
identity and contact information of which is kept confidential by the Company, which has purchased or ordered goods, products or services from the Company, entered into any contract for products or services with the Company, and/or entered into any
contract for the distribution of any Products or services with the Company within the one (1)&nbsp;year immediately preceding a) the termination of any employment or independent contractor relationship between the Contractor and the MPC, b) the date
on which the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the Company or any Affiliate Entity of the Company. Contractor acknowledges and agrees that the
Company&#146;s Customers, Customer relationships and Customer contact information have been compiled by the Company and will continue to be compiled by the Company at the expenditure of a great amount of time, money, expense and effort, and that the
Company goes to considerable lengths and efforts to protect all such Customer information, and that such information is not readily available from public sources or known to third parties in the industry. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">e. The term &#147;<B><U>Prospective Customer</U></B>&#148; shall mean any person or entity, the identity and contact information of which
is kept confidential by the Company, which has evidenced an intention to engage in business to purchase or order goods, Products or services from the Company, has evidenced an intent to enter into any contract for Products or services with the
Company, and/or has evidenced an intent to enter into any contract for the distribution of any Products or services with the Company, (which such intention(s) shall be stated in writing) within the one (1)&nbsp;year immediately preceding a) the
termination of any employment or independent contractor relationship between the Contractor and the MPC, b) the date on which the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the
MPC and the Company or any Affiliate Entity of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">f. The term &#147;<B><U>Restricted Area</U></B>&#148; shall
include any geographical location anywhere in the United States. If the Restricted Area specified in this Agreement should be judged unreasonable in any proceeding, then the Restricted Area shall be reduced so that the restrictions may be enforced
as is judged to be reasonable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">g. The phrase &#147;<B><U>directly or indirectly</U></B>&#148; shall include the Contractor
either on his/her own account, or as a partner, owner, promoter, joint venturer, employee, agent, consultant, advisor, manager, executive, independent contractor, officer, director, or a stockholder of 5% or more of the voting shares of an entity in
the Business of Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">h. The term &#147;<B><U>Business</U></B>&#148; shall mean the business of performing cancer-related
research and development activities associated with genetic and molecular laboratory testing and providing cancer-related genetic and molecular laboratory testing products and services for profit, including, but not limited to, cytogenetics, flow
cytometry, fluorescence in-situ hybridization (&#147;FISH&#148;), morphological studies, polymerase chain reaction (&#147;PCR&#148;) testing, and other molecular testing, to hematologists, oncologists, urologists, pathologists, hospitals and other
medical reference laboratories. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">i. The term &#147;<B><U>Full-time</U></B>&#148; should not exclude the contractor from
continuing his work as a Director on the Board and a Consultant to Health Discovery Corp (HDC) as long as this work is not cancer or hematology-related. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>3. <U>Duty of Confidentiality</U>. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. All Confidential Information is
considered highly sensitive and strictly confidential. The Contractor agrees that at all times during the term of this Agreement and after the termination of Medical Services Agreement for as long as such information remains non-public information,
the Contractor shall (i)&nbsp;hold in confidence and refrain from disclosing to any other party all Confidential Information, whether written or oral, tangible or intangible, concerning the Company or any Affiliated Entities and their business and
operations unless such disclosure is accompanied by a non-disclosure agreement executed by the Company with the party to whom such Confidential Information is provided, (ii)&nbsp;use the Confidential Information solely in connection with his or her
services to the Company or any Affiliated Entity and for no other purpose, (iii)&nbsp;take </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
all precautions necessary to ensure that the Confidential Information shall not be, or be permitted to be, shown, copied or disclosed to third parties, without the prior written consent of the
Company or any Affiliated Entity, (iv)&nbsp;observe all security policies implemented by the Company or any Affiliated Entity from time to time with respect to the Confidential Information, and (v)&nbsp;not use or disclose, directly or indirectly,
as an individual or as a partner, joint venturer, employee, agent, salesman, contractor, officer, director or otherwise, for the benefit of himself or herself or any other person, partnership, firm, corporation, association or other legal entity,
any Confidential Information, unless expressly permitted by this Agreement. Contractor agrees that protection of the Company&#146;s and any Affiliated Entity&#146;s Confidential Information constitutes a legitimate business interest justifying the
restrictive covenants contained herein. Contractor further agrees that the restrictive covenants contained herein are reasonably necessary to protect the Company&#146;s and any Affiliated Entity&#146;s legitimate business interest in preserving its
Confidential Information. In addition, Contractor will not view or access any PI or PHI unless required and authorized by the Company to do so. Contractor acknowledges that he/she shall bear all costs, losses and damages resulting from any
intentional breach of this paragraph, to the fullest extent permitted by applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. In the event that the Contractor
is ordered to disclose any Confidential Information, whether in a legal or regulatory proceeding or otherwise, such disclosure shall be limited to the narrowest disclosure so required and, except to the extent prohibited by law, Contractor shall
give the Company or any Affiliated Entities at least two (2)&nbsp;weeks&#146; notice, if practicable, of the basis for any such compelled disclosure of Confidential Information and shall reasonably cooperate with the Company or any Affiliated
Entities in limiting disclosure and obtaining suitable confidentiality protections. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. Contractor acknowledge(s) that this
&#147;Confidential Information&#148; is of value to the Company and/or any Affiliated Entities by providing them with a competitive advantage over their competitors, is not generally known to competitors of the Company, and is not intended by the
Company or any Affiliated Entities for general dissemination. Contractor acknowledges that this &#147;Confidential Information&#148; derives independent economic value, actual or potential, from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, and is the subject of reasonable efforts to maintain its secrecy. Therefore, the Parties agree that all &#147;Confidential Information&#148;
under this Agreement constitutes &#147;<B><U>Trade Secrets</U></B>&#148; under both Section&nbsp;688.002 and Chapter 812 of the Florida Statutes and California&#146;s Uniform Trade Secrets Act, Cal. Civ. Code section 3426 <U>et</U> <U>seq.</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. <U>Limited Right of Disclosure</U>. </B>Except as otherwise permitted by this Agreement, Contractor shall limit disclosure of pertinent
Confidential Information to Contractor&#146;s attorney, if any (&#147;<B><U>Representative(s</U></B>)&#148;), for the sole purpose of evaluating Contractor&#146;s relationship with the Company. Contractor agrees to show this Agreement to any
Representatives and Contractor agrees that Paragraph 3 of this Agreement shall bind all such Representative(s). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. <U>Return of Company
Property and Confidential Materials</U>. </B>All tangible property, including cell phones, laptop computers and other Company purchased property, as well as all Confidential Information, Customer and Prospective Customer information and property,
provided to Contractor is the exclusive property of the Company and/or its Affiliated Entities and must be returned to the Company and/or its Affiliated Entities in accordance with the instructions of the Company and/or such Affiliated Entities
either upon termination of the Medical Services Agreement or at such other time as is requested by the Company. Contractor agree(s) that upon the earlier of a) the termination of any employment or independent contractor relationship between the
Contractor and the MPC, b) the date on which the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the Company or any Affiliate Entity of the Company, Contractor shall
return all copies, in whatever form or media, including hard copies and electronic copies, of Confidential Information to the Company and/or the Affiliated Entity, and Contractor shall delete any copy of the Confidential Information on any computer
file or database maintained by Contractor and, if requested in writing, shall certify in writing that he/she has done so. In addition to returning all information to the Company and/or any Affiliated Entities as described above, Contractor will
destroy any analysis, notes, work product or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
other materials relating to or derived from the Confidential Information. Any intentional or unauthorized retention of Confidential Information may constitute &#147;misappropriation&#148; as such
term is defined in both Chapter 772 of the Florida Statutes and Cal. Civ. Code section 3426.1(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. <U>Restrictive Covenant</U>.</B> The
Company and its Affiliated Entities are engaged in the business of performing cancer-related research and development activities associated with genetic and molecular laboratory testing and providing cancer-related genetic and molecular laboratory
testing products and services to oncologists, urologists, pathologists, physicians, hospitals, and other medical laboratories. The covenants contained in this Paragraph 8 (the &#147;<B><U>Restrictive Covenants</U></B>&#148;) are given and made by
Contractor to induce the Company to enter into the Medical Services Agreement and to protect the Confidential Information of the Company, and Contractor acknowledges sufficiency of consideration for these Restrictive Covenants. Contractor expressly
covenants and agrees that, during the time the Management Services Agreement is in effect between the MPC and the Company and for a period of two years following the earlier of a) the termination of any employment or independent contractor
relationship between the Contractor and the MPC, b) the date on which the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the Company or any Affiliate Entity of the
Company (such period of time is hereinafter referred to as the &#147;<B><U>Restrictive Period</U></B>&#148;), he will abide by the following restrictive covenants, unless an exception is specifically provided, in writing signed by Company.
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>This Section Intentionally Left Blank</U>.</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Non-Competition</U></B><B>.</B> Contractor agrees and acknowledges that, during the Restrictive Period, he will not, directly or indirectly, for himself, or on
behalf of others, as an individual on Contractor&#146;s own account, or as a partner, joint venturer, employee, agent, salesman, contractor, officer, director or otherwise, for him/herself or any other person, partnership, firm, corporation,
association or other legal entity, enter into, <B><I>engage in, accept employment from,</I></B> or provide any competitive services to, or for, <B><I>any business that is in the Business of the Company, or engage in any activity that is competitive
with the Company, in the Restricted Area</I></B>. The parties agree that this non-competition provision is intended to cover situations where a future business opportunity in which the Contractor is engaged or a future employer of the Contractor is
selling the same or similar products and services in a Business which may compete with the Company&#146;s products and services to Customers and Prospective Customers of the Company in the Restricted Area. This provision shall not cover future
business opportunities or employers of the Contractor that sell different types of products or services in the Restricted Area so long as such future business opportunities or employers are not in the Business of the Company.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the preceding paragraphs, the spirit and intent of this non-competition clause is not to deny
the Contractor the ability to support his or her family, but rather to prevent Contractor from using the knowledge and experiences obtained from the Company in a similar competitive environment. Along those lines, should the Contractor leave the
employment of the MPC or the Medical Services Agreement between the MPC and the Company be terminated for any reason, he would be prohibited from joining a for-profit cancer genetics testing laboratory and/or company in the Business of the Company
in the Restricted Area. The Parties agree that all non-profit medical testing laboratories, hospitals and academic institutions as well as for-profit testing laboratories not engaged in cancer genetics research and development or testing services
are excluded from the restrictions in paragraph 8(b). In other words, Contractor would be allowed under this non-compete clause to work in any non-profit cancer genetics research and development or testing laboratory (e.g., in academia) as well as
in a private, for-profit testing laboratories not engaged in cancer genetics research and development or testing. Thus, the spirit and intent of this non-competition clause is intended to prevent Contractor from acting in any of the capacities
outlined in this paragraph for any &#147;for-profit&#148; cancer genetics research and development or testing laboratories that do any one or more of the types of testing services defined in the definition of Business in the Restricted Area.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Acknowledgements of Contractor</U></B><B>.</B><B></B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Contractor understands and acknowledges that any material violation of this Agreement shall constitute a material breach of this Agreement, and it will cause
irreparable harm and loss to the Company or any Affiliated Entity for which monetary damages will be an insufficient remedy. Therefore, the Parties agree that in addition to any other remedies available, the Company and its Affiliated Entities will
be entitled to the relief identified in Paragraph No.&nbsp;7 below. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Restrictive Covenants shall be construed as agreements independent of any other provision in this Agreement </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that the Restrictive Covenants are reasonably necessary to protect the legitimate business interests of the Company or any Affiliated Entity and to
protect its Confidential Information. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that this Agreement may be enforced by the Company&#146;s assignee or successor or any of the Affiliated Entities and Contractor acknowledges and
agrees that assignees, successors and Affiliated Entities are intended beneficiaries of this Agreement. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that if any portion of the Restrictive Covenants are held by an arbitration panel or court of competent jurisdiction to be unreasonable, arbitrary or
against public policy for any reason, they shall be modified accordingly as to time, geographic area and line of business so as to be enforceable to the fullest extent possible as to time, area and line of business. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that any material violation of the Restrictive Covenants, in any capacity identified herein, are a material breach of this Agreement.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that any failure of the Company or any Affiliated Entity to enforce the Restrictive Covenants against any other employee or contractor, for any
reason, shall not constitute a defense to enforcement of the Restrictive Covenants against the Contractor. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. <U>Specific
Performance; Injunction</U>. </B>The Parties agree and acknowledge that the restrictions contained in Paragraphs 1-6 are reasonable in scope and duration and are necessary to protect the Company or any of its Affiliated Entities. If any provision of
Paragraphs 1-6 as applied to any party or to any circumstance is adjudged by a court to be invalid or unenforceable, the same shall in no way affect any other circumstance or the validity or enforceability of any other provision of this Agreement.
If any such provision, or any part thereof, is held to be unenforceable because of the duration of such provision or the area covered thereby, the Parties agree that the court making such determination shall have the power to reduce the duration
and/or area of such provision, and/or to delete specific words or phrases, and in its reduced form, such provision shall then be enforceable and shall be enforced. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any material unauthorized use or disclosure of information in violation of Paragraphs 2-5 above or violation of the Restrictive Covenant in Paragraph 6 shall constitute a material breach of this
Agreement, may constitute misappropriation under California law, and may cause irreparable harm and loss to the Company or any of its Affiliated Entities for which monetary damages will be an insufficient remedy. Therefore, the Parties agree that in
addition to any other remedy available, the Company or any of its Affiliated Entities may be entitled to all of available civil remedies, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary and permanent injunctive relief, without being required to post a bond, restraining Contractor or Representatives and any other person, partnership, firm,
corporation, association or other legal entity acting in concert with Contractor from any actual or threatened unauthorized disclosure or use of Confidential Information, in whole or in part, or from rendering any service to any other person,
partnership, firm, corporation, association or other legal entity to whom such Confidential Information in whole or in part, has been disclosed or used or is threatened to be disclosed or used; and </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary and permanent injunctive relief, without being required to post a bond, restraining the Contractor from violating, directly or indirectly, the restrictions of
the Restrictive Covenant in any capacity identified in Paragraph 6, supra; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensatory damages, including actual loss from misappropriation and unjust enrichment. Contractor further agrees to pay any and all legal fees, including without
limitation, all attorneys&#146; fees, court costs, and any other related fees and/or costs incurred by the Company in enforcing this Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, the Company acknowledges and agrees that the Contractor will not be liable for the payment of any damages or fees owed to the Company through the operation of Paragraphs 9c
above, unless and until a court of competent jurisdiction or arbitration panel has determined that the Company or any of its assignees, successors or Affiliated Entities is entitled to such recovery. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing in this Agreement shall be construed as prohibiting the Company or any Affiliated Entities from pursuing any other legal or
equitable remedies available to it for actual or threatened breach of the provisions of Paragraphs 1 &#150; 6 of this Agreement, and the existence of any claim or cause of action by Contractor against the Company or any of its Affiliated Entities
may not constitute a defense to the enforcement by the Company or any of its Affiliated Entities of any of the provisions of this Agreement. The Company and its Affiliated Entities have fully performed all obligations entitling it to the covenants
of Paragraphs 1 &#150; 6 of this Agreement and therefore such prohibitions are not executory or otherwise subject to rejection under the bankruptcy code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>8. <U>Duty to Disclose Agreement</U>.</B> Contractor acknowledges that the Company has a legitimate business purpose in the protection of its Confidential Information. Contractor also recognizes and
agrees that the Company has the right to such information as is reasonably necessary to inform the Company whether the terms of this Agreement are being complied with. Accordingly, Contractor agrees that Contractor will promptly notify any new
company that Contractor provides services to of his/her obligations contained here. Contractor also will provide the Company with the identity of the new company that he/she is providing services to and a description of the services being provided
by him/her in sufficient detail to allow the Company to reasonably determine whether such activities fall within the scope of activities prohibited by the provisions of this Agreement </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>9. <U>Waiver of Jury Trial</U>.</B> <B>THE COMPANY AND CONTRACTOR EACH WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT OR UNDER ANY
INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED IN CONNECTION HEREWITH OR HEREAFTER OR RELATED IN ANY FASHION TO THEIR RELATIONSHIP.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.
<U>Governing Law, Venue and Personal Jurisdiction</U>. </B>Notwithstanding anything to the contrary herein, this Agreement shall be governed by, construed and enforced in accordance with the laws of state of Florida without regard to any statutory
or common-law provision pertaining to conflicts of laws. The parties agree that courts of competent jurisdiction in Lee County, Florida and the United States District Court for the Southern </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
District of Florida shall have concurrent jurisdiction for purposes of entering temporary, preliminary and permanent injunctive relief and with regard to any action arising out of any breach or
alleged breach of this Agreement. Company waives personal service of any and all process upon Company and consents that all such service of process may be made by certified or registered mail directed to Company at the address stated in the
signature section of this Agreement, with service so made deemed to be completed upon actual receipt thereof. Company waives any objection to jurisdiction and venue of any action instituted against Company as provided herein and agrees not to assert
any defense based on lack of jurisdiction or venue. Contractor further agrees that any action arising out of this Agreement or the relationship between the parties established herein shall be brought only in courts of competent jurisdiction in Lee
County, Florida or the United States District Court for the Southern District of Florida. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. <U>Successors and Assigns</U>. </B>This
Agreement shall be binding upon and inure to the benefit of the Parties hereto and may not be assigned by Contractor at any time. This Agreement may be assigned only by the Company to an Affiliated Entity and shall inure to the benefit of its
successors and/or assigns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. <U>Entire Agreement</U>. </B>This Agreement is the entire agreement of the Parties with regard to the
matters addressed herein, and supersedes all negotiations, preliminary agreements, and all prior and contemporaneous discussions and understandings of the signatories in connection with the subject matter of this Agreement, except however, that this
Agreement shall be read <B></B><I>in pari materia</I><B></B> with the Medical Services Agreement and the Work Product Agreement. This Agreement may be modified only by written instrument signed by the Company and Contractor.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. <U>Construction</U>. </B>The Parties agree that, notwithstanding the authorship of this Agreement by the Company, such Agreement shall not be
construed more favorably to one Party than the other. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. <U>Severability</U>. </B>In case any one or more provisions contained in this
Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision hereof and this Agreement shall be construed as if such invalid, illegal
were unenforceable provision had not been contained herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. <U>Waiver</U>. </B>The waiver by the Company of a breach or threatened
breach of this Agreement by Contractor cannot be construed as a waiver of any subsequent breach by Contractor. The refusal or failure of the Company or any Affiliated Entity to enforce any specific restrictive covenant in this Agreement against
Contractor, or any other person for any reason, shall not constitute a defense to the enforcement by the Company or any Affiliated Entity of any other restrictive covenant provision set forth in this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. <U>Consideration</U>. </B>Contractor expressly acknowledges and agrees that the execution by the Company of the Medical Services Agreement and the
granting of stock options and warrants to the Contractor constitutes full, adequate and sufficient consideration to Contractor for the covenants of Contractor under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>17. <U>Notices</U></B><B>.</B> All notices required by this Agreement shall be in writing, shall be personally delivered or sent by U.S. Registered or Certified Mail, return receipt requested, and
shall be addressed to the signatories at the addresses shown on the signature page of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18. <U>Acknowledgements</U>.
</B>Contractor acknowledge(s) that he has reviewed this Agreement prior to signing it, that he knows and understands the contents, purposes and effect of this Agreement, and that he has been given a signed copy of this Agreement for her records.
Contractor further acknowledges and agrees that he has entered into this Agreement freely, without any duress or coercion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19.
<U>Counterparts</U>. </B>This Agreement may be executed in counterparts, each of which shall be deemed an original for all intents and purposes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Signatures appear on the following page. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, THE UNDERSIGNED STATE THAT THEY HAVE CAREFULLY READ THIS AGREEMENT AND
KNOW AND UNDERSTAND THE CONTENTS THEREOF AND THAT THEY AGREE TO BE BOUND AND ABIDE BY THE REPRESENTATIONS, COVENANTS, PROMISES AND WARRANTIES CONTAINED HEREIN. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor Signature</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor&nbsp;Address:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics Laboratories, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12701 Commonwealth Drive, #5 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fort Myers, FL 33913 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Signature</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven Jones</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, Finance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>7
<FILENAME>d281487dex104.htm
<DESCRIPTION>CONFIDENTIALITY
<TEXT>
<HTML><HEAD>
<TITLE>Confidentiality</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 10.4 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONFIDENTIALITY, TITLE TO WORK PRODUCT AND NON-SOLICITATION AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Confidentiality and Non-Solicitation Agreement (the &#147;<B><U>Agreement</U></B>&#148;) dated this 6th day of January, 2012 is
entered into by and between Maher Albitar, M.D., an individual who resides at the address set forth on the signature page hereof (&#147;<B><U>Contractor</U></B>&#148;) and NeoGenomics Laboratories, Inc., a Florida corporation
(&#147;<B><U>NeoGenomics</U></B>&#148; and collectively with NeoGenomics, Inc, a Nevada corporation, the NeoGenomics&#146; parent corporation, the &#147;<B><U>Company</U></B>&#148;). Hereinafter, each of the Contractor or the Company maybe referred
to as a &#147;<B><U>Party</U></B>&#148; and together be referred to as the &#147;<B><U>Parties</U></B>&#148;. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RECITALS:
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Contractor is a member of the Board of Directors of Health Discovery Corporation, a Georgia corporation,
which specializes, among other things, in the field of discovering new proprietary methods for genetic and molecular laboratory testing; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Health Discovery Corporation licensed its technology to NeoGenomics to commercialize certain cancer-related genetic and molecular testing products and services pursuant to a licensing
agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, pursuant to such licensing agreement, Contractor agreed to provide full-time services to
NeoGenomics in order to assist with such commercialization activities; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> NeoGenomics has appointed
Contractor as its Chief Medical Officer; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, NeoGenomics and Albitar Oncology Consulting, LLC, a Delaware
limited liability corporation solely owned by Contractor (&#147;Medical Professional Corporation&#148; or &#147;MPC&#148;), have entered into that certain Medical Services Agreement of even date herewith, which specifies how NeoGenomics will work
with MPC and Contractor, on a full-time basis to pursue business opportunities in the cancer-related genetic and molecular testing market (the &#147;<B><U>Medical Services Agreement</U></B>&#148;) and that certain Confidentiality and Non-Compete
Agreement of even date herewith (the &#147;<B><U>Non-Compete Agreement</U></B>&#148;); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS, </B>Contractor will
provide professional services to NeoGenomics through MPC and derive economic benefit from NeoGenomics through MPC; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, Contractor has also been awarded non-qualified stock options and warrants of the Company as part of the overall business
relationship with the Company; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, the Company will be providing MPC and Contractor with access to certain
confidential and competitive information about NeoGenomics&#146; new product development plans, business and clients as part of the business arrangement with MPC; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS,</B> the Company desires to protect and preserve its Confidential Information and its legitimate business interests by having the Contractor enter into this Agreement as part of the Medical
Services Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WHEREAS</B>, Contractor acknowledges that Company will disclose certain Company confidential and
proprietary information, trade secrets and customer and supplier relationships and desires to establish and maintain a business relationship with the Company and as part of such business relationship desires to enter into this Agreement with the
Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Now, therefore, in consideration of the mutual promises set forth herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Contractor, the Parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.
<U>Term</U>. The parties agree</B> that the term of this agreement is effective upon execution and shall survive and continue to be in force and effect for two years following the earlier of a) the termination of any employment or independent
contractor relationship between the Contractor and the MPC, whether termination is by the MPC with or without cause, wrongful discharge, or for any other reason whatsoever, or by the Contractor, b) the date on which the Contractor ceases to be an
equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the Company or any entity that is wholly or partially owned by the Company (all of such entities being hereinafter referred to as
&#147;<B><U>Affiliated Entities</U></B>&#148;). The aforementioned period during which this Agreement will remain in effect shall hereinafter be referred to as the &#147;<B><U>Term</U></B>&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Definitions. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. The
term &#147;<B><U>Confidential Information</U></B>&#148; as used herein shall include all business practices, methods, techniques, or processes that: (i)&nbsp;derives independent economic value, actual or potential, from not being generally known to,
and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (ii)&nbsp;is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Confidential
Information also includes, but is not limited to, files, letters, memoranda, reports, records, computer disks or other computer storage medium, data, models or any photographic or other tangible materials containing such information, Customer lists
and names and other information, Customer contracts, other corporate contracts, computer programs, proprietary technical information and or strategies, sales, promotional or marketing plans or strategies, programs, techniques, practices, any
expansion plans (including existing and entry into new geographic and/or product markets), pricing information, product or service offering specifications or plans thereof, business plans, financial information and other financial plans, data
pertaining to the Company&#146;s operating performance, employee lists, salary information, Personal Information, Protected Health Information, all information the Company receives from customers or other third parties that is not generally known to
the public or is subject to a confidentiality agreement, training manuals, and other materials and business information of a similar nature, including information about the Company itself or any Affiliated Entity, which Contractor acknowledges and
agrees has been compiled by the Company&#146;s expenditure of a great amount of time, money and effort, and that contains detailed information that could not be created independently from public sources. Further, all data, spreadsheets, reports,
records, know-how, verbal communication, proprietary and technical information and/or other confidential materials of similar kind transmitted by the Company or any Affiliated Entity to Contractor or developed by the Contractor on behalf of the
Company or any Affiliate Entity as Work Product (as defined in Paragraph 7) are expressly included within the definition of &#147;Confidential Information.&#148; The Parties further agree that the fact the Company or any Affiliated Entity may be
seeking to complete a business transaction is &#147;Confidential Information&#148; within the meaning of this Agreement, as well as all notes, analysis, work product or other material derived from Confidential Information. Notwithstanding anything
contained herein to the contrary, Confidential Information does not include any information which is generally known to third parties in the industry. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">b. The term <B>&#147;<U>Personal Information</U>&#148; (&#147;<U>PI</U>&#148;)</B> is Confidential Information and includes, but is not limited to, an individual&#146;s first name and last name or first
initial and last name in combination with any of the following: an individual&#146;s social security number, tax I.D. number, social insurance number, driver&#146;s license number, state issued identification card number, financial information,
healthcare information, or credit or debit card number. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. The term <B>&#147;<U>Protected Health Information</U>&#148;
(&#147;<U>PHI</U>&#148;)</B> is Confidential Information and includes information that is created, received, and/or maintained by the Company related to an individual&#146;s health care (or payment related to health care) that directly or indirectly
identifies the individual. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">d. The term &#147;<B><U>Customer</U></B>&#148; shall mean any person or entity, the identity
and contact information of which is kept confidential by the Company, which has purchased or ordered goods, products or services from the Company, entered into any contract for products or services with the Company, and/or entered into any contract
for the distribution of any Products or services with the Company within the one (1)&nbsp;year immediately preceding a) the termination of any employment or independent contractor relationship between the Contractor and the MPC, b) the date on which
the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the Company or any Affiliate Entity of the Company. Contractor acknowledges and agrees that the Company&#146;s
Customers, Customer relationships and Customer contact information have been compiled by the Company and will continue to be compiled by the Company at the expenditure of a great amount of time, money, expense and effort, and that the Company goes
to considerable lengths and efforts to protect all such Customer information, and that such information is not readily available from public sources or known to third parties in the industry. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">e. The term &#147;<B><U>Prospective Customer</U></B>&#148; shall mean any person or entity, the identity and contact information of which
is kept confidential by the Company, which has evidenced an intention to engage in business to purchase or order goods, Products or services from the Company, has evidenced an intent to enter into any contract for Products or services with the
Company, and/or has evidenced an intent to enter into any contract for the distribution of any Products or services with the Company, (which such intention(s) shall be stated in writing) within the one (1)&nbsp;year immediately preceding a) the
termination of any employment or independent contractor relationship between the Contractor and the MPC, b) the date on which the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the
MPC and the Company or any Affiliate Entity of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">f. The term &#147;<B><U>Restricted Area</U></B>&#148; shall
include any geographical location anywhere in the United States. If the Restricted Area specified in this Agreement should be judged unreasonable in any proceeding, then the Restricted Area shall be reduced so that the restrictions may be enforced
as is judged to be reasonable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">g. The phrase &#147;<B><U>directly or indirectly</U></B>&#148; shall include the Contractor
either on his/her own account, or as a partner, owner, promoter, joint venturer, employee, agent, consultant, advisor, manager, executive, independent contractor, officer, director, or a stockholder of 5% or more of the voting shares of an entity in
the Business of Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">h. The term &#147;<B><U>Business</U></B>&#148; shall mean the business of performing cancer-related
research and development activities associated with genetic and molecular laboratory testing and providing cancer-related genetic and molecular laboratory testing products and services for profit, including, but not limited to, cytogenetics, flow
cytometry, fluorescence in-situ hybridization (&#147;FISH&#148;), morphological studies, polymerase chain reaction (&#147;PCR&#148;) testing, and other molecular testing, to hematologists, oncologists, urologists, pathologists, hospitals and other
medical reference laboratories. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">i. The term &#147;<B><U>Full-time</U></B>&#148; should not exclude the contractor from
continuing his work as a Director on the Board and a Consultant to Health Discovery Corp (HDC) as long as this work is not cancer or hematology-related. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>3. <U>Duty of Confidentiality</U>. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. All Confidential Information is
considered highly sensitive and strictly confidential. The Contractor agrees that at all times during the term of this Agreement and after the termination of Medical Services Agreement for as long as such information remains non-public information,
the Contractor shall (i)&nbsp;hold in confidence and refrain from disclosing to any other party all Confidential Information, whether written or oral, tangible or intangible, concerning the Company or any Affiliated Entities and their business and
operations unless such disclosure is accompanied by a non-disclosure agreement executed by the Company with the party to whom such Confidential Information is provided, (ii)&nbsp;use the Confidential Information solely in connection with his or her
services to the Company or any Affiliated Entity and for no other purpose, (iii)&nbsp;take </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
all precautions necessary to ensure that the Confidential Information shall not be, or be permitted to be, shown, copied or disclosed to third parties, without the prior written consent of the
Company or any Affiliated Entity, (iv)&nbsp;observe all security policies implemented by the Company or any Affiliated Entity from time to time with respect to the Confidential Information, and (v)&nbsp;not use or disclose, directly or indirectly,
as an individual or as a partner, joint venturer, employee, agent, salesman, contractor, officer, director or otherwise, for the benefit of himself or herself or any other person, partnership, firm, corporation, association or other legal entity,
any Confidential Information, unless expressly permitted by this Agreement. Contractor agrees that protection of the Company&#146;s and any Affiliated Entity&#146;s Confidential Information constitutes a legitimate business interest justifying the
restrictive covenants contained herein. Contractor further agrees that the restrictive covenants contained herein are reasonably necessary to protect the Company&#146;s and any Affiliated Entity&#146;s legitimate business interest in preserving its
Confidential Information. In addition, Contractor will not view or access any PI or PHI unless required and authorized by the Company to do so. Contractor acknowledges that he/she shall bear all costs, losses and damages resulting from any
intentional breach of this paragraph, to the fullest extent permitted by applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. In the event that the Contractor
is ordered to disclose any Confidential Information, whether in a legal or regulatory proceeding or otherwise, such disclosure shall be limited to the narrowest disclosure so required and, except to the extent prohibited by law, Contractor shall
give the Company or any Affiliated Entities at least two (2)&nbsp;weeks&#146; notice, if practicable, of the basis for any such compelled disclosure of Confidential Information and shall reasonably cooperate with the Company or any Affiliated
Entities in limiting disclosure and obtaining suitable confidentiality protections. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. Contractor acknowledge(s) that this
&#147;Confidential Information&#148; is of value to the Company and/or any Affiliated Entities by providing them with a competitive advantage over their competitors, is not generally known to competitors of the Company, and is not intended by the
Company or any Affiliated Entities for general dissemination. Contractor acknowledges that this &#147;Confidential Information&#148; derives independent economic value, actual or potential, from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, and is the subject of reasonable efforts to maintain its secrecy. Therefore, the Parties agree that all &#147;Confidential Information&#148;
under this Agreement constitutes &#147;<B><U>Trade Secrets</U></B>&#148; under both Section&nbsp;688.002 and Chapter 812 of the Florida Statutes and California&#146;s Uniform Trade Secrets Act, Cal. Civ. Code section 3426 <U>et</U> <U>seq.</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. <U>Limited Right of Disclosure</U>. </B>Except as otherwise permitted by this Agreement, Contractor shall limit disclosure of pertinent
Confidential Information to Contractor&#146;s attorney, if any (&#147;<B><U>Representative(s</U></B>)&#148;), for the sole purpose of evaluating Contractor&#146;s relationship with the Company. Contractor agrees to show this Agreement to any
Representatives and Contractor agrees that Paragraph 3 of this Agreement shall bind all such Representative(s). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. <U>Return of Company
Property and Confidential Materials</U>. </B>All tangible property, including cell phones, laptop computers and other Company purchased property, as well as all Confidential Information, Customer and Prospective Customer information and property,
provided to Contractor is the exclusive property of the Company and/or its Affiliated Entities and must be returned to the Company and/or its Affiliated Entities in accordance with the instructions of the Company and/or such Affiliated Entities
either upon termination of the Medical Services Agreement or at such other time as is requested by the Company. Contractor agree(s) that upon the earlier of a) the termination of any employment or independent contractor relationship between the
Contractor and the MPC, b) the date on which the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the Company or any Affiliate Entity of the Company, Contractor shall
return all copies, in whatever form or media, including hard copies and electronic copies, of Confidential Information to the Company and/or the Affiliated Entity, and Contractor shall delete any copy of the Confidential Information on any computer
file or database maintained by Contractor and, if requested in writing, shall certify in writing that he/she has done so. In addition to returning all information to the Company and/or any Affiliated Entities as described above, Contractor will
destroy any analysis, notes, work product or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
other materials relating to or derived from the Confidential Information. Any intentional or unauthorized retention of Confidential Information may constitute &#147;misappropriation&#148; as such
term is defined in both Chapter 772 of the Florida Statutes and Cal. Civ. Code section 3426.1(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. <U>Agreement Not To Circumvent</U>.
</B>Contractor agrees not to pursue any transaction or comparable concept that makes use of any information identified herein as Confidential Information during the Term of this Agreement, other than through the Company and/or its Affiliated
Entities or on behalf of the Company and/or its Affiliated Entities. It is further understood and agreed that the Contractor will direct all communications and requests regarding Confidential Information from any third parties through the
Company&#146;s then chief executive officer or president. Any violation of this covenant shall subject Contractor to the remedies identified in Paragraph 9 in addition to any other available remedies.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. <U>Title to Work Product</U>. </B>Contractor agrees that all work products (including product development ideas and strategies and testing
methodologies for competing in the genetics testing industry, technical materials and diagrams, computer programs, financial plans and other written materials, websites, presentation materials, mathematical equations, course materials, advertising
campaigns, slogans, videos, pictures and other materials) created or developed by the Contractor for the Company or any of its Affiliated Entities during the term of the Medical Services Agreement with the Company or any successor to the Company
until the date of termination of the Medical Services Agreement (collectively, the &#147;<B><U>Work Product</U></B>&#148;), shall be considered a work made for hire and that the Company shall be the sole owner of all rights, including copyright, in
and to the Work Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Work Product, or any part thereof, does not qualify as a work made for hire, the Contractor
agrees to assign, and hereby assigns, to the Company for the full term of the copyright and all extensions thereof all of its right, title and interest in and to the Work Product. All discoveries, inventions, innovations, works of authorship,
computer programs, improvements and ideas, whether or not patentable or copyrightable or otherwise protectable, conceived, completed, reduced to practice or otherwise produced by the Contractor in the course of his or her services to the Company in
connection with or in any way relating to the Business of the Company or capable of being used or adapted for use therein or in connection therewith shall forthwith be disclosed to the Company and shall belong to and be the absolute property of the
Company unless assigned by the Company to an Affiliated Entity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor hereby assigns to the Company all right, title and
interest in all of the discoveries, inventions, innovations, works of authorship, computer programs, improvements, ideas and other work product; all copyrights, trade secrets, and trademarks in the same; and all patent applications filed and patents
granted worldwide on any of the same for any work previously completed on behalf of the Company or any Affiliated Entity or work performed under the terms of this Agreement or the Medical Services Agreement. Contractor, if and whenever required to
do so (whether during or after the termination of Medical Services Agreement), shall at the expense of the Company or any Affiliated Entity apply or join in applying for copyrights, patents or trademarks or other equivalent protection in the United
States or in other parts of the world for any such discovery, invention, innovation, work of authorship, computer program, improvement, and idea as aforesaid and execute, deliver and perform all instruments and things necessary for vesting such
patents, trademarks, copyrights or equivalent protections when obtained and all right, title and interest to and in the same in the Company absolutely and as sole beneficial owner, unless assigned by the Company to an Affiliated Entity. If
Contractor fails to execute, acknowledge, verify or deliver any such document reasonably requested by the Company, Contractor irrevocably appoints the Company and its authorized officers and agents as its agent and attorney-in-fact to act in
Contractor&#146;s place to execute, acknowledge, verify and deliver any such document on Contractor&#146;s behalf. Notwithstanding the foregoing, work product conceived by the Contractor, which is not related to the Business of the Company, or any
Affiliated Entity, will remain the property of the Contractor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor understands and agrees that any provision in this
Agreement requiring Contractor to assign its rights in inventions will not apply to any invention that qualifies fully under the provisions of California </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Labor Code section 2870 (the terms of which are set forth on Attachment 1) relating to certain inventions that Contractor developed entirely on Contractor&#146;s own time without using the
Company&#146;s equipment, supplies, facilities or trade secret information. By signing this Agreement below, Contractor hereby acknowledges that it has received and read the Notice as set forth in Attachment 1 attached to this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The parties recognize that in the course of developing the Work Product, or performing work under this Agreement, Contractor may use or
incorporate certain of Contractor&#146;s proprietary know-how or technology that exists before the date of this Agreement and therefore will not be owned by the Company (&#147;<B><U>Excluded IP</U></B>&#148;). For purposes of clarification, the
parties do not intend that Contractor assign such Excluded IP to the Company under this Section&nbsp;7, but they instead intend that the Company should be able to exercise rights under the Excluded IP for purposes of exercising all rights in the
Work Product. Therefore, to the extent that any Excluded IP is used by the Company, including to produce or as part of any Company product or service, Contractor hereby grants to the Company a non-exclusive, irrevocable, perpetual, royalty-free,
fully paid-up, worldwide right and license under the Excluded IP (including any patent or other intellectual property rights therein) to exercise any and all rights of ownership in the Excluded IP, and to sublicense any or all of the foregoing
rights (including the right to grant further sublicenses), to the extent the Excluded IP is owned or can be licensed by Contractor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.
<U>Restrictive Covenant</U>.</B> The Company and its Affiliated Entities are engaged in the business of performing cancer-related research and development activities associated with genetic and molecular laboratory testing and providing
cancer-related genetic and molecular laboratory testing products and services to oncologists, urologists, pathologists, physicians, hospitals, and other medical laboratories. The covenants contained in this Paragraph 8 (the &#147;<B><U>Restrictive
Covenants</U></B>&#148;) are given and made by Contractor to induce the Company to enter into the Medical Services Agreement and to protect the Confidential Information of the Company, and Contractor acknowledges sufficiency of consideration for
these Restrictive Covenants. Contractor expressly covenants and agrees that, during the time the Management Services Agreement is in effect between the MPC and the Company and for a period of two years following the earlier of a) the termination of
any employment or independent contractor relationship between the Contractor and the MPC, b) the date on which the Contractor ceases to be an equity owner of the MPC, or c) the termination of the Medical Services Agreement between the MPC and the
Company or any Affiliate Entity of the Company (such period of time is hereinafter referred to as the &#147;<B><U>Restrictive Period</U></B>&#148;), he will abide by the following restrictive covenants, unless an exception is specifically provided,
in writing signed by Company. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Non-Solicitation</U></B><B>.</B> Contractor agrees and acknowledges that, during the Restrictive Period, he will not, directly or indirectly, in one or a series
of transactions, as an individual or as a partner, joint venturer, employee, agent, salesperson, contractor, officer, director or otherwise, for the benefit of herself or any other person, partnership, firm, corporation, association or other legal
entity: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">solicit or induce, or attempt to solicit or induce, any Customer, or any Prospective Customer, of the Company or of any Affiliated Entity to patronize or do business
with any business directly or indirectly in competition with the businesses conducted by the Company or any Affiliated Entity in any market in which the Company or any Affiliated Entity does business; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">canvass, or solicit, or attempt to solicit, from any Customer, or any Prospective Customer, of the Company or of any Affiliated Entity, any such business relationship
that is in competition with the Company or any Affiliated Entity; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">request or advise any Customer or vendor, or any Prospective Customer or vendor, of the Company or of any Affiliated Entity to withdraw, curtail or cancel any such
Customer&#146;s or vendor&#146;s business with the Company or any Affiliated Entity; or </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">manage, operate, be connected with, employed by, sell goods to, or perform services for, or on behalf of, in any manner, any Customer, or Prospective Customer, of the
Company either myself or on behalf of any other entity that may employ, engage or associate with me in any fashion; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">recruit, solicit or otherwise induce or influence, or attempt to recruit, solicit or influence, any proprietor, partner, stockholder, lender, director, officer,
employee, sales agent, joint venturer, investor, lessor, supplier, Customer, agent, representative or any other person which has a business relationship with the Company or any Affiliated Entity to discontinue, reduce or modify such employment,
agency or business relationship with the Company or any Affiliated Entity; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">solicit or seek to employ or retain any person or agent who is then (or was at any time within twelve (12)&nbsp;months prior to the date Contractor or such entity
employs or seeks to employ such person) employed or retained by the Company or any Affiliated Entity. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>This Section Intentionally Left Blank</U>.</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Acknowledgements of Contractor</U>.</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Contractor understands and acknowledges that any material violation of this Agreement shall constitute a material breach of this Agreement, and it will cause
irreparable harm and loss to the Company or any Affiliated Entity for which monetary damages will be an insufficient remedy. Therefore, the Parties agree that in addition to any other remedies available, the Company and its Affiliated Entities will
be entitled to the relief identified in Paragraph No.&nbsp;9 below. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Restrictive Covenants shall be construed as agreements independent of any other provision in this Agreement </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that the Restrictive Covenants are reasonably necessary to protect the legitimate business interests of the Company or any Affiliated Entity and to
protect its Confidential Information. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that this Agreement may be enforced by the Company&#146;s assignee or successor or any of the Affiliated Entities and Contractor acknowledges and
agrees that assignees, successors and Affiliated Entities are intended beneficiaries of this Agreement. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that if any portion of the Restrictive Covenants are held by an arbitration panel or court of competent jurisdiction to be unreasonable, arbitrary or
against public policy for any reason, they shall be modified accordingly as to time, geographic area and line of business so as to be enforceable to the fullest extent possible as to time, area and line of business. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that any material violation of the Restrictive Covenants, in any capacity identified herein, are a material breach of this Agreement.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor agrees that any failure of the Company or any Affiliated Entity to enforce the Restrictive Covenants against any other employee or contractor, for any
reason, shall not constitute a defense to enforcement of the Restrictive Covenants against the Contractor. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. <U>Specific Performance; Injunction</U>. </B>The Parties agree and acknowledge that the restrictions
contained in Paragraphs 1-8 are reasonable in scope and duration and are necessary to protect the Company or any of its Affiliated Entities. If any provision of Paragraphs 1-8 as applied to any party or to any circumstance is adjudged by a court to
be invalid or unenforceable, the same shall in no way affect any other circumstance or the validity or enforceability of any other provision of this Agreement. If any such provision, or any part thereof, is held to be unenforceable because of the
duration of such provision or the area covered thereby, the Parties agree that the court making such determination shall have the power to reduce the duration and/or area of such provision, and/or to delete specific words or phrases, and in its
reduced form, such provision shall then be enforceable and shall be enforced. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any material unauthorized use or disclosure of
information in violation of Paragraphs 2-7 above or violation of the Restrictive Covenant in Paragraph 8 shall constitute a material breach of this Agreement, may constitute misappropriation under California law, and may cause irreparable harm and
loss to the Company or any of its Affiliated Entities for which monetary damages will be an insufficient remedy. Therefore, the Parties agree that in addition to any other remedy available, the Company or any of its Affiliated Entities may be
entitled to all of available civil remedies, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary and permanent injunctive relief, without being required to post a bond, restraining Contractor or Representatives and any other person, partnership, firm,
corporation, association or other legal entity acting in concert with Contractor from any actual or threatened unauthorized disclosure or use of Confidential Information, in whole or in part, or from rendering any service to any other person,
partnership, firm, corporation, association or other legal entity to whom such Confidential Information in whole or in part, has been disclosed or used or is threatened to be disclosed or used; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary and permanent injunctive relief, without being required to post a bond, restraining the Contractor from violating, directly or indirectly, the restrictions of
the Restrictive Covenant in any capacity identified in Paragraph 8, supra; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensatory damages, including actual loss from misappropriation and unjust enrichment. Contractor further agrees to pay any and all legal fees, including without
limitation, all attorneys&#146; fees, court costs, and any other related fees and/or costs incurred by the Company in enforcing this Agreement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, the Company acknowledges and agrees that the Contractor will not be liable for the payment of any damages or fees owed to the Company through the operation of Paragraphs 9c
above, unless and until a court of competent jurisdiction or arbitration panel has determined that the Company or any of its assignees, successors or Affiliated Entities is entitled to such recovery. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nothing in this Agreement shall be construed as prohibiting the Company or any Affiliated Entities from pursuing any other legal or
equitable remedies available to it for actual or threatened breach of the provisions of Paragraphs 1 &#150; 8 of this Agreement, and the existence of any claim or cause of action by Contractor against the Company or any of its Affiliated Entities
may not constitute a defense to the enforcement by the Company or any of its Affiliated Entities of any of the provisions of this Agreement. The Company and its Affiliated Entities have fully performed all obligations entitling it to the covenants
of Paragraphs 1 &#150; 8 of this Agreement and therefore such prohibitions are not executory or otherwise subject to rejection under the bankruptcy code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>10. <U>Duty to Disclose Agreement</U>.</B> Contractor acknowledges that the Company has a legitimate business purpose in the protection of its Confidential Information. Contractor also recognizes and
agrees that the Company has the right to such information as is reasonably necessary to inform the Company whether the terms of this Agreement are being complied with. Accordingly, Contractor agrees that Contractor will promptly notify any new
company that Contractor provides services to of his/her obligations contained here. Contractor also will provide the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company with the identity of the new company that he/she is providing services to and a description of the services being provided by him/her in sufficient detail to allow the Company to
reasonably determine whether such activities fall within the scope of activities prohibited by the provisions of this Agreement </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.
<U>Representations as to Prior or Other Agreements</U>.</B> Contractor represents and warrants that he/she is able to perform the contemplated duties without being in breach of confidentiality agreements or disclosing proprietary information of any
third party, and that no proprietary information of any third party shall be disclosed to the Company. Contractor further represents and warrants that he/she is not prohibited from entering into this Agreement or performing services under it by any
non-competition, non-solicitation, anti-piracy agreement, relationship agreement, or any other restrictions. Contractor agrees to indemnify and hold the Company harmless from all claims or causes of action by any person or entity against the Company
arising out of any alleged breach by Contractor of any such agreement or any other restrictions inconsistent with the foregoing representations.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>12. <U>Company Use of Contractor Name, Image and Voice</U>. </B>The Company may use and publish Contractor&#146;s name and picture, including audio or video tape recordings, for purposes relating to
its business without a specific release from Contractor . </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. <U>Termination</U>.</B> Contractor agrees to bring any claims that he/she
may have against the Company within three hundred (300)&nbsp;days of the day that Contractor knew, or should have known, of the facts giving rise to the cause of action and waives any longer, but not shorter, statutory or other limitations periods.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. <U>Nondisparagement</U></B><B>.</B> Contractor shall not make any disparaging or defamatory comments about the Company, whether true
or not, except to comply with any summons, court order or subpoena. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. <U>Waiver of Jury Trial</U>.</B> <B>THE COMPANY AND CONTRACTOR
EACH WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT OR UNDER ANY INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED IN CONNECTION HEREWITH OR HEREAFTER OR RELATED IN ANY FASHION TO THEIR
RELATIONSHIP.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. <U>Governing Law, Venue and Personal Jurisdiction</U>. </B>Notwithstanding anything to the contrary herein, this
Agreement shall be governed by, construed and enforced in accordance with the laws of state of Florida without regard to any statutory or common-law provision pertaining to conflicts of laws. The parties agree that courts of competent jurisdiction
in Lee County, Florida and the United States District Court for the Southern District of Florida shall have concurrent jurisdiction for purposes of entering temporary, preliminary and permanent injunctive relief and with regard to any action arising
out of any breach or alleged breach of this Agreement. Company waives personal service of any and all process upon Company and consents that all such service of process may be made by certified or registered mail directed to Company at the address
stated in the signature section of this Agreement, with service so made deemed to be completed upon actual receipt thereof. Company waives any objection to jurisdiction and venue of any action instituted against Company as provided herein and agrees
not to assert any defense based on lack of jurisdiction or venue. Contractor further agrees that any action arising out of this Agreement or the relationship between the parties established herein shall be brought only in courts of competent
jurisdiction in Lee County, Florida or the United States District Court for the Southern District of Florida. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. <U>Successors and
Assigns</U>. </B>This Agreement shall be binding upon and inure to the benefit of the Parties hereto and may not be assigned by Contractor at any time. This Agreement may be assigned only by the Company to an Affiliated Entity and shall inure to the
benefit of its successors and/or assigns. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18. <U>Entire Agreement</U>. </B>This Agreement is the entire agreement of the Parties with regard to the
matters addressed herein, and supersedes all negotiations, preliminary agreements, and all prior and contemporaneous discussions and understandings of the signatories in connection with the subject matter of this Agreement, except however, that this
Agreement shall be read <I>in pari materia</I> with the Medical Services Agreement and the Non-Compete Agreement. This Agreement may be modified only by written instrument signed by the Company and Contractor. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19. <U>Construction</U>. </B>The Parties agree that, notwithstanding the authorship of this Agreement by the Company, such Agreement shall not be
construed more favorably to one Party than the other. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20. <U>Severability</U>. </B>In case any one or more provisions contained in this
Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision hereof and this Agreement shall be construed as if such invalid, illegal
were unenforceable provision had not been contained herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21. <U>Waiver</U>. </B>The waiver by the Company of a breach or threatened
breach of this Agreement by Contractor cannot be construed as a waiver of any subsequent breach by Contractor. The refusal or failure of the Company or any Affiliated Entity to enforce any specific restrictive covenant in this Agreement against
Contractor, or any other person for any reason, shall not constitute a defense to the enforcement by the Company or any Affiliated Entity of any other restrictive covenant provision set forth in this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22. <U>Consideration</U>. </B>Contractor expressly acknowledges and agrees that the execution by the Company of the Medical Services Agreement and the
granting of stock options to the Contractor constitutes full, adequate and sufficient consideration to Contractor for the covenants of Contractor under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>23.</B> <B><U>Notices</U>.</B> All notices required by this Agreement shall be in writing, shall be personally delivered or sent by U.S. Registered or Certified Mail, return receipt requested, and
shall be addressed to the signatories at the addresses shown on the signature page of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24. <U>Acknowledgements</U>.
</B>Contractor acknowledge(s) that he has reviewed this Agreement prior to signing it, that he knows and understands the contents, purposes and effect of this Agreement, and that he has been given a signed copy of this Agreement for her records.
Contractor further acknowledges and agrees that he has entered into this Agreement freely, without any duress or coercion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25.
<U>Counterparts</U>. </B>This Agreement may be executed in counterparts, each of which shall be deemed an original for all intents and purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Signatures appear on the following page. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, THE UNDERSIGNED STATE THAT THEY HAVE CAREFULLY READ THIS AGREEMENT AND
KNOW AND UNDERSTAND THE CONTENTS THEREOF AND THAT THEY AGREE TO BE BOUND AND ABIDE BY THE REPRESENTATIONS, COVENANTS, PROMISES AND WARRANTIES CONTAINED HEREIN. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor Signature</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contractor&nbsp;Address:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">27165 Kiavo Dr</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valley Center, CA 92082</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics Laboratories, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12701 Commonwealth Drive, #5 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fort Myers, FL 33913 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven Jones</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Signature</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven Jones</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, Finance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ATTACHMENT 1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>CALIFORNIA LABOR CODE SECTION 2872 NOTICE </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>(Regarding Certain Exclusions
From Invention Assignments) </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I understand that if I am an employee in California, then the provisions of this Agreement requiring me to
assign Inventions shall not apply to those inventions as described by California Labor Code Section&nbsp;2870, which provides as follows: </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>California Labor Code Section&nbsp;2870 </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an
invention that the employee developed entirely on his or her own time without using the employer&#146;s equipment, supplies, facilities, or trade secret information except for those inventions that either: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) Relate at the time of conception or reduction to practice of the invention to the employer&#146;s business, or actual or demonstrably
anticipated research or development of the employer; or </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) Result from any work performed by the employee for the employer.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise
excluded from being required to be assigned under subdivision (a), the provision is against the public policy of the State of California and is unenforceable.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">I understand that I bear the full burden of proving to the Company that an invention qualifies fully under Section&nbsp;2870 so as to be excluded from assignment to the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I further understand and agree that I may be required to provide for full title to certain patents and inventions to be in the name of the United States,
as may be required by certain contracts between the Company and the United States or any of its agencies. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Maher Albitar, M.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maher Albitar, M.D.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTRACTOR&#146;S INITIALS</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ MA</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>8
<FILENAME>d281487dex105.htm
<DESCRIPTION>MASTER LICENSE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Master License Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Exhibit 10.5 </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>MASTER LICENSE AGREEMENT </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LICENSE AGREEMENT dated as of January&nbsp;6, 2012 (this &#147;Agreement&#148;), is entered into among and between HEALTH DISCOVERY
CORPORATION, a Georgia corporation (&#147;LICENSOR&#148;) having a place of business at 2 East Bryan Street, Suite 1500, Savannah, GA 31401, and NEOGENOMICS LABORATORIES, INC. a Florida corporation (&#147;LICENSEE&#148;), having a place of business
at 12701 Commonwealth Drive, Suite #5, Fort Myers, FL 33913 (each, a &#147;Party,&#148; and collectively, the &#147;Parties&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">RECITALS: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, LICENSOR is the owner of intellectual property, including
patents, pending and issued, and know-how relating to support vector machine and other machine learning technologies which is included within the &#147;SVM Technology&#148; (as defined below), based upon which it has developed, or is engaged in
developing, applications including, inter alia, digital image analysis and interpretation, biomarker discovery, and gene/gene product-based and protein-based diagnostic, prognostic and predictive tests; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, LICENSOR owns the Licensed Technology (as defined below), which includes inter alia, coverage of genomic biomarkers related to
prostate cancer, pancreatic cancer, colon cancer and other cancers as well as certain interpretation methodologies and software associated with automated image analysis for cytogenetics and flow cytometry testing; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, LICENSEE desires to obtain, and LICENSOR is willing to grant, an exclusive license under LICENSOR&#146;s rights in the SVM
Technology and the Licensed Technology to develop and commercialize Licensed Uses (as defined below) for use in the Field (as defined below) in the Licensed Territory (as defined below) on the terms and conditions of this Agreement; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties acknowledge that an employment agreement, or such other type of agreement as is agreed upon, by and between LICENSEE
and Dr.&nbsp;Maher Albitar (the &#147;Employment Agreement&#148;) will be entered into by them, contemporaneously with the execution and delivery of this Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties acknowledge that separate consulting agreements by and between LICENSEE and Drs. Stephen Barnhill, Herbert Fritsche, Isabelle Guyon and Hong Zhang will be entered into by them,
contemporaneously with the execution and delivery of this Agreement (collectively, the &#147;Consulting Agreements&#148;). </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, the Parties, intending to be legally bound hereby, hereby agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;1 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>DEFINITIONS </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of this Agreement, the terms defined in this Article 1 shall have the respective meanings set forth below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.1 &#147;<U>Affiliate</U>&#148; shall mean, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under common control with, such Person. A Person
shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least ten percent (10%)&nbsp;of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the
power to direct or cause the direction of the management and policies of the other Person by any means whatsoever. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2
&#147;<U>Change of Control</U>&#148; means (a)&nbsp;the acquisition of a Party by another entity by means of a transaction or series of related transactions (including without limitation, any reorganization, merger or consolidation) that results in
the transfer of fifty percent (50%)&nbsp;or more of the voting securities of such Party, (b)&nbsp;a sale of all or substantially all of the assets of a Party, or (c)&nbsp;the acquisition by any person or other entity (other than a Party and its
Affiliates or employee benefit plans), including any person or group as defined in Paragraphs 3(a)(9) and 13(d), 14(d) and Rule 13d-5 of the Exchange Act of more than fifty percent (50%)&nbsp;of the voting securities of such Party; provided however,
that no Change in Control shall occur by reason of (a)&nbsp;an initial public offering, or (ii)&nbsp;a reorganization, merger, consolidation, or sale, the sole purpose of which is to change the state of a Party&#146;s incorporation or to create a
holding company that will be owned in substantially the same proportions by the persons who held such Party&#146;s securities immediately before such transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.3 &#147;<U>Combination Use</U>&#148; means a Licensed Use (as defined below) that is sold together in combination with one (1)&nbsp;or more products, processes or services which are not Licensed Uses.
LICENSEE acknowledges that a Combination Use shall not include any product, process or service which is expressly excluded under this Agreement, including, but not limited to the exclusions specified in Section&nbsp;1.6. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4 &#147;<U>Development Term</U>&#148; means the twelve month period from the Effective Date until the one year anniversary of the
Effective Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5 &#147;<U>Effective Date</U>&#148; shall mean the date on which all of the following shall have first
occurred: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5.1 LICENSEE has entered into a mutually satisfactory Employment Agreement or other agreement with
Dr.&nbsp;Maher Albitar, and mutually satisfactory separate Consultant Agreements or other agreements with Dr.&nbsp;Stephen Barnhill, Dr.&nbsp;Herbert Fritsche, Dr.&nbsp;Isabelle Guyon, and Dr.&nbsp;Hong Zhang; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5.2 This Agreement has been approved in all respects by the respective Boards of Directors of LICENSOR and LICENSEE, and this
Agreement has been duly executed by officers of LICENSOR and LICENSEE, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6 &#147;<U>Field</U>&#148; or &#147;<U>Field of Use</U>&#148; shall mean the fields of
laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology, and digital image analysis, excluding non-pathology-related radiologic and photographic image analysis, relating to the development, marketing, production or sale of
any Laboratory Developed Tests or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast
cancer; provided, however, the manufacture and sale of IVD Test Kits for sales to third parties and the melanoma screening system and methods described in the patent applications listed in Exhibit D are specifically excluded from the Field or Field
of Use; and provided further that the foregoing exclusion of &#147;and breast cancer&#148; immediately prior to the first proviso of this section shall be in effect only so long as the License Agreement among and between LICENSOR, Smart Personalized
Medicine, LLC, and Quest Diagnostics, Inc. dated March&nbsp;11, 2010 is in full force and effect and Quest Diagnostics, Inc. is not in material breach of any its obligations under that agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7 &#147;<U>First Commercial Use</U>&#148; shall mean, with respect to any Licensed Use, the first sale for use or consumption by
medical or health care personnel or organizations of such Licensed Use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8 &#147;<U>IVD Test Kit</U>&#148; shall mean any
kit or instrument manufactured for sale to third parties, which includes reagents and other supplies that enables such third party purchasers to perform in vitro diagnostic tests on biological samples or any instrument used therewith; provided that,
any such IVD Test Kit must be approved by the U.S. Food and Drug Administration (&#147;FDA&#148;) for sales of the IVD Test Kit in the United States, or be approved by any other foreign regulatory bodies for sales of the IVD Test Kit in countries
other than the United States. Notwithstanding the foregoing, any instruments sold in conjunction with or pursuant to Licenses E and F described in Sections 1.12.4 and 1.12.5 are excluded from the definition of IVD Test Kit. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9 &#147;<U>Laboratory Developed Test</U>&#148; shall mean any test, process or procedure used to test or assay any type of patient
biological sample, the results of which would then normally be entered into the medical record of the patient providing such biological sample; provided, however, any test, process or procedure performed using an IVD Test Kit shall not be considered
to be a Laboratory Developed Test. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10 &#147;<U>Licensed Know-How</U>&#148; shall mean all information, materials, test
results, reports, biological samples, documentation, data and data compilations, and Computer Software (as used herein, &#147;<U>Computer Software</U>&#148; means and includes source code, object code and documentation and comments thereto) owned by
or licensed to LICENSOR as of the date of this Agreement or developed or acquired by the LICENSOR during the Term relating to the SVM Technology, the four (4)&nbsp;biomarkers identified in Exhibit B, a gene-based pancreatic cancer test, and
cytogenetics interpretation methods, algorithms and software, and any other Licensed Products or Licensed Uses which are not generally known including, but not limited to, formulae, procedures, protocols, techniques, and results of experimentation
and testing, which relate to or are useful or necessary to practice the inventions disclosed and/or claimed in the Licensed Patents (as defined below); all to the extent and only to the extent that LICENSOR has the right to grant licenses,
immunities or other rights thereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11 &#147;<U>Licensed Patents</U>&#148; shall mean, to the extent required or useful for
the development, use, production, manufacture, commercialization, sale, marketing or any other exploitation of any product, process or combination based on or relating to the SVM Technology or developed or identified using SVM Technology, those
issued patents and patent applications listed on <U>Exhibit A</U> hereto, including patents and patent applications covering the four (4)&nbsp;prostate cancer biomarkers identified in Exhibit B, and: (i)&nbsp;all patents that have issued or in the
future shall issue therefrom, including utility, model and design patents and certificates of invention; (ii)&nbsp;all divisionals, continuations, continuations-in-part, reissues, renewals, reexaminations, extensions or additions to any such patent
applications and patents to the extent that the patents and/or patent applications relate to or cover use of the SVM Technology within the Field or knowledge discovered using the SVM Technology; and (iii)&nbsp;all patents and/or patents
applications, including provisional applications and any patents or patent applications claiming priority thereto, which are filed subsequent to the Effective Date of this Agreement covering a gene-based pancreatic cancer test identified using the
SVM Technology and cytogenetics interpretation methods, algorithms and software developed using the SVM Technology . </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12
&#147;<U>Licensed Product&#148;</U> shall mean any product or service covered by the Licensed Technology in the Field including, but not limited to, the following products: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.12.1 &#147;<U>Plasma Prostate Cancer Test</U>&#148; shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in blood plasma for differentiating clinically
significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the
Plasma Prostate Cancer Test is identified as &#147;License B&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12.2 &#147;<U>Pancreatic Cancer Test</U>&#148; shall
mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in any type of biological sample for differentiating clinically significant pancreatic cancer from other pancreatic conditions, including without limitation
clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the Pancreatic Test is identified as &#147;License C&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12.3 &#147;<U>Colon Cancer Test</U>&#148; shall mean any Laboratory Developed Test using genes, gene products or other biomarkers for
differentiating clinically significant colon cancer from other colon conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license
granted for the Colon Cancer Test is identified as &#147;License D&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12.4 &#147;<U>Cytogenetics Interpretation
System</U>&#148; shall mean any interpretive software and related technology for computer-aided karyotype analysis for genetic screening and detection of chromosomal abnormalities. For reference purposes, the license granted for the Cytogenetics
Interpretation System is identified as &#147;License E&#148;. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12.5 &#147;<U>Flow Cytometry Interpretation System</U>&#148; shall mean interpretive
software and related technology for computer-aided analysis of flow cytometry tests. For reference purposes, the license granted for the Flow Cytometry Interpretation System is identified as &#147;License F&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12.6 &#147;<U>Urine Prostate Cancer Test</U>&#148; shall mean any Laboratory Developed Test using genes, gene products, or other
biomarkers present in urine samples for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD
Test Kits. For reference purposes, the license granted for the Urine Prostate Cancer Test is identified as &#147;License G&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.12.7 &#147;<U>Tissue Prostate Cancer Test</U>&#148; shall mean any Laboratory Developed Test using genes, gene products, or other biomarkers present in tissue samples for differentiating clinically
significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of IVD Test Kits. For reference purposes, the license granted for the
Tissue Prostate Cancer Test is identified as &#147;License H&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13 &#147;<U>Licensed Territory</U>&#148; or
&#147;<U>Territory</U>&#148; shall mean worldwide. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14 &#147;<U>Licensed Technology</U>&#148; shall mean, collectively, the
Licensed Patents and/or the Licensed Know-How. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15 &#147;<U>Licensed Use</U>&#148; shall mean a product, process or service,
for use in the Field, which if made, used, performed, offered for sale, sold, or imported in the Licensed Territory, would infringe a Valid Patent Claim but for the license granted by this Agreement. Except in connection with the calculation of
royalties pursuant to Section&nbsp;3.1 below, Licensed Use shall mean either an individual Licensed Use or Combination Use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16 &#147;<U>Net Revenue</U>&#148; shall mean any and all revenue recognized by LICENSEE from Licensed Uses, net of any contractual
discounts or allowances from third party payers and less any sales, use or other taxes specifically applied to such revenue, and less any shipping, insurance, or other costs to the extent such costs are broken out separately on any invoices for
revenue generated from Licensed Uses. For the avoidance of doubt, Net Revenue means that amount of revenue booked by LICENSEE under United States Generally Accepted Accounting Principles that specifically arises from Licensed Uses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.17 &#147;<U>Person</U>&#148; shall mean an individual, corporation, partnership, limited liability company, trust, business trust,
association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18 &#147;<U>Royalty Term</U>&#148; shall mean, with respect to each Licensed Use, the term for which a Valid Patent Claim remains in
effect which would be infringed by the manufacture, use, offer for sale, sale or import of such Licensed Use but for the license granted by this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19 &#147;<U>SVM Technology</U>&#148; shall mean all technology and ownership claims
related to support vector machines and other pattern-recognition algorithms (&#147;SVM&#148;), SVM-Recursive Feature Elimination (&#147;RFE&#148;), and Fractal Genomic Modelling (&#147;FGM&#148;) included in the Licensed Technology. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.20 &#147;<U>Third Party</U>&#148; shall mean any Person other than LICENSOR, LICENSEE and their respective Affiliates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.21 &#147;<U>Valid Patent Claim</U>&#148; shall mean either (a)&nbsp;a claim of an issued and unexpired patent included within the
Licensed Patents, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not
been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise or (b)&nbsp;a claim of a pending patent application included within the Licensed Patents, which claim was filed in good faith and has not been abandoned or
finally disallowed without the possibility of appeal or refiling of such application. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 2 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>GRANT OF LICENSES </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>License</U>. As of the Effective Date of this Agreement, LICENSOR hereby grants to LICENSEE and its Affiliates, and LICENSEE accepts the licenses under the Licensed Technology to exclusively use,
develop, make, have made, sell, offer to sell, modify, import and otherwise commercially exploit the Licensed Uses and the Licensed Products in the Licensed Territory including, but not limited to, as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) an exclusive license for the use of the SVM Technology and the Licensed Patents in the Field in the Licensed Territory relating to
Licensed Uses and Licensed Products; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) an exclusive license to the Licensed Know-How in the Field in the Licensed
Territory, including access to and use of the Computer Software that has been developed by or for LICENSOR or will be developed by or for the LICENSOR that may be applicable to Licensed Uses or Licensed Products; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3) an exclusive license for the use of Licensed Products in the Licensed Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Sublicense Rights</U>. LICENSEE may grant sublicenses under any of the licenses granted herein, to import, develop, make, have
made, use, modify, offer for sale, and/or sell Licensed Products within the Field. Any sublicense granted by LICENSEE under this Agreement will not be inconsistent with the terms and conditions of this Agreement. LICENSEE agrees to notify LICENSOR
in writing ten (10)&nbsp;days prior to entering into any sublicensing agreements with any Third Parties and such notice will include the name of such sublicensee and a summary of the material terms contemplated in such sublicensing agreement.
LICENSOR agrees that to the extent it has any concerns about the sublicensee or any of the proposed terms of such sublicensing agreement, it will notify LICENSEE of such concerns </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
within seven (7)&nbsp;days of receipt of LICENSEE&#146;s written notice. LICENSEE agrees that it take into consideration any such concerns raised by the LICENSOR in the final sublicense
agreement; provided, however, LICENSEE shall have the sole discretion as to the final terms of such sublicensing agreement. In the event that LICENSOR does not respond to LICENSEE&#146;s written notice within seven (7)&nbsp;days of receipt of such
notice, LICENSEE may presume that there are no material objections to the summary terms of the sublicense agreement and enter into such sublicense agreement without further coordination with LICENSOR. The Parties agree that any revenue recognized by
LICENSEE from any sublicensing agreement will be included in the calculation of Net Revenue for the purposes of this Agreement and will be taken into consideration for the payment of any Milestone Payments and royalties pursuant to Sections 3.3 and
3.4 below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3 <U>Best Efforts</U>. It is the intention of the Parties to commercialize those Licensed Products described in
Sections 1.12.1 &#150; 1.12.5 (the &#147;Initial Licensed Products&#148;) within the Development Term. LICENSEE shall use their best efforts to develop the Initial Licensed Products and have a First Commercial Use of products related to Licenses B,
C and D and enter into a sublicense agreement for the products related to Licenses E and F within the Development Term; provided, however, the Development Term of any of the Initial Licensed Products may be automatically renewed for up to two
(2)&nbsp;successive terms of one year each (each a &#147;Renewal Term&#148;) by the LICENSEE upon payment of a renewal fee of $5,000 per Renewal Term per Initial Licensed Product within thirty days of the end of the original Development Term or any
Renewal Term; provided further, however, that any Renewal Terms are included only as a precautionary measure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4
<U>Purchasing Rights</U>. In the event that LICENSOR grants a license to a Third Party to develop and sell any IVD Test Kit in the Licensed Territory relating to any hematopoietic or solid tumor cancers, LICENSOR shall use its best efforts to
include a provision in any such IVD Test Kit license agreement that guarantees the LICENSEE the right to purchase such IVD Test Kit, without restrictions on quantity, from the Third Party, at a price not to exceed such IVD Test Kit licensee&#146;s
direct cost of goods sold plus twenty percent (20%)&nbsp;irrespective of whether or not LICENSEE makes any purchase volume commitments; provided, however, in no event shall LICENSEE&#146;s price for any IVD Test Kit be higher than any other third
party purchaser of any such IVD Test Kits without regard to purchase volume commitments. Notwithstanding the foregoing, LICENSEE agrees that it will enter into a supplemental agreement with the IVD Test Kit licensee covering the terms of supply for
any such IVD Test Kit purchases and agrees that any purchases of such IVD Test Kits will be for its own use and LICENSEE shall not be permitted to sell any such IVD Test Kits to other disinterested Third Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5 <U>Loss of Exclusivity</U>. In the event that LICENSEE has not generated Five Million Dollars ($5,000,000) of aggregate Net Revenue
within five (5)&nbsp;years of the Effective Date of this Agreement, LICENSOR in its sole discretion may upon ninety (90)&nbsp;days written notice to Licensee, revoke LICENSEE&#146;s exclusivity under one or more of Licenses B, C, D, E, and F, as
identified in Section&nbsp;1.12 and make LICENSEE&#146;s rights non-exclusive with respect to the specified license(s). Notwithstanding the foregoing, LICENSOR agrees that to the extent LICENSEE has commercially launched any Licensed Products prior
to the time that LICENSOR attempts to revoke LICENSEE&#146;s exclusivity under a specified license, LICENSEE shall retain exclusive rights to such Licensed Products that have already had a First Commercial Use for the remainder of the Commercial
Term (as defined in Section&nbsp;4.2 below) for such Licensed Product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6 <U>Provision of Licensed Technology</U>. Within thirty (30)&nbsp;days of the Effective
Date of this Agreement, LICENSOR shall provide full copies of all Licensed Technology, including complete copies of all Computer Software, documentation and materials relating to the Licensed Patents and any Licensed Know-How, to LICENSEE.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 3 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>LICENSE FEES AND ROYALTY PAYMENTS </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Upfront License Fees and
Development Renewal Fees</U>. In partial consideration of the licenses granted herein, LICENSEE shall pay to LICENSOR as summarized below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:25pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>License</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Upfront</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Licensing<BR>Fee</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Development Term</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Renewal Fee</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A. SVM Technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. Plasma Prostate Cancer Test</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$5,000&nbsp;per&nbsp;Renewal&nbsp;Term</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">C. Pancreatic Cancer Test</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$5,000 per Renewal Term</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">D. Colon Cancer Test</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$5,000 per Renewal Term</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">E. Cytogenetics Interpretation System</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$5,000 per Renewal Term</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">F. Flow Cytometry Interpretation System</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$5,000 per Renewal Term</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All Other Licensed Products or Licensed Uses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent the portion of the consideration payable in shares of common stock of LICENSEE pursuant to Section&nbsp;3.2.2 below is less than or greater than $2.0
million of aggregate value as of the Effective Date of this Agreement, then the amount of the upfront License Fee allocable to the Plasma Prostate Cancer Test shall be adjusted by the amount of such difference. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Payment Terms</U>. In partial consideration of the licenses granted herein, LICENSEE shall pay to LICENSOR the Upfront License Fee
indicated for Licenses A-F indicated in Section&nbsp;3.1 above according to the following payment terms: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1 <U>Cash</U>.
Upon execution of this Agreement, One Million Dollars ($1,000,000). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.2 <U>Shares</U>. Upon execution of this Agreement,
One Million Three Hundred and Sixty Thousand shares (1,360,000)&nbsp;of LICENSEE&#146;S common stock, par value of $0.0001 per share. LICENSOR shall have piggyback registration rights for the stock received pursuant
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to this section for a period of two (2)&nbsp;years from the Effective Date of this Agreement. Commencing twelve months (12)&nbsp;after the Effective Date of this Agreement, LICENSOR shall be
entitled to demand registration rights if the provisions of Rule 144 are not available to LICENSOR for the immediate resale of any stock received from LICENSEE. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Milestone Payments</U>. In partial consideration for the licenses granted herein, LICENSEE shall pay to LICENSOR the below milestone payments (the &#147;Milestone Payments&#148;) within ninety
(90)&nbsp;days of the first date upon which LICENSEE has derived cumulative Net Revenue from all Licensed Uses covered by this Agreement (&#147;Cumulative Revenue&#148;) in the amounts indicated below at each such Cumulative Revenue threshold. Any
such payments may be made in cash or LICENSEE common stock, in LICENSEE&#146;s sole discretion, provided that any common stock issued by LICENSSE is freely tradable or will be within six (6)&nbsp;months pursuant to Rule 144. The share price used to
determine any shares issuable by LICENSEE will be the average closing price per share for the twenty (20)&nbsp;trading days prior to the time when such payment is made. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="80%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:67pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Cumulative&nbsp;Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone&nbsp;Payment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4 <U>Royalty Payments</U>. In partial consideration for the licenses granted herein, LICENSEE shall pay
to LICENSOR the following royalties after LICENSEE and its Affiliates have cumulatively generated Twenty Million Dollars ($20,000,000) of Net Revenue (the &#147;Royalty Threshold&#148;) and all Milestone Payments have been paid accordingly. All
royalties shall be due and payable on a quarterly basis and shall be submitted by LICENSEE along with the report as specified below within ninety (90)&nbsp;days of the end of the quarter which gave rise to any such royalty becoming due and payable.
The period in which royalties shall be due for each Licensed Use shall be from the later of (a)&nbsp;the date on which the Royalty Threshold has been reached, or (b)&nbsp;the date of First Commercial Use of any such Licensed Use and shall extend
until the end of the Royalty Term covering such Licensed Use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4.1 <U>Royalties for all Licensed Uses except for Licenses E
and F</U>. After the Royalty Threshold has been met, LICENSEE shall pay running royalties of six and one-half percent (6.5%)&nbsp;of Net Revenue generated by LICENSEE and its Affiliates per quarter for all Licensed Uses except for Licenses E and F
relating to the Cytogenetics Interpretation System and the Flow Cytometry Interpretation System. Notwithstanding the foregoing, any royalties due pursuant to this Section&nbsp;3.4.1 for Licensed Uses of a non-exclusive Licensed Product for which
LICENSOR has exercised its option to convert the license to a non-exclusive license pursuant to Section&nbsp;2.5 shall be reduced to three percent (3.0%)&nbsp;of Net Revenue from the non-exclusive
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Licensed Products. Royalties for Licensed Uses of all other Licensed Products not affected by a conversion to a non-exclusive license shall remain at the original six and one-half percent (6.5%).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4.2 <U>Royalties for Licenses E and F</U>. After the Royalty Threshold has been met and LICENSEE has recouped all of its
costs directly related to the commercialization of the Cytogenetics Interpretation System (License E) and the Flow Cytometry System (License F), LICENSEE shall pay a royalty of fifty percent (50%)&nbsp;of the Net Revenue it derives from any
sublicensing arrangements it has in place for such Licenses E and F. For the purposes of this Agreement, LICENSEE&#146;s costs directly relating to commercializing Licenses E and F shall not be offset against any Net Revenue from such licenses while
Milestone Payments are due and payable pursuant to Section&nbsp;3.1, but rather will be offset against Net Revenue derived from Licenses E and F after all Milestone Payments have been made. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B>3.5 <U>Payment Method</U>. Unless otherwise provided in this Agreement, all payments by LICENSEE to LICENSOR under this
Agreement shall be paid in United States dollars, and all such payments shall be made by check or wire transfer in immediately available funds to such address and/or account as LICENSOR shall designate before such payment is due.<B><I>
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B>3.6 <U>Exchange Control</U>. If at any time legal restrictions prevent the prompt remittance of part or
all royalties with respect to any country where a Licensed Use is sold, payment shall be made through such lawful means or methods as LICENSOR and LICENSEE shall reasonably determine.<B><I> </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B>3.7 <U>Reports, Exchange Rates</U>. During the term of this Agreement following the First Commercial Use of a Licensed Use,
LICENSEE shall furnish to LICENSOR a quarterly written report showing in reasonably specific detail, (a)&nbsp;the gross sales of each Licensed Use sold by LICENSEE and its Affiliates during the reporting period and the calculation of Net Revenue
from such gross sales; (b)&nbsp;the royalties payable in United States dollars, if any, which shall have accrued hereunder based upon Net Revenue of each Licensed Use; (c)&nbsp;the withholding taxes, if any, required by law to be deducted in respect
of such sales; (d)&nbsp;the date of the First Commercial Use of each Licensed Use in each country during the reporting period; and (e)&nbsp;the exchange rates used in determining the amount of United States dollars. With respect to sales of Licensed
Uses invoiced in United States dollars, the gross sales, Net Revenues, and royalties payable shall be expressed in United States dollars. With respect to sales of Licensed Uses invoiced in a currency other than United States dollars, the gross
sales, Net Revenue and royalties payable shall be expressed in the domestic currency of the Person making the sale together with the United States dollar equivalent of the royalty payable, calculated using the average closing buying rate for such
currency quoted in the continental terms method of quoting exchange rates (local currency per US$1) by the Wall Street Journal on the last business day of each month in the calendar quarter prior to the date of payment. Reports shall be due not
later than the ninetieth (90th)&nbsp;day following the close of each reporting period. LICENSEE shall keep and require its Affiliates to keep complete and accurate records in sufficient detail to properly reflect all gross sales and Net Revenue and
to enable the royalties payable hereunder to be determined. For the purposes of this Section&nbsp;3.7, gross sales of any Laboratory Developed Tests shall be calculated as the amount of revenue expected to be collected on such gross sales after all
contractual discounts and allowances from third party payers, and not the gross amounts billed to such third party payers.<B><I> </I></B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.8 <U>Audits</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.8.1 Upon the written request of LICENSOR and not more than once in each calendar year, LICENSEE shall permit an independent certified public accounting firm, provided such accounting firm signs a
confidentiality agreement reasonably acceptable to LICENSEE, selected by LICENSOR and reasonably acceptable to LICENSEE, at LICENSOR&#146;s expense, to have access during normal business hours to such of the records of LICENSEE as may be reasonably
necessary to verify the accuracy of the royalty reports hereunder for any year ending not more than twenty-four (24)&nbsp;months prior to the date of such request. The accounting firm shall disclose to LICENSOR only whether the records are correct
or not and the details concerning any specific discrepancies. No other information shall be shared. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.8.2 If such accounting
firm concludes that additional royalties were owed during such period, LICENSEE shall pay the additional royalties within ninety (90)&nbsp;days of the date LICENSOR delivers to LICENSEE such accounting firm&#146;s written report documenting the
royalty underpayment; provided, however, if LICENSEE disputes any of the accounting firm&#146;s findings in good faith, LICENSEE and LICENSOR shall work in good faith to determine the appropriate additional royalties due. The fees charged by such
accounting firm shall be paid by LICENSOR; <U>provided</U>, <U>however</U>. if the audit discloses that the royalties payable by LICENSEE for the audited period are more than one hundred ten percent (110%)&nbsp;of the royalties actually paid for
such period, and the difference between royalties payable and royalties paid is greater than Fifty Thousand Dollars ($50,000), then LICENSEE shall pay the reasonable fees and expenses charged by such accounting firm. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9 <U>Confidential Financial Information</U>. LICENSOR shall treat all financial information subject to review under this Article 3 as
Confidential Information pursuant to Article 7 below, and shall cause its accounting firm to retain all such financial information in confidence. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 4 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>TERM OF LICENSE AND COMMERCIAL TERM FOR LICENSED USES
</U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 Term. This Agreement shall commence on the Effective Date and, except as otherwise provided herein, shall remain in
effect from the Effective Date to the expiration of the last of the Licensed Patents licensed hereunder, unless earlier terminated pursuant to Article 8 hereof ( the &#147;Term&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>Commercial Term for each Licensed Use</U>. After the First Commercial Use of any Licensed Product hereunder, the term of the
license with respect to such Licensed Product shall extend until one (1)&nbsp;year after the expiration of the patent life of each of the Licensed Patents covering such Licensed Product, unless sooner terminated as provided herein (such term for
each Licensed Product, the &#147;Commercial Term&#148; for such Licensed Product). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 5 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>WARRANTIES AND NEW LICENSES </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">LICENSOR hereby represents and warrants to
LICENSEE as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Corporate Existence and Power</U>. LICENSOR (a)&nbsp;is a corporation duly organized, validly
existing and in good standing under the laws of the State of Georgia; (b)&nbsp;has the requisite power and authority and the legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to
carry on its business as it is now being conducted; and (c)&nbsp;is in compliance with all requirements of applicable law, except to the extent that any noncompliance would not have a material adverse effect on the properties, business, financial or
other condition of it and would not materially adversely affect its ability to perform its obligations under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Authorization and Enforcement of Obligations</U>. LICENSOR (a)&nbsp;has the requisite power and authority and the legal right to
enter into this Agreement and to perform its obligations hereunder; and (b)&nbsp;has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This
Agreement has been duly executed and delivered on behalf of LICENSOR, and constitutes a legal, valid, binding obligation, enforceable against LICENSOR in accordance with its terms, except to the extent that such enforcement may be limited by
bankruptcy, insolvency, moratorium or other laws affecting creditors&#146; rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Prosecution of Patents</U>.
LICENSOR has taken and shall use it best efforts to undertake all actions necessary for prosecution and maintenance of the Licensed Patents, including prosecution of all patent applications, payment of maintenance, annuity, and renewal fees as
required by the respective national, international or regional patent offices that issued the patents, and payment of all attorney fees and costs for prosecution, maintenance, and grant of any pending patent applications. LICENSEE may suggest
specific countries in which it believes patent protection may be of value in view of its marketing strategy for the Licensed Products, however, selection of countries and/or regions for future international and national stage patent filings of
Licensed Patents shall be within the sole discretion of LICENSOR. However, if LICENSEE wishes to pursue patent protection in a country or region in which LICENSOR has elected not to file, LICENSEE may request that LICENSOR pursue such patent
protection at LICENSEE&#146;s expense, which shall include all prosecution costs and maintenance fees. LICENSOR shall further have sole discretion in determining whether a particular patent or patent application has ceased to be of sufficient
business value to warrant incurring additional prosecution and maintenance fees and costs, but shall notify LICENSEE of LICENSOR&#146;s intention to allow the particular patent or patent application to lapse at least thirty days (30)&nbsp;prior to
irretrievable abandonment so that LICENSEE may request that the patent or patent application be kept in force at LICENSEE&#146;s expense. Any costs associated with patent prosecution and/or maintenance requested by LICENSEE after LICENSOR has given
notice of its intent to forego patent rights or allow the patent or patent application to lapse will be borne by the LICENSEE. Notwithstanding anything in this Agreement to the contrary, as to any Licensed Patent which LICENSOR elects not to pursue,
file, continue prosecuting or maintain in the United States, but which LICENSEE chooses have LICENSOR pursue, file, continue prosecuting or maintain and for which LICENSEE pays the preparation and/or prosecution costs and/or maintenance fees,
LICENSEE shall have the authority to control the preparation and/or prosecution and/or maintenance thereof, and LICENSOR shall assign all rights, title and interest in and to any such Licensed Patents to LICENSEE, provided however, to the extent
that any prosecution is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
controlled by LICENSEE, any arguments or positions taken during such prosecution may not impair the scope or construction of any Licensed Patent to which LICENSOR has retained the rights.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4 <U>Title; Recordation; Validity</U>. LICENSOR owns all rights, title and interests in and to the Licensed Technology free
and clear of any liens, encumbrances or third party rights, and LICENSOR has obtained and recorded or has undertaken efforts to record, duly executed assignments of the Licensed Technology as necessary to perfect all rights, title and interests
therein, in accordance with governing law and regulations in each respective jurisdiction. LICENSOR is aware of no basis for a claim of invalidity or unenforceability of any of the Licensed Technology. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5 <U>Noncontravention; Existing Licenses</U>. There are no existing agreements, commitments, proposals, offers, or rights with, to, or
in any person to acquire any of the rights under the Licensed Technology that would prevent, alter, or hinder the performance of LICENSOR&#146;s obligations hereunder. Licenses previously granted to the Third Parties listed in Exhibit C will not
interfere with LICENSOR&#146;s obligations or LICENSEE&#146;s rights hereunder within the Field. There are no other licensees of the Licensed Technology, except for the parties and licenses specified in and described in Exhibit C. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6 <U>Exclusions</U>. LICENSOR expressly excludes any further representations, conditions and warranties that, except as otherwise
provided in Section&nbsp;10.4 below, any development, manufacture, use, importation, sale, lease, or other disposal of any Licensed Product will not infringe any patent, trademark, copyright, trade secret or other intellectual property right not
owned by or licensed to LICENSOR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7 <U>New Licensees</U>. LICENSOR agrees that it will notify LICENSEE promptly in writing
in the event that it enters into any additional licenses for the Licensed Technology; provided, however, that such additional licenses will not contravene the terms of or LICENSEE&#146;s rights under this Agreement under any circumstances without
the express written consent of the LICENSEE prior to the time any such additional license is granted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8 <U>Patent
Expiration Dates</U>. The Licensed Patents which have been granted as of the Effective Date shall each expire on the respective dates indicated in Exhibit A unless, with respect to those patent applications marked with &#147;+PTA&#148; in Exhibit A,
the date indicated is extended by patent term adjustment or extension, in which case LICENSOR shall immediately notify LICENSEE of the corrected expiration date in writing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 6 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>PATENTS </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Patent Prosecution and Maintenance</U>. LICENSOR shall be responsible for and shall have the right to control the preparation,
filing, prosecution and maintenance of the Licensed Patents and shall be responsible for paying all costs thereof. To the extent that LICENSOR holds exclusive rights encompassing the Field, but does not exclusively own any portion of the Licensed
Patents, LICENSOR shall make all reasonable efforts to ensure that the Licensed Patents are maintained. LICENSOR shall provide LICENSEE with a copy of each </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patent application subject to this Section&nbsp;9.1. In the event that LICENSOR is unable or unwilling to maintain any one or more of the Licensed Patents, it will promptly notify LICENSEE of any
payment that is due with a description of how it relates to the Licensed Patents hereunder. LICENSEE, in its sole discretion, may pay the fees and costs for maintaining the indicated patents or patent applications within Licensed Patents and deduct
such payment from any amounts owed by LICENSEE to LICENSOR under this Agreement. LICENSOR shall notify LICENSEE before any Licensed Patents terminate with sufficient time to permit LICENSEE to take action to maintain the patent, if it so chooses.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>Enforcement of Patent Rights</U>. LICENSOR shall enforce the Licensed Technology and prosecute any infringers, at its
sole expense, when it is in the best interests of LICENSOR and LICENSEE to do so. LICENSEE shall cooperate with LICENSOR in the planning and execution of any action to enforce the Licensed Patents. LICENSOR shall not settle the suit in a manner that
diminishes or affects the rights or interests of LICENSEE without the express written consent of LICENSEE. If LICENSOR declines to litigate any infringement of the Licensed Technology, LICENSOR shall give LICENSEE the right, to the extent
permissible by law, but not the obligation, to bring actions to enforce the Licensed Technology or otherwise abate the infringement thereof and to control any litigation or other enforcement action. LICENSOR shall cooperate with LICENSEE in the
planning and execution of any action to enforce the Licensed Patents. LICENSEE shall not settle the suit in a manner that diminishes or affects the rights or interests of LICENSOR without the express written consent of LICENSOR. The costs of any
such action by LICENSEE shall be borne by LICENSEE, and LICENSEE shall be entitled to keep any recovery, settlement or other costs or recoveries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Improvements</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.1 LICENSEE shall disclose to LICENSOR any and all
improvements made by or on behalf of LICENSEE directly related to the Licensed Technology that are conceived or reduced to practice by or on behalf of LICENSEE as a result of activities engaged in pursuant to the terms of this Agreement
(&#147;Licensee Improvements&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.2 LICENSOR shall disclose to LICENSEE any and all improvements made by or on behalf
of LICENSOR (&#147;Licensor Improvements&#148;) related to the Licensed Technology that are conceived or reduced to practice by or on behalf of LICENSOR during the Term of this Agreement. LICENSEE acknowledges, however, that LICENSOR has granted
other licenses to third party(ies) for use of the Licensed Technology to the parties described in Exhibit C and, further that certain Licensor Improvements to the Licensed Technology, although they may be of benefit to LICENSEE, may arise in
conjunction with such third party licenses. In such cases, disclosure of such Licensor Improvements may be restricted or prohibited, or disclosure to LICENSEE may be delayed due to LICENSOR&#146;s obligations under the third party license. In such
cases, to the extent permitted, LICENSOR will disclose the Licensor Improvement as soon as practicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.3 LICENSEE shall
not publish or disclose Licensor Improvements to third parties or to the public through any communication including, but not limited to, academic publication or other exchanges of information except as provided in Article 7 and shall not so publish
or disclose without first providing the LICENSOR with the opportunity to review the communication and to make arrangements for protecting such Licensor Improvements by patent </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or other appropriate means prior to disclosure. Similarly, LICENSOR shall not publish or disclose Licensee Improvements to third parties or to the public through any communication including, but
not limited to, academic publication or other exchanges of information except as provided in Article 7 and shall not so publish or disclose without first providing the LICENSEE with the opportunity to review the communication and to make
arrangements for protecting such Licensee Improvements by patent or other appropriate means prior to disclosure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.4 All
Licensor Improvements shall be owned by LICENSOR. LICENSEE agrees to provide any assistance and take such acts as are reasonably requested by LICENSOR, at LICENSOR&#146;s expense, to enable LICENSOR to obtain a letters patent for or respecting any
Licensor Improvement, to protect such patent right, to conduct further research and to publish. For purposes of this Agreement, Licensor Improvements shall include all Licensed Know-How, information, patents and/or patent applications, including
provisional applications and any patents or patent applications claiming priority thereto, which are filed by LICENSOR subsequent to the Effective Date of this Agreement covering any of the Initial Licensed Products in which the Licensed Technology
is or was used, and any methods, algorithms and software related thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.5 Subject to 6.3.4 above, all Licensee
Improvements, and all improvements to the Licensed Technology which are jointly made by LICENSOR and LICENSEE (which shall also be included within &#147;Licensee Improvements&#148;), shall be owned by LICENSEE; provided that, LICENSEE shall not own
any Licensed Technology. LICENSOR shall provide any assistance and take such acts as are reasonably requested by LICENSEE, at LICENSEE&#146;s expense, to enable LICENSEE to obtain a letters patent for or respecting any Licensee Improvement, to
protect such patent right, to conduct further research and to publish. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.6 All Licensor Improvements shall automatically
become subject to the license granted in Section&nbsp;2.1 above and any patent rights therein shall be deemed to be Licensed Patents for the purposes of this Agreement, subject to the same rights and obligations applicable to Licensed Technology
under the Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.7 All jointly made Licensee Improvements shall become subject to a grant-back from LICENSEE to
LICENSOR of a non-exclusive, sublicensable, worldwide license to make, have made, use, perform, sell or offer for sale any such jointly made Licensee Improvements outside of the Field, subject to a commercially reasonable royalty and all other
customary license provisions to be negotiated in good faith by the parties. Notwithstanding the foregoing, and except as provided for in Section&nbsp;6.3.4, LICENSOR understands and acknowledges that any work performed pursuant to the Employment
Agreement and the Consulting Agreements described in the preamble to this Agreement in the Field shall be &#147;work made for hire&#148; and will be owned solely by and assigned to the LICENSEE. LICENSEE understands and acknowledges that
LICENSOR&#146;s development obligations under preexisting licenses identified in Exhibit C may preempt certain claims of ownership by LICENSEE pursuant to this Section&nbsp;6.3.7. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Limited Power of Attorney</U>. LICENSOR grants to LICENSEE a conditional, limited power of attorney for purposes of maintaining
the Licensed Patents as provided in Section&nbsp;6.1 above or enforcing any patent rights of the Licensed Patents as provided in Section&nbsp;6.2 above, but only to the extent permitted by law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 7 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>CONFIDENTIALITY </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Confidential Information</U>. Except as otherwise
provided in Section&nbsp;7.2 below, during the term of this Agreement, and for a period of ten (10)&nbsp;years following the expiration or earlier termination hereof, each Party shall maintain in confidence all information of the other Parties
disclosed after the Effective Date by the other Party and identified as, or acknowledged to be, confidential (the &#147;Confidential Information&#148;), and shall not use, disclose or grant the use of the Confidential Information to any Third Party
except on a need-to-know basis to those of its own, and its Affiliates&#146;, and assignees&#146;, directors, officers, affiliates, employees, agents, consultants, clinical investigators and contractors, to the extent such disclosure is reasonably
necessary in connection with such Party&#146;s activities as expressly authorized by this Agreement. To the extent that disclosure is authorized by this Agreement, prior to disclosure, each Party hereto shall obtain written agreement of any such
Third Party Person to hold in confidence and not make use of the Confidential Information for any purpose other than those permitted by this Agreement. Each Party shall notify the other Parties promptly upon discovery of any unauthorized use or
disclosure of the other Party&#146;s Confidential Information </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Permitted Disclosures</U>. The confidentiality
obligations contained in Section&nbsp;7.1 of this Agreement shall not apply to the extent that (a)&nbsp;any receiving Party (the &#147;Recipient&#148;) is required (i)&nbsp;to disclose information by law, order or regulation of a governmental agency
or a court of competent jurisdiction, or (ii)&nbsp;to disclose information to any governmental agency for purposes of obtaining approval to test or market a Product, provided in either case that the Recipient shall provide written notice thereof to
the other Parties and sufficient opportunity to object to any such disclosure or to request confidential treatment thereof; or (b)&nbsp;the Recipient can demonstrate that (i)&nbsp;the disclosed information was public knowledge at the time of such
disclosure to the Recipient, or thereafter became public knowledge, other than as a result of actions or inaction of the Recipient in violation hereof; (ii)&nbsp;the disclosed information was rightfully known by the Recipient (as shown by its
written records) prior to the date of disclosure to the Recipient by any other Party hereunder; or (iii)&nbsp;the disclosed information was disclosed to the Recipient on an unrestricted basis from a source unrelated to any Party to this Agreement
and not under a duty of confidentiality to any other Party, or (iv)&nbsp;the disclosed information was independently developed by Recipient without use of any Confidential Information of the disclosing Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.1 Each Party acknowledges that the other Party has certain time-critical reporting obligations by virtue of its status as a public
corporation and agrees to cooperate in preparation of a joint press release regarding the execution and general terms of this Agreement to be issued concurrently with a Form 8-K report that must be filed with the SEC by each Party within four
(4)&nbsp;business days of the Effective Date. The Parties further agree that once they have mutually agreed upon descriptive language that describes the material terms of this Agreement, either Party may continue to use such descriptive language in
its future SEC filings or other investor communications so long as such future communications are not materially different than what was previously agreed upon. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3 <U>Equitable Relief</U>. Each Party hereby acknowledges that, in the event of any breach
or threatened breach of this Article 7 by the Recipient, the disclosing Party may suffer irreparable injury for which damages at law may not be an adequate remedy. Accordingly, without prejudice to any other rights and remedies otherwise available
to the disclosing Party, the disclosing Party shall be entitled to seek equitable relief, including injunctive relief and specific performance, for any breach or threatened breach of this Article 7 by the Recipient, its Affiliates, or any of its or
their employees, directors, officers, members, agents, or representatives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4 <U>Non-Use of Names; Confidentiality of
Agreement</U>. No Party hereto shall make any public announcement, issue any press release or publish any study (collectively, all such communications, &#147;Publication&#148;) concerning the transactions contemplated herein, or make any Publication
which includes the name of any other Party or any of its Affiliates, or otherwise use the name or names of any other Party or any of their employees or any adaptation, abbreviation or derivative of any of them, whether oral or written, related to
the terms, conditions or subject matter of this Agreement, without the prior written permission of such other Party, except as may be required by (i)&nbsp;law or (ii)&nbsp;judicial order (and then only following consultation with any other Party) or
as may be agreed to pursuant to Section&nbsp;7.2.1 hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5 <U>Compliance with Laws; Reporting Obligation with Respect to
Protected Health Information</U>. Each Party shall comply with all Applicable Laws. &#147;Applicable Laws&#148; are the international, federal, state, and local laws, rules and regulations that relate to the conduct of the Parties&#146; business and
the performance by the Parties of their respective rights and obligations under this Agreement. If a Party or its permitted representatives gain access to protected health information (&#147;PHI&#148;), as that term is defined under The Health
Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), that is not required for performance of this Agreement, each Party shall immediately report to the other Parties any incidents of access to PHI or any incidents of use,
reproduction or disclosure of PHI of which it or its Permitted Representatives become(s) aware. Each Party shall enter into a Business Associates Agreement covering any PHI upon the reasonable request of the other Party. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 8 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>TERMINATION </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.1 <U>Normal Termination</U>. Except as otherwise provided herein, unless terminated earlier as hereinafter provided, and subject to the provisions of Section&nbsp;8.3 of this Article, this Agreement
shall terminate on upon the expiration of the last of the Licensed Patents licensed hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Surviving
Obligations</U>. The termination of this Agreement shall not relieve LICENSEE of any obligation hereunder to keep records nor shall such termination relieve LICENSEE of </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">any liability hereunder for damages resulting from the unauthorized disclosure or use of any Confidential Information by a party, or other party or person affiliated
therewith; or </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">LICENSEE&#146;s obligations to </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">make payment of any sum due to LICENSOR pursuant to Article 3, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">furnish written reports as provided in Article 3. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The termination of this Agreement shall not terminate LICENSOR&#146;s rights under Article 3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.3 <U>Termination by LICENSOR</U>. Effective immediately upon LICENSOR giving to LICENSEE written notice of termination, LICENSOR shall have the right to terminate this Agreement, or the licenses granted
hereunder, without prejudice to any other rights it may have, whether under the provisions of this Agreement, in law, in equity or otherwise, if LICENSEE fails to cure a material default within sixty (60)&nbsp;calendar days from receipt of written
notice to LICENSEE by LICENSOR. Notwithstanding the foregoing, if the subject matter of the material default described in such written notice from LICENSOR is the subject of a mediation or arbitration as described in Article 12 at the end of such
sixty (60)&nbsp;day notice period, then LICENSOR agrees that it will not terminate this Agreement for such material default until such time as the mediation or arbitration has been concluded and only if an agreement to resolve such material default
has not been reached as a result of such mediation or arbitration. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 9 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ASSIGNABILITY </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.1 This Agreement and the rights or licenses herein granted to LICENSEE, shall be freely assignable or otherwise transferable, in whole or in part, by the LICENSEE, in the LICENSEE&#146;s sole
discretion, upon written notice to the LICENSOR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 LICENSOR may assign this Agreement in the event of the sale of that
portion of its business to which this Agreement pertains or as may be required in connection with a Change of Control upon written notice to LICENSEE. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 10 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>APPLICABLE LAW, LIMITATION OF DAMAGES AND LIABILITY, AND INDEMNITY
</U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Applicable Law</U>. This Agreement is acknowledged to have been made in and shall be construed in accordance with
the laws of the State of Florida without regard to the principles thereof relating to the conflict of laws, provided that all questions concerning the construction or effect of patent applications and patents shall be decided in accordance with the
laws of the country in which the particular patent application or patent concerned has been filed or granted, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>10.2 <U>Limitation of Damages and Liability</U>. <B>EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, IN NO EVENT SHALL EITHER </B></FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXTRAORDINARY, OR CONSEQUENTIAL DAMAGES, OR DAMAGES FOR LOSS OF PROFITS, REVENUE, DATA OR USE, INCURRED BY EITHER PARTY
OR ANY THIRD PARTY, WHETHER IN AN ACTION IN CONTRACT OR TORT, EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR ITS INDEMNIFICATION OBLIGATIONS UNDER SECTION 10.4 BELOW, LICENSOR&#146;S LIABILITY FOR DAMAGES
HEREUNDER SHALL IN NO EVENT EXCEED THE AMOUNT OF FEES PAID BY LICENSEE UNDER THIS AGREEMENT. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3 <U>Indemnification by
LICENSEE</U>. LICENSEE shall indemnify and hold LICENSOR harmless from all losses, liabilities, damages and expenses (including reasonable attorneys&#146; fees and costs) incurred by LICENSOR as a result of any successful Third Party claim, demand,
action or other proceeding arising directly out of the use or sale of any Licensed Use by LICENSEE or its Affiliates, or their respective distributors, customers or end-users. If LICENSEE proposes to seek indemnification from the LICENSOR under the
provisions of this Section&nbsp;10.3, it shall notify the LICENSOR in writing within thirty (30)&nbsp;days of receipt of notice of any such claim or suit. LICENSOR shall have the right but not the obligation to participate in the defense of such
claim, and the parties shall mutually agree upon counsel and monetary settlement terms with respect to any such claim. Each Party agrees to promptly make arrangements to pay for any legal fees pursuant to the foregoing indemnification provisions
during the pendency of any Third Party claim, demand, action or other proceeding giving rise to the claim for indemnification. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4 <U>Indemnification by LICENSOR</U>. LICENSOR shall indemnify and hold LICENSEE harmless from all losses, liabilities, damages and
expenses (including reasonable attorneys&#146; fees and costs) incurred by LICENSEE as a result of any Third Party claim, demand, action or other proceeding related to breach by LICENSOR of the warranties set forth in Article 5, or any legal action
filed in any court based upon the allegation that LICENSEE&#146;s use of the Licensed Technology infringes upon such Third Party&#146;s intellectual property rights. Indemnification by LICENSOR shall not include any allegation of infringement by a
Licensed Product used or sold by LICENSEE or its Affiliates to the extent that the element or feature of the Licensed Product that is alleged to be in breach of warranty or infringing is unrelated to the Licensed Technology. If LICENSEE proposes to
seek indemnification from the LICENSOR under the provisions of this Section&nbsp;10.4, it shall notify the LICENSOR in writing within thirty (30)&nbsp;days of receipt of notice of any such claim or suit. LICENSOR shall have the right but not the
obligation to participate in the defense of such claim, and the parties shall mutually agree upon counsel and monetary settlement terms with respect to any such claim. LICENSOR agrees to promptly make arrangements to pay for any legal fees pursuant
to the foregoing indemnification provisions during the pendency of any Third Party claim, demand, action or other proceeding, giving rise to the claim for indemnification. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 11 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>FORCE MAJEURE </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1 Neither Party shall be responsible to the other for
delay or failure in performance of any of the obligations imposed by this Agreement, provided such delay or failure shall be occasioned by a cause beyond the control of and without the fault or negligence of such Party, including fire, flood,
explosion, lightning, windstorm, earthquake, subsidence of soil, failure of machinery or equipment or supply of materials, discontinuity in the supply of power, court order or governmental interference, civil commotion, riot, war, terrorism or
terrorist threats, strikes, labor disturbances, transportation difficulties or labor shortage. Notwithstanding the aforesaid, if either Party fails to a substantial extent for at least three (3)&nbsp;months to fulfill any of its obligations under
this Agreement, the other Party may terminate the Agreement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 12 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>DISPUTE RESOLUTION </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Alternative Dispute Resolution</U>. In the event that a dispute arises between the Parties, the following procedures shall be followed: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) <U>Negotiations</U>. In the event that any dispute may arise, the Parties shall first seek to resolve such disputes by negotiation
among the Parties, as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notification. When a Party believes there is a dispute relating to the Agreement, the Party will give the other Party written notice of the dispute.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Meeting Among Parties. The Parties shall meet at a mutually acceptable time and place within thirty (30)&nbsp;days after the date of the notice to exchange relevant
information and to attempt to resolve the dispute. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality. All negotiations shall be confidential and shall be treated as compromise and settlement negotiations under the United States Federal Rules of
Evidence. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) <U>Mediation</U>. If the dispute has not been resolved within thirty (30)&nbsp;days after the
date of the notice of a dispute, or if the Party receiving such notice fails or refuses to meet within such time period, either Party may initiate mediation of the dispute by sending the other Party a written request that the dispute be mediated.
The Party receiving such a written request will promptly respond to the requesting Party so that the Parties can jointly select a neutral and impartial mediator and schedule the mediation session. The Parties shall use their best efforts to mediate
the dispute before a neutral, third-party mediator within thirty (30)&nbsp;days after the date of the written request for mediation. The costs of such mediation shall be borne equally between the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Arbitration</U>. If the Parties have not succeeded in mediating a resolution of the dispute pursuant to Section&nbsp;12.1 above,
the Parties agree to resolve the dispute through binding arbitration. The arbitration shall be conducted by a board of three (3)&nbsp;arbitrators (or one arbitrator if both Parties agree) in Jacksonville, Florida, in accordance with generally
accepted arbitration procedures, but need not be limited to administration by or the rules of a specific organization such as the American Arbitration Association (&#147;AAA&#148;) or JAMS. The arbitrators
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall be selected by the mutual agreement of both Parties, or failing such agreement, shall be selected according to the applicable arbitration rules and organization. Each Party shall bear its
own expenses, but those related to the compensation and expenses of the arbitrators and the arbitration shall be shared equally by the Parties. Any arbitration award shall be final and shall be enforceable in any court of competent jurisdiction.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 13 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>MISCELLANEOUS PROVISIONS </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1 The parties agree that the Licensed
Technology is &#147;intellectual property&#148; as defined in 11 U.S.C. &#167;101(56) and that this Agreement is an executory contract that is governed by 11 U.S.C. &#167;365(n) in the event that LICENSOR commences a case under the Bankruptcy Code.
In any such case, the parties agree that LICENSEE will retain and may fully exercise all of its rights and elections under the Bankruptcy Code, and that LICENSEE will have the right to retain and enforce its rights under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 LICENSOR and LICENSEE each has all necessary corporate power to enter into and perform its obligations under this Agreement and has
taken all necessary corporate action under its respective certificates of incorporation and by-laws to authorize the execution and consummation of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.3 Notwithstanding any other provision of this Agreement to the contrary, LICENSOR shall not be required to grant any additional right with respect to the Licensed Patents or furnish information as to
which LICENSOR will incur financial or other liability to a third party, and no information shall be required to be furnished over governmental prohibition or objection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.4 The use and disclosure of technical information acquired pursuant to this Agreement and the exercise of the rights granted by this Agreement shall be subject to the export, assets and financial
control regulations of the United States of America including restrictions under regulations of the United States that may be applicable to direct or indirect re-exportation of such technical information or of equipment, Licensed Products or
services directly produced by use of such technical information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5 No license or right is granted by implication or
otherwise with respect to any patent application, patent, trademark or copyright of either Party except as specifically set forth herein. No right is granted by this Agreement to use any registered or unregistered trademark or trade name of either
Party to the other Party, and neither Party shall use any registered or unregistered trademark or trade name of the other Party without such Party&#146;s written consent. Notwithstanding the foregoing, each Party is authorized to name the other
Party in any filings that may be required with the Securities and Exchange Commission or any other governmental organization. Each Party further agrees that it shall coordinate with the other Party with respect to any press releases it may issue
with respect to this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6 The rights and remedies provided in this Agreement are cumulative and not exclusive of
any rights or remedies provided by law or in equity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7 This Agreement embodies the entire understanding of the Parties and shall supersede all
previous communications, representations, undertakings or agreements, between them, either verbal or written, relating to the subject matter hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.8 <U>Amendments</U>. No amendment, alteration or modification of any of the provisions of this Agreement will be binding unless made in writing and signed by the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.9 <U>Notice</U>. All notices, requests, and other communications to any Party hereto shall be in writing and shall be addressed to the
receiving Party&#146;s address set forth in the preamble to this Agreement or to any other address as a Party may designate by notice hereunder, and shall either be (1)&nbsp;delivered by hand, (2)&nbsp;sent by recognized overnight courier, or
(3)&nbsp;by certified mail, return receipt requested, postage prepaid. All notices, requests, and other communication hereunder shall be deemed effective: (a)&nbsp;if by hand, at the time of the delivery thereof to the receiving Party at the address
of such Party set forth above, (b)&nbsp;if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (c)&nbsp;if sent by certified mail, five (5)&nbsp;business days following the day
such mailing is made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.10 <U>Further Assurances</U>. Each Party agrees, upon written request of the other Party, to do all
acts and execute, deliver and perform all additional documents, instruments and agreements,&nbsp;which may be reasonably required by the requesting Party to implement the provisions and purposes of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.11 <U>Severability</U>. If any part of this Agreement is declared invalid or unenforceable by any court of competent jurisdiction,
such declaration shall not affect the remainder of the Agreement and the invalidated provision shall be revised in a manner that will render such provision valid while preserving the parties&#146; original intent to the maximum extent possible.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.12 <U>Successors</U>. This Agreement shall be binding upon and inure to the benefit of the successors, permitted assignees
and personal representatives of the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.13 <U>Insurance</U>. Each Party shall name the other as additional insured on
their applicable liability insurance policies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.14 <U>Counterparts</U>. This Agreement may be executed in two counterparts
or by facsimile or Adobe Acrobat PDF file, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>[Signatures Appear on the Following Page] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Parties have executed this Agreement and have entered the Effective
Date on the first page hereof. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">HEALTH DISCOVERY CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven Barnhill, M.D.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairmen and CEO</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2012</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">NEOGENOMICS LABORATORIES, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Douglas M. VanOort</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairmen and CEO</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/12</FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A - Licensed Patents </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patent/Application No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date/</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Issue Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expires</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,128,608</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery Using Multiple Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-1999/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-03-2000</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,157,921</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery Using Support Vector Machines in a Distributed Network Environment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-1999/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12-05-2000</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,427,141</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-09-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">07-30-2002</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,658,395</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12-02-2003</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,714,925</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">System for Identifying Patterns in Biological Data Using a Distributed Network.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">03-30-2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,760,715</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Biological Knowledge Discovery Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">07-06-2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,789,069</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method of Identifying Patterns in Biological Systems and Method of Uses.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-07-2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">04-13-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,882,990</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method of Identifying Biological Patterns Using Multiple Data Sets.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">04-19-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,944,602</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Spectral Kernels for Learning Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">03-01-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-13-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-19-2023</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,996,549</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer-Aided Image Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-07-2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">04-21-2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,117,188</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods of Identifying Patterns in Biological Systems and Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-03-2006</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">03-09-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,299,213</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method of Using Kernel Alignment to Extract Significant Features from a Large Dataset</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-12-2005/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-20-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">03-01-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,318,051</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods for Feature Selection in a Learning Machine</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-18-2003/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-08-2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-25-2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,353,215</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kernels and Methods for Selecting Kernels for Use in Learning Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-07-2003/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">04-01-2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-27-2023</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,383,237</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer-Aided Image Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-06-2006/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-03-2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11-04-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,444,308</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Data Mining Platform for Bioinformatics and Other Knowledge Discovery</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12-15-2003/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-28-2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-28-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,475,048</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-Processed Feature Ranking for a Support Vector Machine</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-07-2004/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-06-2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">07-22-2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,542,947</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Data Mining Platform for Bioinformatics and Other Knowledge Discovery</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-02-2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-20-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,542,959</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Feature Selection Method Using Support Vector Machine Classifier</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-21-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-02-2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No. 7,617,163</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kernels and Kernel Methods for Spectral Data</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-09-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-10-2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-10-2023</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No. 7,624,074</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods for Feature Selection in a Learning Machine</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-24-2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,676,442</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selection of Features Predictive of Biological Conditions Using Protein Mass Spectrographic Data</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">03-09-2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,788,193</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kernels and Methods for Selecting Kernels for Use in Learning Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-31-2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-06-2023</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,797,257</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-31-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-14-2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">07-28-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,805,388</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method for Feature Selection in a Support Vector Machine Using Feature Ranking</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-28-2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,890,445</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Model Selection for Cluster Data Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12-15-2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">06-08-2024</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No. 7,921,068</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Data Mining Platform for Knowledge Discovery from Heterogeneous Data Types and/or Heterogeneous Data Sources</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2007/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">04-05-2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-20-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No. 7,970,718</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method for Feature Selection and for Evaluating Features Identified as Significant for Classifying Data</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-26-2010/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-28-2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No. 8,008,012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biomarkers Downregulated in Prostate Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-30-2008/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-30-2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-13-2026</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;8,095,483</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Support Vector Machine-Recursive Feature Elimination (SVM-RFE)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12-01-2010/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-10-2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Patent No. 764897</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-processing and Post-processing for Enhancing Knowledge Discovery Using Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-1999/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-08-2004</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canadian Patent No.&nbsp;2,330,878</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-Processing and Post-Processing for Enhancing Knowledge Discovery Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-1999/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">03-01-2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indian Patent No.&nbsp;212978</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-Processing and Post-Processing for Enhancing Knowledge Discovery Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-1999/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-31-2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">South African Patent No. 00/7122</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-processing and Post-processing for Enhancing Knowledge Discovery Using Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-1999/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-31-2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Patent No. 780050</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-16-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canadian Patent No. 2,371,240</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-09-2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chinese Patent No. ZL00808062.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">04-13-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Patent No.&nbsp;1192595</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-30-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Spanish Patent No. ES2254182</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-30-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">German Patent No. DE60024452.0-08</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-30-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indian Patent No.&nbsp;223409</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery for Multiple Data Sets Using Multiple Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-09-2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Israeli Patent No. 146705</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-01-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Norwegian Patent No.&nbsp;319,838</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-15-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">South Korean Patent No. 724104</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhancing Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-25-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-24-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Patent No. 779635</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and Devices for Identifying Patterns in Biological Systems and Methods for Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-02-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canadian Patent No.&nbsp;2,388,595</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and Devices for Identifying Patterns in Biological Systems and Methods for Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-30-2000/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-31-2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Patent No. 2002243783</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer Aided Image Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-11-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Patent No.1356421</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer Aided Image Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-11-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Spanish Patent No.2337556</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer Aided Image Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-11-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Japanese Patent No.&nbsp;3947109</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer Aided Image Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-11-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Patent No.&nbsp;2002253879</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods of Identifying Patterns in Biological Systems and Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">07-02-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Patent No.&nbsp;1459235</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods of Identifying Patterns in Biological Systems and Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">07-02-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Japanese Patent No.&nbsp;4138486</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods of Identifying Patterns in Biological Systems and Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2002/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">07-02-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Patent No.&nbsp;1082646</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-Processing and Post-Processing for Enhancing Knowledge Discovery Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-1999/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-24-2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Publication No.&nbsp;2296105</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-Processing and Post-Processing for Enhancing Knowledge Discovery Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-30-2011/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-03-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Publication No.&nbsp;1236173</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method of Identifying Patterns in Biological Systems and Methods for Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2000/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Publication No.&nbsp;2357582</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method of Identifying Patterns in Biological Systems and Methods for Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-01-2010/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Japanese Application No.&nbsp;2001-534088</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method of Identifying Patterns in Biological Systems and Methods for Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2000/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10-27-2020</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publ. No.&nbsp;2005/0165556</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Colon Cancer-Specific Biomarkers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-11-2005/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020<BR>+ PTA</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publ. No.&nbsp;2010/0256988</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">System for Providing Data Analysis Services Using a Support Vector Machine for Processing Data Received from a Remote Source</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-11-2010/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-01-2019</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publ. No.&nbsp;2011/0106735</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recursive Feature Elimination Method Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11-11-2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020<BR>+ PTA</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publ. No.&nbsp;2010/0318482</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kernels for Identifying Patterns in Datasets Containing Noise or Transformation Invariances</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-25-2010/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-07-2022<BR>+ PTA</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publ. No. 2011/0184896</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method for Visualizing Feature Ranking of a Subset of Features for Classifying Data Using a Support Vector Machine</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">04-04-2011/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-20-2022<BR><B>PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publ. No.&nbsp;2010/0205124</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Support Vector Machine-Based Method for Analysis of Spectral Data</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-04-2010/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">08-07-2020<BR>+ PTA</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canadian Application No.&nbsp;2,435,254</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods of Identifying Patterns in Biological Systems and Uses Thereof</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2002/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-24-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canadian Application No.&nbsp;2,435,290</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer Aided Image Analysis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2002/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-23-2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publ. No.&nbsp;2011/0125683</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Identification of Co-Regulation Patterns by Unsupervised Cluster Analysis of Gene Expression Data</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-02-2011/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">05-17-2022<BR><B>+ PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publication No.&nbsp;2009/0204557</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2029<BR><B>+ PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Australian Application No.&nbsp;2009212193</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2029</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chinese Publication No.&nbsp;101981446</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2029</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Publication No.&nbsp;2252889</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2029</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indian Application No.&nbsp;5526/CHENP/2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2029</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Japanese Publication No.&nbsp;2011-515655</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method and System for Analysis of Flow Cytometry Data Using Support Vector Machines</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">02-08-2029</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publication No.&nbsp;2008/0050836</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biomarkers for Screening, Predicting, and Monitoring Benign Prostate Hyperplasia</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">07-26-2007/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11-14-2025<BR><B>+ PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Publication No.&nbsp;1828917</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biomarkers for Screening, Predicting, and Monitoring Prostate Disease</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-12-2007/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">06-12-2027</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publication No.&nbsp;2009/0215024</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biomarkers Upregulated in Prostate Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02-04-2008/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11-14-2025<BR><B>+ PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publication No.&nbsp;2009/0286240</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biomarkers Overexpressed in Prostate Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">09-30-2008/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11-14-2025<BR><B>+ PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publication No.&nbsp;2009/0215058</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods for Screening, Predicting and Monitoring Prostate Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12-04-2008/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11-14-2025<BR><B>+ PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publication No.&nbsp;2009/0226915</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods for Screening, Predicting and Monitoring Prostate Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-06-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11-14-2025<BR><B>+ PTA </B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Publication No. EP2373816</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods for Screening, Predicting and Monitoring Prostate Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12-04-2009/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">12-04-2029</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent Publication No. 2011/0312509</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biomarkers Downregulated in Prostate Cancer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">08-29-2011/</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11-14-2025<BR><B>+ PTA</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;6,920,451</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-19-2001/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">07-19-2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">06-09-2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent No.&nbsp;7,366,719</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-06-2004/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">04-29-2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-19-2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">European Patent No.&nbsp;1252588 (validated in UK)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets <B></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>i.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">01-19-2001/</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">06-27-2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">01-19-2021</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit B &#150; BIOMARKERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFIDENTIAL </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:16pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Num</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Archival<BR>Unigene&nbsp;ID</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Current<BR>Unigene&nbsp;ID</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Symbol</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Affy probe</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pathway</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Target Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">12337</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Hs.7780</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Hs.480311</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">DKFZp564</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">212412_at</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Unknown</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Consensus includes gb:AV715767 /FEA=EST /DB_XREF=gi:10797284 /DB_XREF=est:AV715767 /CLONE=DCBATH02 /UG=Hs.7780 Homo sapiens mRNA; cDNA DKFZp564A072 (from clone
DKFZp564A072)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">9373</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Hs.21293</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Hs.492859</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1">UAP1/AGX-1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">209340_at</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Aminosugar<BR>metabolism</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">gb:S73498.1 /DEF=Homo sapiens AgX-1 antigen mRNA; complete cds. /FEA=mRNA /PROD=AgX-1 antigen /DB_XREF=gi:688010 /UG=Hs.21293 UDP-N-acteylglucosaminepyrophosphorylase 1
/FL=gb:AB011004.1 gb:NM_003115.1 gb:S73498.1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">876</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Hs.79037</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Hs.476231</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">HSPD1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">200807_s_at</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Mitochondrial<BR>control of<BR>apoptosis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">gb:NM_002156.1 /DEF=Homo sapiens heat shock 60kD protein 1 (chaperonin) (HSPD1); mRNA. /FEA=mRNA /GEN=HSPD1 /PROD=heat shock 60kD protein 1 (chaperonin) /DB_XREF=gi:4504520
/UG=Hs.79037 heat shock 60kD protein 1 (chaperonin) /FL=gb:BC002676.1 gb:BC003030.1 gb:M34664.1 gb:M22382.1 gb:NM_002156.1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">1961</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Hs.75432</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">IMPDH2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">201892_s_at</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">de novo<BR>guanine<BR>nucleotide<BR>biosynthesis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">gb:NM_000884.1 /DEF=Homo sapiens IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2); mRNA.&nbsp;/FEA=mRNA /GEN=IMPDH2 /PROD=IMP (inosine monophosphate) dehydrogenase 2
/DB_XREF=gi:4504688 /UG=Hs.75432 IMP (inosine monophosphate) dehydrogenase 2 /FL=gb:J04208.1 gb:NM_000884.1</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit C &#150; LICENSES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Licensor has granted or intends to grant to the following companies, licenses in the indicated Territories, Term and Fields: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quest Diagnostics, Inc. (Madison, NJ):Non-Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: United States of America, its territories and possessions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field:
Laboratory Developed Tests (&#147;LDT&#148;) in Urine for Prostate Cancer. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quest Diagnostics, Inc. (Madison, NJ): Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: LDT and IVD Diagnostic, prognostic, or predictive
tests related to breast cancer, genomic test and IHC testing only. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clarient, Inc. (Aliso Viejo, CA):Non-Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: Laboratory Developed Tests in biopsied prostate
tissue. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer, Inc. (New York, NY):Non-Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: Research and development. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bruker Daltonics, Inc. (Billerica, MA): Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: Only for use in the software of their Bioinformatics
products. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smart Personalized Medicine, LLC (Milford, DE): Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: LTD and IVD Diagnostic, prognostic, or predictive
tests related to breast cancer as well as radiology imaging. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vermillion (f/k/a Ciphergen Biosystems, Inc.) (Fremont, CA):Non-Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: Manufacture, sale, use of SELDI-based mass
spectrometers; development, clinical testing and commercialization of tests and test kits using SELDI-based mass spec methods. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVM Capital, LLC (Savannah, GA):Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: Research, development and implementation of
investment methodologies </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abbott Molecular, Inc. (Des Plaines, IL): Exclusive </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Field: IVD test kits and reagents for assay of prostate
cancer markers for diagnostic, prognostic or therapeutic uses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Retinalyze, LLC (Savannah, GA): </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Territory: Worldwide </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Field: molecular diagnostic and image-based tests to assist in the detection and treatment of eye diseases </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit D &#150; EXCLUDED IP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The patents and patent applications identified below, along with the corresponding know-how, are excluded from this Agreement: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">U.S. Application No.&nbsp;12/975,306&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;System and Method for Remote Melanoma Screening </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">International Application No. PCT/US10/61667&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;System and Method for Remote Melanoma Screening </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>9
<FILENAME>d281487dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g281487ex99_1-pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEOGENOMICS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NeoGenomics Enters Into Exclusive Worldwide Licensing Agreement </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>With Health Discovery Corporation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Ft. Myers, Florida &#150; January&nbsp;9, 2012 - NeoGenomics, Inc. (NASD OTC BB: NGNM)</B>, a leading provider of cancer-focused genetic testing services, announced today that it has licensed from
Health Discovery Corporation (&#147;HDC&#148;, OTCBB: HDVY) the exclusive worldwide rights to utilize HDC&#146;s extensive intellectual property portfolio to develop laboratory developed tests (&#147;LDTs&#148;) and other products relating to
hematopoietic and solid tumor cancers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">HDC owns intellectual property and know how, including some 90 issued and pending
patents, related to support vector machine (SVM), recursive feature elimination (SVM-RFE), fractal genomic modeling (FGM) and other pattern recognition technology as well as certain patents relating to digital image analysis, biomarker discovery,
and gene and protein-based diagnostic, prognostic, and predictive testing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the License Agreement,
NeoGenomics was granted an exclusive worldwide license to HDC&#146;s technology, subject to certain limitations, to use, develop, make, have made, modify, sell, and commercially exploit products and services in the fields of laboratory testing,
molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis relating to the development, marketing production or sale of any LDTs or other products used for diagnosing, ruling out, predicting a response to treatment,
and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer (collectively, the &#147;Field&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The License Agreement will allow NeoGenomics to develop and sell any gene, gene-product or protein-based LDTs based on HDC&#146;s technology in the Field and provides for sublicensing rights and the
assignment of the License Agreement, in whole or in part, at the discretion of NeoGenomics. The License Agreement further provides NeoGenomics with access to certain HDC personnel and consulting resources in the fields of mathematics and in genetic
and molecular test development. The licensed technology also includes, among other things, certain tests, algorithms and computer software which have already been developed by HDC. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics paid $1 million in cash and issued 1,360,000 shares of common stock to HDC in
upfront licensing fees. In addition, NeoGenomics will make milestone payments, in cash or stock, based on sublicensing revenue and revenue generated from products and services developed as a result of the Agreement. Milestone payments will be in
increments of $500,000 for every $2 million in revenue recognized by NeoGenomics up to a total of $5 million in total milestone payments. After $20 million in cumulative revenue has been recognized, NeoGenomics will pay a royalty of 6.5% on product
sales and will share profits from sub-licensing arrangements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Doug VanOort, Chairman and CEO of NeoGenomics, commented,
&#147;Our agreement with HDC is an important strategic building block for NeoGenomics. We are executing well on the fundamentals of providing high-quality service, and have developed strong market-based partnerships with leading pathologists and
clinicians. The ability to develop and successfully market innovative and proprietary genetic and molecular-based tests is an important third element of our strategy. This Agreement provides the tools and resources necessary for NeoGenomics to
execute on this essential strategic initiative.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;VanOort continued, &#147;Initially, we plan to focus on
developing LDTs for the detection of prostate, pancreatic and colon cancer. We also plan to develop interpretation software targeted at automating cytogenetics and flow cytometry analysis. Our new Chief Medical Officer, Dr.&nbsp;Maher Albitar, who
recently served as Chief Medical Officer for HDC, has significant experience working with HDC&#146;s technology and in developing new genetic and molecular tests.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;VanOort concluded, &#147;We have gained strong momentum in the marketplace over the past few quarters. Now, we are very focused on solidifying our gains and capitalizing on future opportunities
available to us. With demographic changes in our country driving a significant increase in the prevalence of cancer and the possibilities offered by personalized medicine, it is an ideal time for us to invest even more in new genetic test
development.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About NeoGenomics, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics, Inc. is a high-complexity CLIA&#150;certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The
company&#146;s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics
has labs in Nashville, TN, Irvine, CA and Tampa and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about
NeoGenomics, visit <U>http://www.neogenomics.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking
statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially
from such statements expressed or implied herein. Factors that might cause such a difference </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
include, among others, the company&#146;s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be
read in conjunction with the company&#146;s periodic filings with the SEC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For further information, please contact: </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NeoGenomics, Inc.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Hawk Associates, Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven C. Jones</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Julie Marshall</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Investor Relations</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(305) 451-1888</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(239) 325-2001</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>neogenomics@hawkassociates.com</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>sjones@neogenomics.com</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>10
<FILENAME>d281487dex992.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 99.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g281487ex99_2-pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEOGENOMICS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NeoGenomics Appoints Dr.&nbsp;Maher Albitar as Chief Medical Officer </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ft. Myers, Florida &#150; January&nbsp;9, 2012 - NeoGenomics, Inc. (NASD OTC BB: NGNM), </B>a leading provider of cancer-focused
genetic testing services, announced today the appointment of Dr.&nbsp;Maher Albitar as Chief Medical Officer and Director of Research and Development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From 2003 to 2010, Dr.&nbsp;Albitar served as the Medical Director for Hematopathology and Oncology, and Chief of Research and Development, for Quest Diagnostics Nichols Institute. He was responsible for
the development of numerous tests and inventions in molecular testing and plasma-based testing.&nbsp;From 1991 through 2003, Dr.&nbsp;Albitar held various faculty positions at The University of Texas MD Anderson Cancer Center where he also served as
Director of the Leukemia and Molecular Laboratory in the Division of Laboratory Medicine and Pathology Medicine. He was also a tenured full professor in the Departments of Leukemia and Pathology. Most recently, Dr.&nbsp;Albitar served as the Chief
Medical Officer of Health Discovery Corporation (&#147;HDC&#148;), and he will remain as a member of the Board of Directors of HDC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Albitar attended medical school at Damascus Medical School, completed his Anatomic Pathology and Clinical Pathology Residency at Brown University, and completed a Hematopathology Fellowship as
well as a post-doctoral training in Genetics at the Howard Hughes Medical Institute at the University of Pennsylvania. He holds numerous patents and has authored more than 300 peer-reviewed papers, book chapters, and review articles.
Dr.&nbsp;Albitar has served on a variety of medical editorial review boards and is a frequent guest speaker at national and international conferences. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Doug VanOort, Chairman and CEO, commented, &#147;We are delighted to welcome Dr.&nbsp;Maher Albitar to our company. Our company&#146;s roots are in the diagnosis of hematologic cancers, and
Dr.&nbsp;Albitar is world renowned for his expertise in Hematopathology and Molecular Oncology. Additionally, Dr.&nbsp;Albitar&#146;s passion for innovation and development of new molecular genetic tests will enhance our ability to develop and
launch novel new tests targeting a variety of cancers. We expect innovation and the launch of proprietary products to be an ever more important driver of future growth for our company.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr Albitar commented, &#147;NeoGenomics has established an excellent reputation as one of
the premier cancer testing laboratories in America and I am honored to join the executive team. The recent agreement between NeoGenomics and Health Discovery Corporation provides the perfect environment for innovation and the development of clinical
models based on pattern recognition and multi-analyte analysis. I look forward to helping NeoGenomics commercialize a number of new proprietary laboratory developed tests and other products based on combining recent developments in molecular
techniques with HDC&#146;s pattern recognition technology.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About NeoGenomics, Inc. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NeoGenomics, Inc. is a high-complexity CLIA&#150;certified clinical laboratory that specializes in cancer genetics diagnostic testing, the
fastest growing segment of the laboratory industry. The company&#146;s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular
genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Tampa and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout
the United States. For additional information about NeoGenomics, visit <U>http://www.neogenomics.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are
forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could
differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company&#146;s ability to continue gaining new customers, offer new types of tests, and otherwise implement its
business plan. As a result, this press release should be read in conjunction with the company&#146;s periodic filings with the SEC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For
further information, please contact: </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NeoGenomics, Inc.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Hawk Associates, Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven C. Jones</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Julie Marshall</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Investor Relations</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(305) 451-1888</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(239) 325-2001</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>neogenomics@hawkassociates.com</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>sjones@neogenomics.com</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g281487ex10_2-pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g281487ex10_2-pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`@`%R`P$1``(1`0,1`?_$`+$``0`"`P`#`0$`````
M```````("08'"@$$!0,"`0$``@,!`0$`````````````!@<"!`4(`0,0```&
M`P`"`0($`P,%#0D```(#!`4&!P`!"!$)$A,4(3$5"B(6%T%1<2,U&#@Y89%"
M,R1D9396MC=76#)28S0F=W@9&A$``@$#`P($`@@%!0$```````$"$0,$(1(%
M,09!42(3<0=AD;$R0B,4%8&AP6)RT5(S)1:C_]H`#`,!``(1`Q$`/P#OXP!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`>/D'QY^6O'G6O/G7CSO?C6O
M/]^][\?XX`UO6_.M;UO>OPWXWY\?X_W8!6QT;U^D7],TAPO0SWJ07G-9I&YS
M=:B/J-*4](<]P-T12R;.TL7)M[*:I#81+>3'FQ"8+ZPPN@CA:!KZ/U0+)PZ\
M!#K6M!UH.M?'6O&M>-?EK6ORUK`/.`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`*S>M_9U4W/,@-IN
MJHO)>INJ5Y)H6.@:>T6Y+6E0#P';C:4PT6HCU9QQ"+>A*SU@QJB"OX]D:!OY
MZRA"=R2MVTY7).B23;;?1)+5OZ%J?)2C&+G)I02JV]$EYM]$BDPQ!U]VW9+V
M[]&S^9V<N_0Y;$T'-O(L^U5?-G.Z&9,RB-JWMXO!P3+1VU>+$A<SCFY47]PV
MH590CBCSR@Z3:L3!^7VWAKO-=R9V/QD(U4+5S<[UQ[7)/9%-QB]-:/KX$-N]
MX0R<U8/`V)9C4U&<TU&VM?5ME^/;JFTJ*5-6JM3(EM@=@<.<R3V!S_IZ:=+F
M1XQ`?'YVQ5(%^Z`K&JUY/VP-SE9%7EU6395'@G[.6R+2$H9*=-\M';V:`0*\
M5N;M^[MD[2_$DZ>'CT\5UIU1,93A%J,FE)NB3T;^CXZ$P_5?1O'\(K21W3SA
M937?DYNQ:E=K<NX]0(Z7.KB6$]2EBSFSKQ'/T#;VDXXP>VM;L*LY4(2A2,XP
M0=AP,BUK`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P#";"L&+U?$GB:S!8I1L3(D-5K!H6]:[+S`%!V(
M0$36VD*EZPW0=;%O0"]Z+!H0Q["6$8@@4[W]T/=]ZD@C[.LFG.U6R89"!O8(
M6@&X]46TC6%&;`0RITIVR:P874C0=?=G;+.T4(0P"4Z_R>2+A>V.2YI^Y;V6
M<%:RNW6HP45]YQK3?M6K4?A5'.RN4Q,6<K#E%Y2@Y;:_4FTG1MZ)4<GX)E<\
MR@[+3TBCO-D*CK5$IG/22I)):<@CVG?Y46W)AC-3N_35J:$6\S.6NYH330,6
ME!#>B``1PRTVS"RS)A^_]M=J0_2]FVOU?<L=%GW$W&,WH_9M/1JE4FUXU4G1
M,B%[@>3[BDLON>^[7"[6WB1]*IZO5<FG5M)JB;:T]44WM4^(VXLU+5ND2*7<
MB.)0-1"?;1&V=X;GQ*I-"`Q40S:80&;5K3=;&#9A9`A:V+Y[%H7\6NAC=N<]
MW#R_[MWI/WYR;K!RVIMIU<6FHQC^*BDVUU>[KI9/=O$\9C/&[?MS5JM7/;II
M2J54Y3DTTO#:DMJH?I$W9YNMQ"X3J.BC<<84YNH5:\9:K58>@6%62'9:$S;L
M^L#>V2-A(+'O6TZDPW9@!;"6?K0=^>WR'%W>U\7V^VU;DKM?=L3G"]9G'_<H
MM2>ZFFK4:43C+0T^,[BAR48SY._.VKBDE.<%&:HUM2@M*-MTE2375.-:D5)Y
M4[]S++1])1!U=*W^_-^L[=3\\118IB;VF^KO9*3K#G8E.0`HL\P&Q*W=$C*,
MV(.S!@7&;^88QE=L\#W1DWK/;G_6]P65^9AY,XQMSDOO+'G5ZUTC%U4G)**B
MGI(<;E^8X6;ASWMWN'E.EG)MNLM6Z0NQ=*-/TQEXZ)MRU=L/,O>:*Q4\(CMH
M-S*2ZS46VZ$6G5BP4SIBREI`?X]-#PW:4K(LZ?$/E0A<@DB2&;V$[Z&_`,KK
MD^)Y/ALN6#RMBYCY4>L9II^#37A*+3333:::HR4\?RG'<K9_4<=>MWK7BXNM
M-6J276+JFJ22>CT+)-;\ZUO^_P#'.<;XP!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(2=PF'D1R@SDIQB=2
M#J*H@E'DF&$F@^J:^$&:"84((PA-)-$`>M;\"`+8=^=;WK,H]:>;7VHQFZ0<
MO*+?U(@9+S9HS5Y`552GIHJ\VT&PWNP+'4[--FZHA/*RV].T)I$,:EQ;$BA&
M;Y-+2?3&=]$.MF!UK7F_N%XRSE<UD8/,S]]8,+*LV%7V(*5J$I3VNM6G1+<Z
M5;:3;TJ^7,8W&<?:N\MNN<E==S=*":=WV[ER"3>D4HK:I4I7=K%QT(101SA/
M-=J7>\S50T,S[*]1-S9Y7+W)1HEUC`8L46E;DHSTYXU(#)0E6C."66,X?D0A
M>=@#F'`XN#F]W9G%Y.+&'-.]-VG&,%%6FE24:).J^]71Z^6BUN<RK]OM;&Y*
M3D^-G;?NPBW%1<FY*B\HQK%*M)2H^C/SJ\XWH:=*979C0ODS2SNGV<-;-15:
MUQ1X4>`F(]M!#S^J.#T46`X!GU"B"0&:^.O.O.@9;?,6,3MKCO:3]F[!-W7I
MI&,57T435$I;O%I4470KCC+U[G;WO8UJ-ZSNC&%N*BK>Y25&UTFXU<7)T2=7
MX.LZ+FASS7U;BE-E.<9JN&@0?;M:0/Z>DDZQ>(S8$Z8]F4,3FWFZ5`"+XI"@
MFK#!BUOZ81;_`(:6GW5F\SF7./[.PGDY&NV[1^EO\:4FG_"5&^E"U9\#Q_$V
M(\ES=Z-J2EOE;TD]/PVY;JJ56E5/:HZ4TJ4%K>D)I5URK+)I>0NT-6%IW!"L
M*(**&U2%`(!AZEHE4+7(=,+PP+Q%B$,A248$.Q#WH.MZ_#T7V)\A\7(X[.SN
M^)6LGEN2=J<':WVO8:Z2C)-/W(N2]-%\5)IJM^YOFER<\"[RO:EO'N</QV9C
MPO0N.4IN$YN%W:XU@W1MRWO:E2B==SL#8D+3'+HM]5`V!JKEGMOG?@"[);"H
M.-Q885N>V98B!;-'%LCQ*LQ*V$.WW'TAD%^"]D_(O>M@$+0J`^96/FV>QL-\
MG=>3EV>>SL.-ZY7WG#$BHTF_I5R-:ZMQU^F=]K8>)QGS%Y+#X^+MXMSC[-YP
M3>S?.475+HJ5E1*BU?A1+JXRA"VA@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`0)[_<3&V(\\F%;"$1_6M(
MI=B$'Y?$LY<\?4WK6_PT+X!\:W_9_CF4*[E15=5I_$QFMT)1\TU]:(\UQ&CY
MQ3=*".,$;I,JM9+K8Q:"#29/82THH)F@!^H(LI.G`$(`^!#\?G^>\NZ'+1XC
MOWD;N4U''>);W)I;JJ%MQBGI3J]SU5$D_`A/+<-Q]WBK$LJ%RY[5^4HPBWZY
M7'K%UK2,FDW2E*/Z:PR]H]8\[S^ED=%3B6NT2N9_2!?*UD,.TW!DD02MZPP"
MJ42$+D(I`GA8QA-!]`XS0SSB=;3_`(E&BR!<ESW(9O=\.7X1SM<K[L(V7!UE
MO7IM[7TW.J7@J_34[.-@X^1PTL;E;=O]%<6YP:2C"-.FJ5-M*J77QT5"._/O
M05?\G-1-7TG&Y+)[,71Q)I==%KB=US>]*DI8B!&MABH273L+?T!BT2W$MS*`
M>]?'1NMA^4MRN0Y7NCN:QC?-;(R+=N*48148PC.;I&CE!43=*2EJZU58U9'^
M.XS`X;BIV>Q(6)94IMSG<;DXU3:E+3=232V:*+Z_#*I;`[POQ>1-;/DBQY=S
M!F[0'/;@%*E;D*W03!%,3*$DQ*S-6O`?`$Y).S->/.A[U\LO#B'Q'!6%8X#%
MMVL7=6O5MI;:UZUT:;W.I6O,8O&<KM_])R-_(Y&-=SQXUMJOX*3I'256ML8I
M=/&IJ6<\R2%$SG&+$2-[;DZ<XQ3O6R7`@HKP,LS>DVR4ZTKX$?CO998@_#\]
MZ_+)%@=TY.-D*Y;W6[K>C@W&55KX_>UU_F<6?9_`<E8_1<3GWK>3=]$X9$=L
M+L:ITK;T5**B=5)KP-^V$TIH=9;V<W$ZT%/R3ZWV`O9NC!ZT!':2!,G^J8(>
MQ#%]KKQK\=;_`(=?G^.47\Q+]W+^7=C+GK&YW9RDUHJ1<XVZQ7C^&K^GX(MS
MMS`G9[LR,[(FIYDL"S9EI2OMQMR<Z>4G+^%$E6IU"90)8XP!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`*S_
M`&>.`FV!<Q'%C"`9_:_/R0.Q_+X[VH6R`/QUH/CR,7]GG\-;S.TJ7X2J_O1^
MTQF]L)/R3?\`(^5R0I_4N>ZH7'!#L_:VW0BWH'Q"$9=DNY>_IZ\[\:WK^WSY
MRS/F9B6\?NWD8PKI9QI+7_=&"?\`(A'9_-9/-<+@9N3M]VY=O1E145;:E1I5
M?BM/]2L.YX?$7/M2]'2VU#<]FONHK%8^SR!HD1X(]`6Z&L9[.XMSLD9%T;(+
M=W1S5[.V<>2/0Q^//R^7R[7RRP.`>-/D_P#E[AMSHHRI2$?#8I:.<E^+XQ5*
M.NAWKG\C;NO"C*,,1PA.'IE64U))J;U3CN:<7Z7&<==R=8^NT5DYU\X-\!EK
M?-;=JF1N*,V$3=E:(C)4=9'"-,"G:EB6(/B)_0HDXC]AT>4T[T,K7Q&/?D0-
M6EW3^U=]\=<LRGA8W,QC1MQIK'6+2E]V<DFJ[EJUIT*]XSD\GM?DK%V=F]*$
MI/?1P3:G*CW4@I3BGZHMUI1ZUJR:T0;V>,-Z%KE(QG+4K:-4G%ID>D"A2B3;
M`5]RG3OK8VE&&@)"$8R-"$(.O/PV+6_.Z*_=^=[%Y:[8A)W^.E)TC<E*4&JJ
M3<9)Z36YIM=6ZR5=%<F-8X#N"VLZW:L2R8MZ[8[D_P"Y*M>B\_&CZFP%D"C[
MTR$R>*.J1Z9%NA["J;C]#2Z*`#0%.AZ#K0@&$GZ&`P&@@&6+6_EH/]EG<#WM
MQ_.9$+%NMO)HVX26K?@DZT7QUW:I4ZD0S^U,+WW[]EX\W);9PG6U-N5**+3<
M715:;6KHGJB$G96R(O)YH80G`DT17?K^92/&M@T6E)N%B2$)Q?CL>RBMC$'6
MO/G7RW^.0/GLF]D?*W!E>DW-\YERDGX2DIM_QT5?@=#BHWK?S&SK<Z^U^V66
MO)NL(R:^+BD_@=)V5.6*,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"K#VN*BDM?\D;-\[V?WSS4F+#\?D$
M0S5TF\:'O_@Z\!_/QO\`',K3_/@O[E]J,;B_)G_B_L9KODR<H$'-5$+2C]C0
M.J^WQ`V+82S!%[LYV!L>PC_'S\A[\A\_+7C?C\<N;N'@[W<??&9B;YKV\+'W
M-Q='*%JW':WY[JRBWI+QTU*O[,NKC^T+-J$K'[A#*R%%.::G)79*<8M>:]&G
M1_Q1^?6G.:>[XZ*<P%8:@LYC0B+2#;'UR929>B;QG*VYE5NS(N;ER58D4B'I
M&9]4(-['LH>PZ$$9<.4>8[$YJWG87N4AMDW*"<9><9QDI0IY;D]&NI);63C=
MS8$\+D$L;/4VE"J4XU^ZU&5-R:=&FFG1]-*5QT[T5&YIM[HV\D\>(>TC@J8%
ML%L53*Y<^`*0$C^H<>CF4#EQ84Z,OY",T8[A,(T#Y[WKSHP5H\7W7PO<&1[N
M#*6-R\DI.,+:B]RDJ[7%QC*K<4FH[E1=$B$\KVIFXN,[=U2NXR@T](236]-0
ME+TR4=U''TIK5:T1(^'NDHJT]/`G$H3[4<B$8A@TFJU%-?IL&G%6;H3+)"F6
MP+.)2I/ICUI.<!H0IRM:WO9.M;WH/8YCB<+F<24,J7KC2L+E(UVKK%[85;K2
M2W-JM&W5$:Q<G(X+D%+`3MSC5).4MB5%^7/63T;5=VC:45HF8A&93.>:^LJT
MANS]O-`]/R4=8.S.HD:=W=(Q9ZV//3Q'940E"V,:YN"[*F?]-/\`*4`3@'_$
MS?U"R=Y3G(<-G=I<Y9SK,6L*5RD)2>ZE4UMDTM>C::K5+S+7P>4M=R\-<C*D
M<^TTY45(QG%[H-.6FM%][I75'M>Q_8&YWL);OX!+$AX-0!\BWYU\;WC@@!_B
MWOSL01[\?V[W^&\V,^[7Y78%KQ7*79?7&:_H;%C#<.[[W(Z4GB>WUU],K4NG
M3\3U7P\CI)RNB4C`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`J&]Q3AMMK7C([0=&;.]CG**7X;WL.A:/=)
M4$6OEK6_Q^.OR_+?Y9^EE5O07]\?M1A<_P"*7^+^QE>G/UC)(?R!RHD=Q"-;
MW)QZ8T>>$1ARQ(%NO*0E)/MTH`C&<#6S/A\=?'6M;\^=>/&_8_+V(2[YY.[8
M<8VEB<<I4C1.?Z&U)MM*NYM.O@VZOS7GCM[AY\OVIBQLW(K,A/(<(.26ZN1.
MKU:Z>:3==/'23T=NUKV0/;?+4^B_)6STBU2:D.#_`)+0B-&D[$7\@AT/SH0?
MEKY>=?+\-ZS5R,3%S(>WF6H7;;35)Q4E1]51I^1V+>3W5QEZ$K]F5^4*[)26
M^BIMI&2=5TKX2?CIH01[1K.&WB6V3N)3-57_`$+&QI%T(LZ-%JD2L*IM4EA;
MBIA]$"94X($VP;T0I)V-:2`(M!":3H1>X)R_R\Q,[(_7=OR>)FJ,EMM:1G)I
MJ*6M8N4FHRVU6VOI)7P',]P9,I6.5LPG@MTW.BE%4U2IN4W_`)4HWK+HG#5A
M[PDTFBP>1^R8Q)$E]*#%C1$YPDAC985=V4,M?]6-NC:D`C=50E6TX@DG&E%:
M"$>@F[&D-V,O7Y]F=W9'`=Q6N%[\M3L7'=3]RD52+3KNIZ6FUI*KCU4J45.=
MW)VS9S^(NR[:G&>U2W036[?5-4=*I-T]"I&C<E7H3%Y'CMIWA;]&@EK:;'JB
MY%>5UG2C>G![<&Z06R6QOS#6;`A$\R*3C(-8DKN-Q.2E+#2B2R];WHKZI188
MMWKSV+WEW/8XSA=>,]VL6HJ+<Y+U.M%Z8I:-K75ZZ'7[0X?D>"X6Y?Y2->2<
M5%1;KZ4DXIT;U<I-.K;2BEHM%O7VKK_L(W/5VA!T(2SUXZ^J/Y>=[4=",)6O
M(M?Q>=E[_'?Y[T'^_.!DMOY<XJEX<I=7_P`W_4FT8Q69)I)-P3?\O]%]1TR9
M!3;&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8!3K[ED+VYU[Q$A86M>ZJO_`-D?+"U64WH5*X2)J;39JX.;
MLM^V).^Q:VQ&F&<H5&_$@@H&Q#%K7C,[3VW8R\I)_P`S"YK;DEUVO[&5+16L
M9_/^<:NKF!MB=WNCF]]OEMMVA'(U1&;@1))I:KO-H\^PUC>RT::7)M,ZH/W*
M9*8)4$8PZ`$6_P"'/:^3S'&\%W-D<ERK_P"CY7%PYV<VU2]CQ=K'MV;ENZX5
MVJ,TZMT55X]#S7/M7(RNW\+#N2]CG,5WY>W7UN-R[OC2*6Y^'W?4JRJG0C4F
MMEP1KS68TV3-+LG5?8N#>X-)B1>W+0?`(T;BG-"%<2:2<+98M"+W\3-;\^/S
MW.I]KX4\-\G;GB3P%#=[D;R4-O6M:J,?325)-/:UH1SD.\N[.#A&SG9NZXTW
M&#A&]=HGMTC[4IZI;EYQJ^NA+RA:#FM^.9*IXDVH-"S0;^NZGE`V\.).PA^N
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M7Y]S:55/`GNT:UNUQCVH0GK]&XFA52R'V4M6-3$G8R&]Q-),2%*"-*"P>0I@
MF$;$6FC-C'_\#WJL6<YY.&XO:X1J[FZ,MC4=5)QEIZ&UKUZHG./R#YWM^WRD
M(1M7Y132FVE!RT;3:6JBZJJZIQ6NIF/LR5)K%J>>.-<"<)ZA9ISP7#E,DC;:
MY*V9S<X%>3(X3`3`;]L%2[I6EMT-6K-*`,M,C*$>8()6MBUH<U:RL'LS$P\_
M;;S;N?=O^V])J,DU64.L57ITT:H=.Q=N3Y%PCKCQLTKXU6WK\=:=&]:K2KZD
ML@)U1@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`:$Z4YIJ+K2H971]WQY7)Z^F!"4#FVH7YZC:XI4WJ-+&Q
MQ;WAA6H'!&N;UH0FE[^8BA"#K1A8P>0[`H@DO"/6''*\D6GR7]V<O1HPD4(>
MSU)#-W%SDSH]_).F8YXF+%_5V*,H/'TDJL)X@%AV$LA"#0C127@N[.9X"#QL
M6YOXV==UB=96I5Z^FOI;IUC3Z:G+S.&XW.O?JK]FW++224W%.6G1-]6EX:IK
MP:(03"R7[O\`ZM?X\Q)Q"H#D;<39K\ZK25"8AN*4225-9#\3%)8P)UI!KR?5
MQ0"TJHTK1A*98,XXX\TH24HWM6.6Y'F<C_SW;%^]A\?E1;ECW+WY3G1N5NVZ
M-J$M=L9/KKZ6:%WAN+M3_<^0Q[5[/A#V]]*RE!T24MSI.3Z5E5O15;+4G1L_
MIM6S#_H\'M=K1V8.862.RAD-D$W++<P%`.'N5$L=$V.="G8L`M_%*XE)R`BU
M\="WOQG9X+MSAN+ON7<]O)P^1QENG"XHN*5?3=MIN&]=)>ERIY^)&.?Y7F<W
M\OAKUJ[A2DDG:I64G*GLW'NE):M)I*+:;;HDT8DGA<!I>9MCA?(FZ]>DI%LE
M3%Z$KR%5-+9<4$P@TPDI[?6VD80[P)I`6;K9BA>+[H(/G\"]ZT+S/,CE.7[F
MP9W.VO\`K^W[$JW<_(E*$7%I)^W&=Z;GN:=:1I35M-Q2C6/PW'\3=E?[AA;S
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MY.K;^E_9X)$NMVK=FVK=I*,%X?U^E^;>K+L-:T'6M:_+6M:U_AK\-9^)F><`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#QY_/\?RW_O?CK_>W@%23-P"PJYETS^CN<AI^VWZ^YM>5=WI!
M/*5<[LUPIF-Z5M\B2_6`AD@(W+VYT:U2)1\3--Y:06A?2/T'?U-Q:E%M271K
M1H-)JCU3*7[8:>E.+>C5AME1&]JK<YTQ3!2+HG@Z/@FE3="(HE$'J0*8=85'
M*U:!-5=Z25G9A$LCFCTD3J'00-`1[V+:G5E87S)RI\7'B>Y\2QRUJS3V)WW^
M99HZI;J/?!MNJEJZT;:T*^S?E_C/E7S/!Y5_C\F::N1MNMN=51^EO31*B7I3
M2:2)L\?<<=96Q&%<KG5>)^)ZVG!ZU8;6CI(E$WZ;L)`M/-'J0]&V7HDE60Y.
MA?TU.XXWZ0I$YPA`-3EC\G#B7.]R\KW!D.]FRC&WI2W;2A;2Z);5UVQHDW5I
M:*A+>,X?"XNVHV4YWDDG<GK<E3SD]7]?2BKHB[^@>=JTYOAO\GUPT`1!7*MN
MDE>CBR-N\I>AEZ+&Y.Z@LL&A:*!_`G(!\24Q?\(-?B+8N"=0WK@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@%8G0W5MGR;H(7'/*K()UL=H:&E_N*Q#"R_T6KF1_+`I;&\:X\)J)
M(\K&[85!IQ@1F%%'E%IBS5`A?2^JGB"8]/4N"MFK1KW(7"62]?\`)0]ORDX_
M11RPX83CMIRSS#5!VOJAU_E#QC&+>M"\`_`.O@-Z8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`CZ^=9\L1F7JZ]DG2E`Q^P6]R2,J^!OER5RSS
M1"\KQ)PH6A;%W*2)7I(Z+!*RM%)S"0G&;-!H(=[%KR!(#0@B_+>M_P!^O[=?
M[F]?GK?^.`:0G?3G-E6O>XU9O0M'5U(]%@.VP3NV8%$7O11I*506;MJD#^WK
MOIF)UQ(PB^GXV`X`M?@,.]@;8C\C8)8T(W^+O;3(V%Q!LUN>V)R1/#0XDA&(
MO9Z!R;CU*)63HP`@[$6,6M"#O7YZW@'V<`8`P#^1""#7R$((0^=:\BWK6O.]
MZUK7G?C7G>]^/\<`BM:W<O'-%RT,"N/I^B*UFYB0Y>&&RVT8>U2X#<0(DLUP
M4QDYU_6D2`)QX2_K'D%%['OXZWO?X8!L>"]"T=:D:C$PJRW:TLJ+S1Q&S1-_
M@TWCTH:)`]%M#B_FLK8X,:Y>F4NY#*SJU1J70OKE)TAPQ@UHH?@#<F`,`8`P
M!@#`&`,`8!CDPET8K^)R6=3:0,L3AT.87:3RJ42-R3,\?CL=8D)[F\O;VZK1
ME)&UJ:V],8<>>:(("B@;%O>M:P#6W/?1M'=6U7'[MYVL^(V]5DH-=$[)-(6Y
M?J+0K5LK@H:G="9HTI,M0N+:X)AE'IE!)1Y0M:^0=:V'>P,1YZIU-6$FZ.D*
MAJ))DML7Q(IXZR#981+9"R*V*.)H@48K$'ZPT$;:BAH""=BV`DPL[8=:^>_(
M$FL`8`P#1T\Z<YMJM\,C%H=`TE6LC+"`8F"?VM`X:]?3&F2JP&Z:I$_MR_90
MTJTDS0OI_'8#`[\^!:\@9G7MKU;;;4<^U39,`LUC3FA(4/->S&.S1J(/'\_B
M2<XQMQ<DA1HOI"\!$/6]_'?]V\`S[`&`89/;#@U71IQF5BS"*P.),Z<]6[RF
M:2%HBL;:4J8D1YZAR?'Q6A;49990-BW\S-;^(=[_`"UOP!C%'7M472M8QNZ*
M)GK#9]53']7%%)Y%E!JR.R(MA?G6,.Q[0M,)(^\3(W]D5I=F!#\!#(%L.Q`V
M$6P-M8`P!@#`&`,`\?(/G>OEKSK>M;UYUYUO?Y:W_=O>`><`8`P!@$;Z:Z]Y
MDZ%L&Y*JI*\:VL^P^?9`1%KEB,-DB9X>J^?E![@D+;WY,3K00B"N:5:4PPD1
MI12Q*<G&()Q0P!`DA@#`&`,`YU/W'_#E`]#^OV=RISJFLB;^!;7,T(JZ\5D3
M0$32`NMR=+5#43FM-DS02DD3I'U39-#M+6\X\U,=K83=%Z/*),`!HWT6>RFY
M&><S7T]>R/2B(][\K(_Y8KY\D[JB'_I#5+'6=M41O;;(5CB)1-IZSQ<T+D0O
M+#LR21<9+AOY*4KB/`+`_;?74!ELS]3BF60J*2=2A]KU!HT2B01]J=SDB134
M5_.RE(G,7)3Q%)5#I'4"DPK6_IC/1$#%K8B@;T!:K9-G5Q2D*>I[9<NCT`A4
M?^Q&[2*1+"6QJ3J7IT3-#0A`8+P-8\/STN)1H4A`35:Y:>6006:<8``@(B5E
M[.N-;/Z$#R@CLQ_@W2"II_7&.F;KJ*X*$G,N:`I5B\QR@S7<D&A6IPF`A;CS
M]_I0U8]%$C%\?`!_$"2%W](4ASC%T4PNBQXY!&EX?$$5C29T4F'2":2]W&`I
MEAD!BC<2NE,]FCT<8$")H9T:YQ5"'KZ9(M?C@&D*:]BW(]X7,Y\X1JRW")]$
M-C1J2?T%N>O+(H6XG.,"0@<M26.U[<L3A$DE<?TB$,S:QL(5D@`2;L6PZ*,V
M$"K#WZ^Q:\.<&GF;A?C=Y3L'8WL2L5#4%?SWZ859M-0=R?X_$9'8J8HK1RA#
M(%;G+"$K:NV4,#>0F7K`_$]*2((%K'$7"W/G"E.,=;TW&4?ZV:4-QLRXGKX.
M]KW?/7$W:R56-:4_7[52.5R"4O0C%8]*E1I*4(PIR`EDE%@"!&*_?6K"%7=W
M'7?E`0B(0BV*SL>5Q;H@<=:FU@26S1EC5)8D*4/4A:TFDC4\V1`Y0^H!H'<1
M.W+;0I5IQ&F@+3%E@60VI<]9TA$T<PM.7-L3:7-[9XFQ`4`5KGF53.0C&3'X
M5"XTUIU\CF4S?SRAA0M#6E5N*O8!?2)%H`MZ`C%0OLDY!Z-N*7<\5[:#@W=`
MP1L/>Y/0]I5I:%(7"E8TQ*(Y0_H*^N*(PB2/C"4%S(\JT*=20'Y[V(6@ZV+`
M/U5^R[A-!>[SS<KZEIW^KL7K^76C-8VDE:)P05O"('I!_-CO:$R0"40>MS&C
M;D7L:9Y<4BH0-[$$O8=><`PSE7VU^O;M2U9=2?.'2<9G=I0YN.>ET(<([.8$
M_NK$E.`2K?X@BL.,Q8R<,";ZQ0S%C3I62`DTLW8OI&`'L"7%X]"4KS;#2Y[>
M-DQ>MHRL=V^.,ZR0KM`7264O)OVS'$8<P)`*I#-IB_*]Z)0,[0E6N:TW>@$$
M&"_#`(\5/[(.2;?N[_1J9K'<X9T,8R@DK?1=W5M:'/MN/\8$B.7_`,R1&#73
M#H.]3-F"G2GB&<U%J]%A2*-B\:(.V`#)^J>_^.^*4#,KZ9O^`58MDRYH;(K&
M71R&[SN4+GU?MM;2XW7<<)=YT^D&JP[T-0F;QIB=!$(PP.@B\`1VMOW2>M"B
MK[;.:;7ZRKZ)VPX2)/#ST8FZ7O$+C\L/5"1"C,QM9CCSC5L.?TBD&P+$;D\)
M5#>+8=*P$;WO6@,AZC]P7K@XSLYOIWHSJ6%0&Q%"MJ1O#`G:)A,@P@Y\`D.9
M@6:ZP>.R)GJ\3HC7%*D^G\]O$:CW]P$.R?X\`DAT)8O+"_G*=.?14VJ(/+UC
M5V[M$SDUBS*-M=1RZN)K%UFG),IE*YV2-#DS2.,*CME_:GF&*DXMC3_/QO80
M-'>KYEX)8>,:X-];"!D2<CJWF?C@BN/%3D2:0/C=.GV,35[4+[*!J<ORU5+6
M-23I<O$/:@DDK9(MIM$^`/=N#V><;4<KL8,TLF2.C-32T3;=,OK*FKJN6`TJ
MO*TA,5H;?L*IX!,H973@V)UP3EJ9T6ISVXC0C%0"0!WO`)%)NGN>5U)`Z407
M56"KGL<-,L'^MH)JP_TN+A9/RT?)#)J):%A"V)C0"*-%L_6RU`=DBUHW6P8!
M%XSVH\;-LAKB,2Z:6/6KG<\OBT`I-3;/./1M5QVYYE.'-&T1!AK&5SZK&".2
MY<_JG!.80%,IWO:0\*D7Q3Z&:$"Q0K8]@ULS7Q%YWYU^'X>-[UK\M[_/6`<F
MO[R.,QQ9ZI(Q)5C"S+)$R=7U.2R/JIL1'O+*4[1*S$[L6TN9A(ES>6Z)TY9:
MD)1@0G`+#H6M_'7@#I,Y0BT;AW,G/4>B;$T1IA:J0JE`ULK$WI6IJ;D2:#L@
M2$B%O0E$)$J<K6]^```'7G>]_GO>`2`&+0`B'O6]Z"'>_`=>1;\:\^-:_MWO
M`*TYG[=>#80GGCZKMN32BO*L?#(U:%R5?1M[V]1=;/R-<%M>&F<7=5]<2VKH
M^KCRH6M.GUG30&L'D2L16M"\`?C[!5-"]0^J_J^P6PJLKTK)^XOOVTJRDPT$
M?G476C!1TU<HK.(HM5IUR8AP2;$$Q,M3;+4IC=;UH0!A%K0%+7J']JG`_KI]
M*GK<9.O^B8Q4\CGD#MMSC,2"SRV;S-<S%="W"5N1'Q*`,$H?VJ-C5$C(*<%:
M<A(H4EC)*&,P!@0`=05-7=570591"Y:9GD;LJKI\RDO\.G,17!=&!^:S!#(-
M.2*BO\H6H1K"C"%*<X!*I(I+&2>46:`0-`1KMCV0\CTZ_6'''ZP9#+W*GF\Q
MSNL%+5/;5^)Z,1EHU#B,R[5]+PJ<H:I4A;42A5]J^&(E?VB<P_9>B@;'@&\Z
MEZ@YZOBG$'05.7+75C4JXH'-R)LR,2II5P].E9-&;?=NKR<I3I&%0P?2'I>2
MO$F.0B#L)X2Q:WK`(3OWNI]9,<@MX6>OZ]JY777.LQB%>6I,X]_,4K84D_GI
M3PHBL*A*R-,KF&UI*K2Q]<>>FB_ZOM&0C.,/V`LHP8`-X/'L<XQ8*=I.\UUZ
M1MP@G2B-*LY[*BC5*9G.KL&J1;<-ME8U1$V)[M"8/C>G_!>A1-!REN-_@5`)
M%KQ@'M4-[".4>C[4F5&US8[DWWA7[82^RZD;4KFRZ/MYICAXDP"I277EQ1&$
M2IUBYAJX@'Z@C2J$81FAT(P.]Z\@5%VK[RJF)]L_/W($1?[)C-)1*O+RG_1$
MQ=J3M5*DG\D#&S8Y5\8@;(?!SYS)8C'']`ZK5S^V-VV96N`G+(6&@3G>0+SY
M;T]S_7M*(>A[`M6*U]3#@RLKVCG4_5FPA`8CD)`#F%+MOE1#0]EOSOH82TS6
M)+IS./W]$"?9O\&`1\A/LTX_F=U17G958T@K*[I\@*=*YK+H"I;>YSE5GMIA
MRXC:NL4EW0:"DV`(!C<=K9#48J4:^'_L>=ZUL#/.K^_>-^'X^BD/4G0E>5(%
MV/0IH_'GAT,<YW)SW)4:C1@BU>1Y.[SB2%FJ2#`"-1MYQ)/TQB-&`(!B"!@T
M9]G_``E*^JIWQ.S]*5VMZ6K&,O\`*YY7Y1[F4CCC=$T!;K+DBN<J$!<`'((>
MUCVH>&P#H)P:BB3]JBB_MU'T@-!^NM!ZEU?1O<\L]=8JD?[I>YK$WOL28U0Y
MR64,1\RF*Z;.[*WHI0K4+Z]V%:]-KVL7(HJH$B*<!#$J"$[8,`F9>/9U#<_.
M*IAG$@E#Q+6R*[GK[`JIK"T+SL:.5_\`>+T!=@2.OZ:A\YET?@ZE<UJ2"'1:
MC(1J3R#"B1F#`/00/I\N]B<U=HU>GN3F"VXO<-?'NA["H=XR8L+6LDA2$$*5
MD:E$?=4K=(HM)$B=2688A<$B90$HT`]!V`6A;`T)+_:AQ5#$$ID[E9\H7UA"
M'-]99C>\3HZ])[SI%7>+J%+=)4#[T%!J\D-0I!QQX3"1.!GZN(E"MUM.>,!V
MA`"!LO\`T_.3O_-]G_U/_P#3S_S-*/\`5/\`_.7_`#)_U>_YM_G+_F^`1E]U
M_P#J#/&O[^I_7KK?^&_8!S+K>`1:]Y?J4>^V83#.J>27AQJOV0\G#W->>+&B
M[J3&ETY`S.J:0FUM)WO[<T8E0!E*#XRI/'HA$YG#2G;"@7J_`%?5->UUE]GU
M2>KW<Z;0UYV+0/MRYU@O5U+*T#DRN$6EB.G>I&1),FQD=TR5:@CDR4-!PC$@
M@:.978M2W'Z^1)1IX$O?9A;EC23W7>I;DF)V!"JY1*Z[Z4ON*.%A5V[7'#7.
MZD,/?H["'%VK-OG-;)5K]"XU'WL<?<CW8'Z8O=3#R@Z.`#8P,T[X],M^^PR5
M<T67=/?4(@<UY.G:ZQJJGE+\<@A4G;'50LC+N<0ZOLEZ;FA@FI$X0Y*H**!H
MDH!^AB,T9K>M:`BYJYUO0'[L%NI">$(7""\0<,RYXI5N4GEF)FVT;:C=62:<
M60U)_P"$.I(XQ.P?TC6_`]DHVX!A>@[UH6@,7_=L0Q/4W-W(7L*K)6HA_3?)
MG64$;ZRGC0#9;R8R3%OD4F71UQ7`,`>I:29)!$*HL@W1Q7@:HKX:`L4:&!"K
MW2SUWKOWC>A[LJSDZM@IZ41&D`J1?>+=L\6E7]7E"^?D_<K4R1M(`SMUN,RE
M7L&]*3DB;R,H.@E:V!W7E`"I3%Z.T$7\7D>@:$`.AEF[\@^.]!%K01!^(M;_
M`-W6`<@_M;LWJBAO<AZM>9J:[4ZDKZB^TY<T--PU\@GK<\)4Q#+9;<QNAD,?
MI"P.LDC?\V,;CM.I+`J$4D$`)B71(M[U@$A+;G-N3;]PC5')D#N6*5X;S[ZV
M9-9%,.=TUW*>DRG*P;,M%M;;#DZ9K/M2L#FRP_Z81_346_J7-4K"SZ7I@A^+
M@;\`-[]%>F>Z>ENU.1.\[:[KB<8M;CA\8E4:54YR:EKC4TA[=,2I,YP69/4C
MZ(L!4>U.R14XMI?\(B$R=X5[T09LX6A`0.L2E*@G?[M2`QF75K")!&BO6LVV
M$&/.,<:U+`?.(Y-9'_+TJ<60Q-MJ>GAC,1)C4AJXE3]N>D3'`UHU,G&6!GGL
MW8F>+_N/O15,XZWI626S>.=%Q"8R1J*^Q>)1%V.*OQ#.PORQ/L`W-N;D\E7E
M%@-^6_I*C`;WL.]:T![5CW6YWO\`NK^>^<YVD2N5=<:<<SZQ:L8UYNE"4BYK
M5A*)TD5C@2_$M.:_E0]W2-:3Y@-$E`@VH*V$PSR$#T/W;%>(8EQ51/<,&5FP
MOHSCWIZLGBH;(9=?0D+<CF*I<6\L&UY9Q)NFS;^R-+F$`]'`T:AV7H&@'G;V
M!JO]S8X-=N>J;UZW3(HBSMLOLOKCC^3/`BDN@N[2&PJ:LN2/<=0O_P!!(^I&
MTE6I^G],`R?^+`+XA&`/Q`F3^YEI.H(CZ(NCX[&*TA4?8:G=J)?JT9V6/-K6
MWP=\57O`(PJ>8XE1)R26YT6L$K<TJ@\(?JJ25Y^C1"V:+>P,YZ*HZH6S]N#=
M+4CKN*@:W?UE.=RO"0;40>8^6[J@45D_U2D#@I^LYR"PA3U"2[">%IQZ\Q:7
MHP9HM_F!C?KX0HIK^V7K$V9(D<M$G]=%SHR`R5*G?"B4K#";09F1.60YEJ20
M%-+.E+2)]:#X*3%A+#X!KQ@$)?6Y?T[YC_:**+\K56%!8M<45UDY0IWV(LL;
M%)%O0]LQYFD)'S3J"C5L=4N@%I`!@V$TY.$(MZ^6Q:`MB],M04W._2AQ]6Z-
MN0R2N;FY9-+MM(8>:<.82BX$\B%?AKXO$%.O5NSY-G]Y)6'B$(X)FO&C!_`(
M]@:4O#TJ-L!]2,U]<W`MGRB//T3LUCZ"IYTO"3(9FG'941M1FNII@\X-31Q"
MS((.]O+"2405^EC3$JM@5JBE.Q*!F@1(IKV]-MV6A6?KK]VO)TCXCZD_JW44
MRJ*Q'0M3_H]6K=-06,PSJOI57TT7DJT4/<W>;Q](!":0X/+$X?="0_?DC4A(
M&!UG$CV,L(M^?._/GY!^.];T+>MZV'_@^-Z_+\?\<`Y4OWC?^R):_P#\M*7_
M`.Z]HX!TG<Z?ZOE$_P#V;K#_`+DL>`9=/D31)(K*8.X/A[*.6Q&2-`E36ZDM
M3\A;G%M,:5SPT*Q:-,0J&K]2+&!7],1:8X18A?GK6P.:/C#^3ZB]=5S<1>L>
M.N74_,]%Q[I6(3GM/IJ1(8C2LN?Y2*=2:UHM4C)#8>M?>B38:J>1MPSF]"S1
M,XW_`"6G\X>C?(&B/3&K.6_M1+C&I5*UFT/-GLF;TOW:@X_[1"6&[#B4*;Z@
MQ!(2%[,V()8-:`$0Q;UK6Q;\@2I_;F\?<PS#TG<Y+IA158S)7T+#K&U="V:1
M1LE[A8:=KN"S8BU-3ZXR0AT6Z8&6/-9!#>W$#*0M^]FFIR2SSC31@5<^L"R9
MAZOV']S-3-5.*Q\JGU^/LCMKG../)ZY8BC$C<XS<NFI$(QS4K4YZ=,AB4?"O
M"('R<#6_9Q@M;-WX`NV_;5-3>K]-7,<ZT46KG-POE^6A:LD5*1K7>:V9([\L
MEN?Y;*59PS#5[ZXMK.D+-V;YW]$DL'C0-:U@%:7J(;B.6OW!/N$]=-=(][Y9
MDD9:^GFB!'$BU$X-.'?51/JEK8&09:QM2MRE#>2MMV`(RM&HF5$$18OH!T4!
MZ?H[Y-YPNONK]PHCMZG(%9#`T]O6#531#9A&VIZ@C)"IK.KE_F]M8X4K3&QU
MF4R$B.-Y"E4G(`J$E1E%!,"`.]"`L.ZXH3A'C7L;UM7Y'U=MEWI1%:3_`)AX
M3]>W.Z.-._\`5M'*V&0,[RJ;8V]EIQ1-@A3!*%*J0RIT>6MF2(TA!K@K$83]
M)0!`VXGF]G?]S]ZG7Z\(!7=22"3<N](-[7#*XG;Q8;F7`T$*Z&4M2&S)P;&8
M6U/+_MT+,/$W-R-0U-PM!"4K6;W];0&YK9,'_P#UW\OE_,>P!]6TG`$.QBWK
M0=RR^1[#^._/QV/7R\?^]^/YX!Z'L+N9QL_]R#Z?>)Y@E(7TK6D3LCJX<?6'
M%FMS]<ZZ"7LCKR3N2?X!TH7U\IK!.)IT/8OIG+U`M:\F8!N/]U51T7G'JAL"
M^1?48[4Y$L2IKDIN>-0C$LHBTC>K.B-=O*9H>$ZA*O;D[JWRX"DSZ9@@Z6-R
M0[X;,(+&`"M?WS60Y]+?M\?7#TS83*A0VQ<5I\13"4R%&D)(D:!ZF5.6"ZR,
M]F>]HTKFT:7NAPU(2R=E%E"'K0=>->=@=6]>\!<;5C-H):$*YNJ:.V=7=5.%
M*QRP4$3;0S(-<.Y@37I@>7\)(%,E$^'[.-6*W#2E:><L5C$;Y5J?J@4,>@AL
M;6;V;?N-FEG;D#0U(.VH&2B;&M&F;V]&3_,W3`ME)42,LE,G!L6][\`#K7G>
M]_GO>`?SZ0IKU?U[!.YNCJYZ0I&N)?8/L+Z!2V2RSOEZ473,V_47!%VZLHR*
MQ]=$U5]W"(56HF]N8&XIK`D;"23M%[T8:<'0$N.+?2V\<=]&=UWV/K]7)U/L
M!BL]33ZK8%2[53,+A]@3![5/9=D0%&39\Z7HW*+&2%R*2)]CWOPY[$:H$((-
MX!4U2/?/4?H_@\)]>OMTY,73SAR(,Z^E*K[THF,KY/5[Q4;@)P:&ECMN$I6L
MQ`L&>RKM)EZ49J"0Z(^7S1.AOR5&@7#?T\]/W_J(KC_8[_T!_P#&-D_V8?\`
MVW_XK_J]_P!-?\=_\/`-T>W6`=47]SH"AN6^?DEJ2IPM[G&S5TBEMLP*L86V
M-E%WY`+P6-6S'5P<98N=WLZMB&XOZ;5I(3IP^OLX>R1$B`LP@,CD<NCB%UF%
M>.M;/IA8=K8H_/D2D:UO4?`K9F@.D,>G]E5IOK;$$!@3PF"T#R(L'G6L`H*[
M']*+=,/:_P`3>T;G%(R,4RA]VQEQ[!A)JTMI1V'&6UD4L3';\>)/-+;13B(I
M=%I79($(#'A'])47_P`M3':6@9=[VO4];OL`C%#7_P`@6*CJ'N/CR6+)A2DP
M5O)\7)?VM:-$ZKHD*4HD"Y0Q/Z:2,#>L9%AX1-Y!@EA"L/T%AAA8&G>>&7W[
M]JLC5SA[$Z<YHY.YY+$TI>@K3KF3-\KN?HN)1QQ;E3W6<)C$0L>70FNVBYRB
MMM\C=C2"=)F8Y<6A3%GG$A+`SKV*>M#I(7L!YF]N7`+7!I+T73#,;6-W\[3J
M2IH"T="4P>WOS(<BC4^6)'-FB4\31J0J6PD:TLI(,D*(_P"L6-$).J`V3UQS
M/?7MP<^7*NO/G*1<M<@5!=,-Z#Z!C%QS:K9-;UV3."M#V7$*;@K%2TJM>)-E
M8`=GL8Y%(G%];7!8GU]L@0>=B4:`EK[/?6!1'M%YH=.?+D4N475MCJ5,:JM"
M-(T*F5U/8")&I0I)`R)UHB"7%G6H50TKHU"/3E.*0?Q^J4>4F4$`:!X_G/M2
MY7KF.T-V-S8H[4-@#>*-0WJ[E*SJ@;GJQ8HT!TEC!]PT_P!`32C5\:GP&PH`
M%SBU.+LF7F>!FA"?]4X\"(%Z\%]C^Q'V?\%=U3ZHFCC6E^#Y"N?4L6M"RXA9
M]V7'_P#63?)DJ<N'4X=(Z_KDE0)L$4,U5+7$911I9FRA#T,G0'T/=KZG>JNA
M[MYX]B?K8L1MK?O7F=N'&4:=Y?DT9:[,@(756YMS/IV7H%,>&[-)\C=DJM$^
M"TT/;$X'(E`P[+(T(#->8F/W2]JR"NVCV6TUSSR%SS6DOA]D36`U+(MV#9_3
ML[KE[9Y%`(N\G)+%GD2K.HFR<-*:0/)11AZ]VT@3-@-!2F*18!B#OR;W2H]^
M3%[)$_-",[FYDY9'RL(XR\ZK(L95LPUW?!68&([=/T\+0%]=/M/TT3H!;M*#
M[KY!-_Y%@'M=_<D]OWE[</6]V15'.K=)J1X;-G9<U7NEUUC%95/B+.TH:75=
M!XNX.1XR$\6:M%JB].REO.<CMB(V!+H.CQ`?>]DWK5Z-FW97)7M?X%20HWL#
MF=&7$;&HVT)`CAT=OVG%Y#\F<83_`#^C3OC)&9TVM$N=6D*HX`T1R=<`\"D(
MD)05`&PNO>;>A_;NP\\T%=?-TCY1Y1BMN0*\>HV^YI_4LNM.TE->$JW%@HFJ
M6:EY9:T=U#GMY<M"D$J='1F5!2I=$(4)PS31@`P']P-Q5UWW?S]0G.W)%),,
MO%6/1M<7Z_2>66M!JVB:-HKR.S1D0P=F;G$UQD"AS<-R@&M'[1%(DB<GR$1X
MQ;+`!MOW2T/UMW_ZQ)WRY2'.XD=N7V*NA/Z&;V]5S%'*J+@UD1*P7+3O(4CT
M[E2\Y?J+?;H0M90RQA.^J>8F$7L@0'V[@J+K2>^F%^X^;.=!%])3'C?7)JJ(
M'W'5X(4R/IM1-M9.$],L#]5^V<8<2(1ZPD@I"%U4?#1)B5.$SZX0-;<@<_=G
M4-Z34_#4MYF)6='0WG>R^?&5B:;JJQ1!I:NG#;.D#/--SDQV)$P1]"7($PG!
M,>W&.!1@]A3%+`!$;H#U?4UP!<E7^H\/J_[CJ(B()M0N^*QEKU#[.B4T9IS#
M+ME<UD9SC&%S"=IVB[^T(YL:3\%R(192E*6>4<=HW910%7O(7+O[C'U&N4JX
MQY5KCFWM+C@V7R%715L77/VR%)JA;I$YGNRAQ=V%!.([/F-I.6.!BQU8$R%]
M2_J?W!S:?H!X@F@70V!0GL'H3D9"_4"]PKH3V#37IJN>A+\4.CV35U/6@(]R
M9&*T:S;%#Z<>MBM+QRHF9)%XT2:)6ZED-J188`U8(T.P-%=\\T7[[@Z.J+F:
MQ.,9IR0G:KQK>T;!N:Z;%H&7*:J98`\JETA0<_%4W8-COL[GU@M&C6DDUR21
MMI2H5HU*DT9A1208'0HF*$22`L6]"$'S^.M[WYU\M_'SO>M;V+X^/._[=_C@
M'.E^XKXU[0]DG*3'R+RK1C,^&I[IAEHOEI3JVH#"(P0TQ&+R1&!H96)0X.,J
M='5<[2K99@E*5`G)+1C$$1VC"]X!.>F[I[[@U15E"I9ZWWDV41&NX?%'TR+]
M8\^N$=&\QR/(&5:H8UKPM87,YJ5*$>S21J$9)V@"UH9>MZ\8!HFK.6^SNI'7
MOBVNW8I%^:9?>G/CKQCRW`ZYLEON%PHRCY!%Y&KG$_63IE:HZE>)_9%D2A"M
M7A+(3:*)BR$@H```T<>!`?UGT%[G*(X)>?6'.^8^?ZA1US&+EK^O>T9+=K%.
MHB[0VQ%\K<VTQBH"`HU4HEDO3.\I5%E+'MUC;>2B.3J%9"@X@:-6!D'J1X']
MB].>J6XO7'T=55-T`T.=-]BU?$Y,HM$%KS2:SWH)0^`ALP7MU?IE,5@5:PY)
M)G'2HD2]X?'K1B4TM.W:(-*4@;P]6L>]B/KRXAKWA:?^OYXLN<4*VR]BK.XZ
MPZ3H<SG^TM26P)S-4CG,G.922)VW5)"$]]"2H**B$A.,3[*-*+V>88F)`FEQ
M-ZU8[1="]4Q?H1Y:;NN?ON>6C:/9TO:TBYHBLJ>+8:5K$OK6OB5YGZZW577\
M7<36IB^[&%;O1AZH02!'Z()`KR]8G,O?7IX8[1XQ44')>U>/0V7+[&Y8NJD[
M"I6*V5"FV6&)E+M75R5O<<_J\*82IT&)4!U:'%V)(6&JQ?`9!Q)1`$V^".&[
M)Y]MSM?O_H6/1>2=B=L2]I>G:`55($SVQU34$!CK>RU=1<?FLL105MDTE2I6
M\&W][.+;T"]>2G^G\22/K&@1']._)?<G(_7_`+,K*Z+YQ8H767>O1CUT1"I-
M&;PKR=KZX,,DMDO"2%3EA;Q-J]><N03<@`5[4!466J),"84$H6C@@?"]C'(/
ML"KOVW<G^U+BJFF3KUHB%'2#F^Y>=WFSX=53JSQAS<)<L_FF$R6>*B&5K->B
M9B(P\\D)YQ2ML"`P@TA8/Z8&F^DN1?;Y-_;AP)['VCGKG:;(JLJ>U*Y<*A;+
M[!&(USX&9QRP8^@U9UN/D;%++:5GCL?3HI51:(A)"-,8UD)?B$MU5@;)[%Y'
M]C<&]OG&WLYYYH.N^MQ1KDP7+]]PM-;$<Y\;X_)UZF<J'2?Q]?/%4C<TD&/<
M)OI4G`!,^KDZ9,-.828<,L[8&R/9KZMNL.EG+A3NRBI93#3[,^(WUFDY[8,A
M^B]$W*S*7=+)I54B9R=1/K\PM+4Y#7)V5<X!$8N1."P*L24U068F`V)V)4G8
MGMEYTB_'%A<OR7BRJ[*FM9O?9$PM2UJ>G+N*NX!.(].'6L>:2:=DME&R^1S)
M[CA0`2&0EQ9,SH2@F;3*CSA)R@-8^^S@?IKL/CBB>,>)*,C#HSUA;E26.2[R
M:T857$%AL)J"*2V)Q^OV=M<U*Z4.BTQ,\)"@&:2$)4Z4GS]<PSR5H"^6!S6>
M/5:-4FFM4/$*L4;")<^U43*X=)UZ!^))$(Y@;)>A>B(F[%J5(?@E5F*DI8@C
M!L_2<7S"`"A_U)\E]M\M]U>T>\N@N<6R&UKW_>;;<T%=HU=E;SESKU-'7^U%
MJ6.SMB0*6]8>L=FVP21_<->UQ2=42,H01%["HT!`NPO6M[=_5MWS?O5?J%C=
M:=$\S]92QPG=H\BV)/&B))&&7/:\Y]=U)2:0R.`-Y(6B3O#@;'79G=-+D36J
MVVK$QY(`B&!<OSO2OL+G,-O+J3L];6T)ZTF7/LSI;GR@.?754K@W.#0M)7/(
MUQ5AOCV[F2JV;3GS<Q+75RTI`V-:)B;4R?>_IJ#-@:T+F?L6O+BJ9\N]9^M@
MZ0=!6!2#E4,LF26]N?73CZ=O<GAZN.JI_+7O^?5-M0QF2"-`YKV]%#7M<F<=
M"*;AJ`Z)5;`J!_\`Y$T7_K#</]GG_H[_`/517_K$?]M?_G?_``)_Z$_SO_SG
#`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g281487ex99_1-pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g281487ex99_1-pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C`!#`P$1``(1`0,1`?_$`+0```("`@,!````````
M```````)!P@&"@(#!00!``,``P$!`0`````````````&!P0%"`,!`A````8!
M`P,"`P0$"PD!`````0(#!`4&!P`1"!(3%"$),146(B,D%T$RQ8=QH;$S0S2T
M-C<8>&'!4H*2LD1%1PH1``(!`@4"`P,'"@8#``````$"`Q$$`"$2!08Q!T$B
M$U%A(W$R0E*R%76!D='2,T,4-!8(H<&BPG0U<H(E_]H`#`,!``(1`Q$`/P#?
MXT8,&C!@T8,&C!@T8,&C!CB8Y2`)C"!2E`1,8WH4I0`1$QC#L4```]1_1KX#
M4T%:X#D*GIB&L#YOI_(:B*9*H)UW50/<;_4H:76[9D+`G0KE,TQU88E5(>A:
M$EG\&LJT4^*B`E-^G6QW/:;G9KE;2\(-QZ:.1XKZBAM#"@HRUH1[NIQK]KW6
MUWBT_C;*IMB[*"00&TDKJ6O532H/CB9]:_&PP:,&#1@P:,&#1@P:,&.ATZ;,
MFSAX\<(-&C1!9TZ=.54T&S9LW3,JNX<+JF(DB@BD43'.80*4H"(B`:_2JSL$
M0%G)H`!4DGH`!F2?`8^,RJI9B`H%23T`]^-:_GQ[G=DY/Y%B?;K]M^5^K[]E
MB45I.3,[P!W"E>J-;<"5M:T*7,-"&!RUBXH[A27GDQ!JV;)'19J*KJE42Z,X
M)VTM>-;:_<+N,ABL;1?4AM6`+.X^89%/BS:0D?4D@O0"AYBY[W8;EF\)VP[:
MR-/N=VXCN+N+-((Z_%T-E4A0=4@-%!\I)S#[^.N$:EQNP;BO!5&2[55Q92(*
MGQ9Q3!)1\,4T*F^F7)`WV?3DB95VOZC]ZL;4'WW>+KD&\W6]WQ)NKJ=Y&J:T
MU&H6OL444>X#'1.Q;1;[!LUMLMH2;>VA6,$]6TBA8^]C5C[R<31K4XVN#1@P
M:,&.)CE(4YSF`A$RB8YSB!2%*4O48QC"(`!2A\1'T#7P&I(P8JSD3D[!PZTA
M`8Y:)7:QLFSEP_D@<IM:=7&[8IC.9&:G%5$&GA,B%$RJG=3;)E`>M<NPAKTB
MCDFE6&%6>9V`50"68GH`!F2?8!C\R.D4;2RLJQ*"68D``#,DDY``=2<*)Y!>
M_OA'C_,2M9JQH3D]8D(B/0#\KY8D?58"W)1R2$ZQF[PLT=Q#^/:S;=8=HY!X
MH"2A!*H)1#:V<4[#<QWPK<;R!MFWL-59165A4?-B!!%16A<C,=,0'G7]QG!N
M(Z[3;V.Y;L%!"1&D1K49RT(.8Z*#^A9L38_=<]\65DHAG+,\&<5`>$:SXQ@2
MM7Q@5@H<XBU<'2='NF9I84$1_#"K\M!00[GB@/I79(^U/9-%<J;WE&FHJ5DG
MKD1U`2W&8(:@)`--9&</M+OO-_<%/I23[JX:'\Q35''2@\M#Y[AA\I2M?F"F
M-D_@?[;W'C@%3EHO%\2M8<@SS%LTO&7+0BT7N5G*@8JWRULHBF5"NU=%V`J(
MQK39/JV.L==4.[KG'G?<7D'/KSU=S?T]N1R8H$KZ:>\_7>F6L^_2%&6.J^W?
M;+C?;?;VMMG0O?RT,T[T,DAI^94KF$&7M).>&`Z0<47!HP8-&#$29+S51L7(
M=$Y("\G%2`+&LQ70ZFG9U/1'J0`X%9(*&$`!182`(#]D##Z:,&$Z\X_<1J>$
MX!1UG.S.Z\K)MCN*CQSQZZ:N<FW!,?ZNXM+ER9-O48$YNGNO)7MAT[^.R7/L
M`T/A/;+DW.)EDLH_1VG51KB0$1BG4(*5D;W+D#2I&)QW![I<4[<V!N-YF#WS
M#X<"4,CG+P^B!6K$]!^2NNA;\E>XK[H9K#7,)XANJ.!8)TR.\QCB5HX8T)B<
M[@2ME;_=Y5U%JY1M*1`!4R3IPMV@()VS%`@@`]7;3Q[MGV?MDDO9XAN\E1Z\
MQ5IY*#]VG[M?_'2"31G)&.*MYY;W>[\3/;[+!+%QZ-B&C@)6(*:#XA)!E('4
M&IS%`,73QU[3F,<18\/<LFXWYE67+U>5;6(MCFL)8W88)KZD5^(2CWE2E<JN
M96<8)O2E,+QZL?NCM^!$/N15IN[^Z;INHLK#[L79Y*IH2X<W;!A0LKA`BM2M
M%`H,_/\`2Q4^.=@^-[#M0OKX7\W(HB7#M`/1#`5"^F2=0)H*GWT6OF-_L'\M
MVCIK$2UYKUBP'8$.S$QF3*C674=07*Q!%)LQO5&C/+:54CM)$%.J+[S44Q$Q
MF)2@(A+N9=J)YIGW'B\\E[,[$R0R.#,,@2RNS`R9D@CJ,J$XM?'>=R;3%!M7
M+K?^#4H/2F1-,++4@:D4?"^6@'BP&&XT'E*=JTB$\J-H\T3+E*$!E*FKI3M'
ML28"!?(\J,,Y12.'Q4!$3'2'T411V$`B%W:7=A<-:7T4D-TAHR.I5A\H-#_E
MBL6]Q;W<*W%JZ26["H92&4_(1EBX47*QDVQ;R</(,Y2.=D!1L^8.4G358@AO
MNFLB8Z9MOTAON`^@ZQ\>V/0T8,4AY"Y\G*Q%R3N'M%,H>.X]=2-G<HR$\U>R
M+642ZR.:]'5YN1::1L740X(M4FKAVN!!43%,@&.&=MNV7^[WJ;?MD3S7DA\J
MJ,\LR?<`,R3D,8.Y;E8[19O?[E*L5H@S9O\``#VL>@`S)POZH-\R9V))SV%(
MJ7QAB]NA)/[9R@R>V[EWGH]DBJO+.<=0*ZRWRI11LW4%)PBHJY*.P*/T!W(%
M1M=BXEPXK_4;KN/*FH$M(R&ABD+443L,F-:5!.0KY"2#B>R[_P`CY2A?CR/M
MVP*"7NI5^*Z@:O@QGIE](U'OZC&OSQPX56CF1;)[E'F.0RLC09>Y.I/'D2MQ
MJY`YRC,JU&(EGK,R,M9\7.(5&-ATG+3QUB,I8SYXZ*X'9,/O%.A>;]R['A-O
M'QG:HHCNXA59-$L,:VQ*@@Z7IJ8@U&H!5%-5:Z1R1PSMI<=RMWDYIR][L;*9
MRL$8AED,P5B*LR`Z4&6I\];5-5%*M>O;+#N$:X1J[PQQ_B3$:N#UJGJ>UCRK
MKREC?$!+NIQKN7R>S8E[KA0G>64,;H#]83&]!BVU2[WS6Y,9GW"6(FDDKWEL
MRQK\ZC5S^B**#F:&E*8Z8BX_L6WV7I6=I;*$%0@LI(\JTU%30UH"2Q%6H:#H
M,0?!<>;=FB7)=<AXPC\05<PM3Q-!JGMN<L7T9+L1,1PN9P$+8D'"*+@%-TW2
MKI9;<0[9$TR@&F;<.;[9Q^U7:]JFFO=Q5:/-)=6U%8#+2#I%`:@QCH.K>)PU
MXO:W=RSM"([8H&5EM)*&HZ*0:T(\S'V&@ZY6U:XPI-=CT0:81Q!'1\*4KH'3
M[VF.9*GB@R((I23^1>9%*)UFZ0"8SA8XF`=S;AMI$?E^Y32F62\OO48U.F^M
M%`^0#H*]`.E/'&[M^.[7;*B""*JK05LINE*$9DUK7QQ`V.+A<6N:HBE\2K]%
MY13RFHZ<RF,6&(KM0L5,%FJ:KEZSFJSE>YVN4*0$VZAS/]X\8M/H*DY$1#H+
MOG/&M^MTV?EMG-)+&"@O`R/.E`='S:"0!CYCJS&8KTQ]L^&\BV8G=N*7,,<D
MQ!:VDC:.(KF::6),;5R`IE7J!EA@6+LXS=6OB5`3:3W';-+EVT;N</Y$.LXQ
MY=G[M7QVY:59GPBW'YBL.S5)Z8IE.H"H/UC;`*IO7")+2UDW?8+J'<]BC"ZI
M8R`Z5KE)'74M*9GIF*5S.&S9N7K=W:[/OEO)M^_L3IB>I209D&*2E&%`<NOR
MX8-_F(D>S_6\7^5\K^2[?4TQX?YF^?O\H\GY5O\`37R?U\WI['G?<=_;[>D.
MHPYX6;R.CV4@K%-GK1N\;N^;6/&;ILY2(L@Z:NCVINX:N$E`,19!P@J8ARB&
MQBF$!]!U1>WD\MM]]7%NQ2X39)RK#)E(:/-3X'Y,(?<"&.:RVY)0&0[Q:@@Y
M@AF8$$>((P]![#Q[V&=P*J":40\BW$0JT;$*W338.&IF9T&Y4R@1!,C8PE*!
M0V*'P^&I^DKQRB93\16#`G/,&N=>N?MZX>'BCDA,##X3*5(&61%*?FQI7XJS
M.IP7N.9.#^>J[&,[%A.T6-]BB?M^;N5=#99'I-GLBC^FPE:@<.S#JK-5'T9)
MA(-W!T6X.BJ*H&_$HF*?K??N))W%@L>;;`ZFWO8D2Z"Q6[/$\<='?7*%:JL`
MA7(``."0:XXLXEOT7!=^NNVW**0SVURPLY9Y;M4EC=P8E`@=4HQ?573D"$S*
MD">\>1]2M,P?*^7+WAZ7=RC=P>-Q[>\Q<_40I[=-VHJU!PHPITE((&8I(%41
M2,]$$3B*AQ$X^F@Y!-?V%E_3/&+:>.U234\HCLVUL*'R,'44U5)/3H%H,5_;
MH;69S+N%S:ZE%`6FOR6'75^U72HJ0HZZ3YO?+.0.3E"I+*%?5Y#%F7RR9D%E
MF^-^6W/0Q&,4;<%7;J6LTE"Q:+L"D^[;=1E/7<P$+MO$KG<H+=Y8):K=I44-
MI:4U@_-8BM!7J14CV'#C#Q>6;T9X!;RV,C`L5NK]3Z9^E'6=E8D?-!H.AJ1C
MX,8\?^6/-::=R]71MV+,*38)LW+FSY)RW,X_-%)KBL8L9'7JXV.:OD@(D#J5
M2*1J<Y2@91$H``+EW?37FGUEB&GZD:)^?0HKASVW9[+:2YLO5'J4KKEDDZ=*
M>HS4]N7B3A\'%'A9BCB=".2U5-Q9+U--DV]FR%.(H%F9%$A@4"-C&J/4W@($
MBH`8&J(F,H8`,LHJ8I3!AT&-IB#_`'"$&_UCPQ<BDCY0<CJ^@5?MI]\&X^*H
M=(%NGN@B*I"F$H#TB8`$0W`-5;MA&SP[Z2"81L\E?JUU+IJ/;DQ7V9XG7/60
M7>RY@2_>:D>VGIO6GY=-?R8KO_0_O`_:&I%^IBD?IQCO(,=G<$(?$.<>-1#^
M$'-F$/X]4;@?['?/P*X^U'A$YW_*;=^,VGVFP]H?74_(J*8>,:T/OI80Q9E3
M)F))"X24E3+9!XUGE:G<JC'LWUG6?_.7:\?%2K-5]%&D:\28:MC`H=RDI'"=
M15N;K,=-2W]K^YL/`=DOH[D?Q"RW$96W+$%@11G0FJK05#$BC5`()TD2/N=V
MJVWN0L7KN]IN4%&AN8P-:L-1(?*I7II\U0:TIG5?%[YOY[88HQ+BK.?)*ZL\
M?/3%IK*ZV%C+ME;FDB];)2,K>+!3X127N$;5$%T_+,(N3HMRE%8JZP]9U"TX
M[OG<O?KZ\XI80Q1`M*8E=42-3T52["K-T`44+'(*,;N??]D[:<=L+/E^XEF"
MI")I!G(R@`D^V@IUJS#,`G(/XX<>W+QD@JS4\LR=EK_)>0FV+6>KUG;*LY'%
M()J@0R+JN0S9P]93GCJ%,7OR"C@>K?9%$Y=BI-Y97>W73V-]%)#=Q&C(ZE64
M^P@@$8=K&^LMRM([[;Y8YK*50R.C!E8'H01EAM***3=))!!)-!!!,B***)"I
MI(I)E`B:229`*1--,A0`I0````V#6-C+QV:,&%I^X.'5<>%Q?^+DG`%_Z@9A
M_OU8>UG_`%W(/PL_[L3+N!_VFQ_\\_8Q7?MCV?@/^(G;^)?C\P^'Q^/\6HQ3
M[&*A^MC%<_&$ZL"8?B;G!C81V^']9LVJ+P/]COGX%<?:CPB<[_E-N_&;3[;8
M>L[<I,FKEXN8"(-&ZSE8XCL!$D$S*J&$?T`4A!'2!AXQJ.Y'K=JY(66]YVR[
MDNO8RG[?+/G%(@,V5/-=9HTQ0E&RGTN-<RQ`T][38>&:MC)-VQDW"W6H"BZO
M08?MM_%-NVY[Z*^WV*2?:`X!6%X]>JM!J1G5BO4Z1\X>XX5^0;XVW@16TD*3
M@C7ZJRA2C?5E12JN*]6\M:`E>H^.MK0_)7'*?$?)*>4[JBR(:$CH?'W(SC-F
MFL-'L6F1!B^QVPS?7JO:*S9&S<5>P6,G"&7(0.T8X*BGJZ26D_$+Q>7\8$"V
M"U>GH31LT3#]Z8V96B!"FF@%6)/08D'(-JMN6;2=FWM9;JUD8:5ANH+BAJP!
M#2D21R+J%7#@,2J]<5[J]AYV>S#?).=Q%2,[Y#X;JBC+6VH9JQ9+U"N1YU3(
MHR0R$I7']TJ%*M!3]LJ,W$OU&+L!_%H'$`3TX3P\)[U;>J;K+:6W,>B/!,LC
MT-2HHP1Y%`KK1EJI^:1F<19)>X?8/=#<;6E]N'!9I"9([B(C1YA5O(S+$Y\V
MEPVEQ0%>F-J'A5S[X]<ZZ&%LP]9@1LD:V;'NN,+"HU97RD.UB%`Y)&+(L?YC
M#J+[E;R3056;CX`<J@&3)R_S/@G(.#WW\)N\=;9B?3F0$Q2#W,1DU.J&C#WB
MAQUKP/N-QCN)M@W#8)@9E`]6%B!+$?8R^RO1A53[:Y8NSI,P]X6I[@O]\^%?
M^I6O?RLM6'M9_P!;R'\+/^_$R[@?]IL?_/;[&*_?T/[S/VAJ,_JXJ'Z<87GS
M]>O_`.N#&W]ILVJ)P/\`8[Y^!7'VH\(G._Y3;OQFT^VV'K/6:$@S=L'1.XU?
M-EVCE/<0ZV[E(Z*Q-P]0ZDSB&I^1J%/`X>!EGC7DQW?GF!KQ9.,N1<T\V:3D
MVE6J5A**EBIE'YKI-DQ\J524J#]ICBW4>_R$4S;UPB22;2.1\<Z1>E,I%`4(
M#+MEQ_'NMJ\&W_#2NJ0B`MH!RUJZ:G/R$L:$YYX6=VM_X0BZ2?<5]1PNF(&=
M15JDLA1]*FM#T`6@6E!CQ,YT/`^=680U[Y/\5'=T(Z%6&E^3/$:4X\9.CWNQ
MBE:NK0A*XP%VCNJ(F3/$G(93<4^D=QU1^-;]R#C$DMYM]K>KMLC!'2.X$L)`
M^H&JV9%02S`CK4`83;V.RO)`!>;>]PFJOKVIC;2S9!F4H,F"T8**D56ASQ#,
M2AE+CF@ZJ-V0L.3L9V%L=M`Y!XG<T[._J\D@H`HR$`[HN5!M&,WC`T>8=XZ2
M;IG!,QP%15'I-ILNK7;>611[ML)2UWF(J9([FT",IH-+B2,*U:BJNIZ**D-4
M8QH]ON?5>Q">IM<OJ(1!?:E6,TJWIRAPVMM0*"NGV"IU4HSUP'ROQZF*YRQ]
MO^I\S:?<X)^>SK1[JI8]N<8I$R2BK]U+4B\8`FIRJ2=3*V#H?04I$HMEVX]`
M`82]@7/C?<2QW[U.&=PSMTL,BF/66,?F2BZ94F`996;S(\;DU).0`..<N7]J
M-[X5,O->UB;K!?1L6DA*)**$U^&T-0RBI!1DH`*>YG;^U?[Q=-YKD:X7S&TC
M,=<FXM@H*35%0K2I9:3C2*_,I"FI.5CN8JR,2(&4?PJHF.0`,JV.JD50B$A[
MH]HKOA9.\[06N.-R-[R\%<P)#2A0]%DK[`]"06M_9[OAM_<!!L>]A+3F$:YQ
MYJLP`S:.OTJ>9H^H&:U`-+.^X+_?#A9_J8KG_:W'^4-+W;261;C=HE8B)MEN
M:CP.G12OR5-/E.'WGBJ9MH8@:ANB9_+')7%?/Z']YG[0U+_U<47].,+SY^O7
M_P#7!C;^TV;5$X'^QWS\"N/M1X1.=_RFW?C-I]ML/@T@8>,4.YM<*(7E'`QM
MDK4DG3,W4A,%J1<TQ5;INTVZPO4*_/.&8>:FQ!Z'=:NDNI>/<&%0@&*91,Y@
MPEB+Y$YJX_3-@Q/R=O/,"/NS"303;EB+)B+)T+)1SYP5%-PO5.0U?EJ[+U],
M@B=N\CIIJBL@)BF`#$$=,.W;A;OHLKB"R1=-!,XE0J0&(9FB;54FBUTTZ5H*
MG"YN6US*DUU;W%X0V9B71,#D00B2@]:UT:BI(%%'C+5KJ>-IN$"5RAC[##UG
M(MO,;6+D![>V2<..5F;OI4*[;\@.+TW/T11PNFKN60:@5,I3"=/</B[V6XW]
MI,DVT7$R2G3E;7:3UH"`/2GHU`NKRYUR'2FE&NXH((_3OHK=;=GH1/9RP5.2
MLWJVVJ/S?68>WZ/6M]&MUAXV6Z)C:;EV8LF$+$I*%@6?$7G1$WAQ4)`ZZ*K5
M.0HV=X%NV3>-$``%$7[1-%9(1,8W6!MJ+<VUESC;9+V6WCAY-'I!%S:,BR(*
M/E)$P`J*C4`66M*@4.,.);K;;E#9/(\)>L@MKORU-49O2FHJE6"E8P0ST(`&
M*]<\.$ELA9-]S1PHAR]JF>ZA+1639$+OQ_JT;"3:D"*$DI>8S(G&EO+XX:6I
MH*!7KE9V1HVE&R:IU%"*"85F/M_S^WG4<#Y"NWOMCAX%*S,6J:TB,<X#%2"4
M6A)5M*TJ,H7W1[7SVUV.XO$A>IO,#1SL'A4H_I#49EDC9@&8KJ;4`I)4T6N'
M2Y6S67D;ASVN<XD;I-ULH9)QC;I)JB)2HLYU_%199YB@!3*%[+.;\A(OVA^R
MF'J.I9QOCLFQ\BY/81D-#865S"*FA9&;RL,O!5J105)Q==QY$G)=DXOO(4J;
MZ>*8CZK>BVM:>YF(Z^&.?2;L_J__`$WI_P";YA^K\-0W]7%J_3C#\^`';KP_
MI_SS8V#?_9W;..W\6J+P/]AOGX'<?:CPB<[_`)3;OQBT^V</;U/\/&#1@Q7;
MD;Q?Q1R?IYJOD>&`7[--8]9N$85)O:*J]4#?R(J0,F<3M5#@'?:+`=LX*&QR
M;@4Q3!C7@OF)L[>WWD=M]<2F7K+A61,,;!6?$N8<D8QCG;8JIW+4C(L!.FKU
M9MS<PF[D?*,G;5V7J!,QR?>$V%IN<]G$T,:0/"S5(DC1\^F1(U#\AI[NN-9?
M;3;7\BS2//'.HH&CE=*"H/0'2>@ZJ<9])*Q/*O&T@Z%/D#9(^7;NXI-WD[CE
MQ6Y=R\%((%,!3&EL2GJF?(99J<Q#%441*J9%3T!3J'JI?'-^CV^^AW"Q>$F,
M`E([B>VH/*E&23U$=JG5UH2#G08G>YV#11/:7T5[)&T@TM)##.'9#ZJ@R1Z)
M-'E*YJ3U)J!3"H,E<I9W'6*"\9,)K2JF>;]8I3$S=CC>\<H\<6*M,Y9\R@SP
MUXPE;K!*XUE'MG(]4AVC,A$7C9,!652$"IBIT38\)M+O>/ZJWG3'LUO''=%6
M2VD21PFK6)U`D"J*.3D&:@\IU4Y\[@<^GLK3^AN.R)+R"_98%_AVN(F@20^>
M-XVJ6+B0#,U)J:THHV%,DX4/QUPE[66$G"B*S_&&2<75.66;["@O.MHN--8%
MFXEW`4%9LRYBC^DH@.H-Q[=AOG)N3;XC,+6>QNW"FM2'=5CJ,Z$!L_!03T&+
MK?[$O'>/\7V0^::TN((BV6;+`^L_^S"N/6_\3]Z/[:U#_P!3%J_6Q'?(-TW;
M-X1=RNBW;-^;^.W+APLH1)%!%`UH46665.8J:2*2)3&,8P@!2@(B.P:I/;V*
M6X^^K:!2\\FR7`51F2=4>0P@<^=8[+;W<@(-XM"2>@&HX>^FJDL0BJ2A%4E"
M$4343,4Z:B:@`9-1,Y1$IR'*.X"`B`AJ=^[QP]8[-&#!HP8KOR;RQQLQ5BJP
MR?*6VX_K6+7[59A+MLA+-CLITHEZACHJ%437D9^4Z@`R2+%%9R4X`8@`8`$-
MQLG']ZY)>C;MBMI;F\/T4%0/>S?-4>]B!C4;WOVS<;L&W/?;F*UL4ZLYI7V!
M1\YV/@J@L?`'&A[R7Y&X^O>:)JI\!J;D=U59-R[95"1N-=;6#(!C+-%!EC4&
M&2;24O%Q**74=D]>[RS1-/NB*9R%5#J_M[V7M^)N.0\PN(S<JI^"K@0*":#U
M7-"YZ>046IH2P)!XI[H]_9>87"<8[>V?\2AZ3M&S2ZV!'P5&:$=237I^9IGL
M0<5<-AFV;S!R`GDIGD_"&6E<24*PN3O21*3U@K]3WI60='=(6?([3NF2`G=,
MI&(&47+W%#&401N\'=V'>H7XAQ1G79E;1/+IT^KH.4<8R9801YM04N0!0*,Z
M3V*[*2<;9>;\M83\BG0-$K'5Z.JM68L*F0@BGU3JZ^4AY_N!.F@WKA6R\IOY
MW^9*LNRLN^EY9FHJ-6XN@;=7>%N"YRDZ]NGK$`WW$`T@]M(0$WJ^DJL,>T3)
MJ.2ZI"@"D]-1IY16IQ8>>,#<[/"*&5MS4@>)`CDJ0.N517Y1B#NHOB?K%_Q1
MW^(?#YWMO_!OJ54/^G%'J/\`5BS_`"(P%-2["1CV6/J;D+%+]ZI-3-&+&+I6
M0\XL"P+V89@CD;`M.I>2H#=RQ<$.@D<R?CF3$X&W&T;QN6Q7R[CM4K0W:Y5%
M""#U5E-0RGQ!'^.-7NFU;?O5DVW[G$);1B"5-1F#4$$4((]H/NZ$XIQC.SYU
MX['$N!;!)9GQDP5-\TXX9*>F)DJIM$14.Y0QW.=!2SR+3J$"(-4B+AL`'C3"
M'<T_#=^)<R'H[_%'M6^E<KJ%:6\C"N4L*CR:JCS+XBI.=,(DNV\JXC\;8I'W
M+8U.=M)G-&M1E#)U>@!`#4I[#UQ?.@<_^,]PHUCNEEO\1B-2BQ[B0R#7<K/F
MM0EZ@FS$$W1G(2"J:$F@5T()$%J910YS$(*95#E3UJ=T[;<MV^\BM(+9KQ;@
MJ(I+>LL;Z@"!4"JFAJ=87+.I&>-Q9\_XM<6DEU<W4=H8$+2I.1&\87KJ#'P.
M7E)J>F$"\W/_`-&2_>E<?\&:HD<I%G3-SG/)$4HH5=-$QB+.\?8^54!11+I(
M8R3Z8,4HE$#>"(;&U<.#_P!NZK2_YU+6H!%M"W0D=)9?=4`I%X_3\,<T\_\`
M[I8D>3:.WELT]U72+F1:K4==$5/-4=&<Y>*5Z*<I_%KDSSNE2YNY$\K<)1AG
MKAFL[6S]R<I$'D=W`K&,=Q]-4TJDXVI3,K<GW"+QI&H%$P=+<Q0'52W#E_%>
M#1G8^.[=<272JVE+6V9H@PI^TD%"<SF5]1O:>E9'M_;/N)W-*[_R_<HX[>20
M46XF8,_M$:!652.E*`@GIUQ?"B86Q!!F?XVXF4FN4ZU-JU(165,^-.>HJ(W"
MFMDB+2@N9!M3:S"Q\,_<*`*R32.`%^DB221R")CIEWNN^SPQ[OR]IIE$JR06
M<=DPT2$'2AI(S2^4C-C0'S'H"+_Q_@7'.+1JG'[6V2]2/XLWWB4F?1GZIU1`
MPJK`FE%%:>X8E2,QV64:QV2>-&-\OU"P8:E9"?MF5;!F5MD.O3#RN-6[B+>U
M6S3,)6B_-G2[%=1./23,LX36Z!;"!M]2OE''-DL[S^I.:W<7Q$4I9VJ+%<2Y
M$4D`)",I(URYUTFN9RHVS\FY!NMM]W\5MG>4U]2[N6+01MD&,=%`D&K40@\3
M6AKABG%[$LQFE.L9SBT+%D7*-E9Q\[,9IR^=-S%T>925-W6-`@B@X8%=0;M(
MR;=R8KE8G0!D468;;(>]<\W#<=M^X=KAAV_CX_<PC-Q4D>K(:LY\3TJU3XTP
MW[1PZTLKU=YW6:6_W\?OI3DAITBC'E11G3*H!PU7\EIKL[?4];\KY)Y/D_EY
M`=/YE^;U?F%XW7V?,^3_`(3L?J=7XC^=]=(N''%A=&#%?\UXDQ=98"<N5K`M
M5=5J)?V!_=XGH9R$<PA6BTB\?2`D`$I!%FV;&.(J@*A2D^P<H^NO6WMYKNXC
MM;<:IY'5%7Q+,0%'Y2<><TT5M"]S.=,,:%F/L514G\@&-+Y[C+DM[O.47V:Y
M=M,TWB'1+,I36F3@J;9W)KP<<X[B+@S-%5BYR)D15AVS.7[YR9I$"J1L+@.@
MJ2G9J[_QOL9Q>/8KB1[SE;1B1H59C5WJ*DFJPQ"A`%*N%J%-:XX0EXYS3^XK
ME<VZO_\`/X+!,\<<F@+J532@I1IGI6K&H6I6HZ8O?B3BDQX`M+/?*9'90R/3
M))F#<F8<(VK'T;;T5.SVT(R]1F2,;7)>CIN?B=/\''=X=R*+Z4]SY9:]X(8-
MOL[N/;[U)*M;S!Z$4))C9'3U,Q3ZP'LZ8I6S=MX.TEQ->):S36#1E5N+<KZA
MH:TFUQR&,/722M`.E<1LQD<Q<GK2ZKEC4SE>';ABJ[I-3AW/'RQ)$.J[6(D>
M[24+C%,D<UB&PBHL\<M$^Z`?SB!3=6FM=KVCAFWI>E[>UBC)]260S"5C0U]/
MXGF9AD*'IX$XV5MO-_NNXQ#9S=3;IH\B1FWD1-8!.J1H%":2,V;4Z@Z:U+8O
M'A[A=`).JM'WN(@LT9$KL>=E'T''==K5;H5>5743%Q(9"N],B*_]5OEUB`9V
M1F9NS4$O0H\5*`$U'.4]W)GE:WX8)+:!C5IG)>1J"@"B35Z8&?2ASQ0-E[<"
M>?[TY@R7-X:$0KE&OCYRH7U37P^9[B,AGG)+-^/L.QA\=LI"'RYG15L-9JN+
M<?MDDL38D=2R81[=!XTA"H-9>R(*NBE;Q+0H&4=@'EB(>JD6GGGNIVN+EVDG
M<DLS$DDDU-2<_;BIPPPV\*P6ZJD*"BJH``'N`R&&X\2,62V%>-V(,:3Y@&P5
MNHMAGR`8#`VG)ARZGI9B!RB)#_+W\HHAU%^R;M[AZ#KRQZ8L7HP8-&#$$<HZ
MQ9+MQJY`4^G=P;7:,+Y-@:X1'J[RTW*TR991C=+I^T"CEXL1,!#U`3;ZV_'[
ME++?;.\DTZ(KF-CJ^:-+@@GV@',^X8TW(K1K_8;VQ6M9K65,B0:,A!`*Y@D&
ME1G[,13[>452HS@OQ2CZ)%LXNLA@G'9_EK8$U")3#FMLEK85Z)"D!:35LZKW
MS3&`#'<BH)@`VX!L.:W5_>\LW"ZW)P]X]RY+`$*5KY-(;,)HTZ1X+3&!PFUL
MK+B6WVFWJ5LX[5%4$!3D,RP&08M4M[R?'&;7GC?"R+YQ9\;21\<V]1-8JIHU
M(/IN8(L!@6:3$*4HMA:N@,)52D(*1P$>M)3?2R"58,I(8&H(Z@^T'P.&CJ*'
MIA=^9,A8"XW^?6;?::C5Q=-&#ZSX:XZ0T6G;;G;U&H*33FV/V:;6+KL,>2Z@
M11?N"@DF(=EJ0-AUEWFX7^X,'OYYIV'0R.ST\,M1-/\`/&+:V5E8JR64,4*L
MQ8A%5:L>I.D"I.*.RO)[D[RK=K83XKXW>XVHKPP-GU?QT=<T\\9*G.D#S)&4
MG`,2L&JB2H@J`*,TC$W*(K!L&L/&5AG/"/VUZUQ[>QV4,JNX^\YA2)Y,2W;D
M,M5:`Y7*85EHCR4R*S5D*"@D-(K$("0[]@A1^],8,-0T8,&C!@T8,&C!BI=L
MO.#.#F/[#*6>RDKE+FK;8[-4Z,U1([E0F[.[4GK'7J-#HJ$7<,'UC>N7X)B"
M;5@=Z<#*)H]`%]9YY[F3U9V+R4`J34T`H,_&@R^3&/;6MO9Q>C;+HBU$T'0%
MC4T'@*]`,AX`#+"F;5RBYP\]I.1J/&2D3N-<4]]6/D+`P>!$JN$#]1#%M.2U
MR(-F!SH"(GCH;=QTB)3"L&O+&1B;L$>SM28,[:?Y"W1W?I8Q@<N:?4E7D)5A
M<&,510LK/J]NS3W<$3`<4_E_4([CU;Z,&&]43'E%QA7FE4QY4X&FUUD``A$U
MZ-;1K7K`H%%=<&Y"G=.E`#[:RHG5./J8PCHP8S+1@P:,&#1@P:,&,8NMO@<?
MU"SWFT/"1]=J,%*6*:>'$OW$;$,UGSLY`,8@'5%)$0(7<!.<0*'J.C!A-N$N
M)]JYOY!<<N.6))1M19]P#G$>&%'+IL0:0FIW(+YR9-1%:+KR[8"*BW1!-Q++
M'.Y6.5(Y"*&##HX*!A*Q$1\!7(B-@8.*;)LXR(B&3>.C6#5(.E-NT9M4TFZ"
M1`_04H!HP8];1@P:,&#1@P:,&#1@P:,&*^\IOH'\B[G^:GF?EOY5-^M_!VZ_
MIOZZK/S3S-__`$_C;^?MZ^#W=O7;1@Q/+/P_#:?+_&\#QD/!\/M>'X?:+XWB
C=C[GQNST]OH^ST[;>FC!CZ=&#!HP8-&#!HP8-&#!HP8__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g281487ex99_2-pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g281487ex99_2-pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C`!#`P$1``(1`0,1`?_$`+0```("`@,!````````
M```````)!P@&"@(#!00!``,``P$!`0`````````````&!P0%"`,!`A````8!
M`P,"`P0$"PD!`````0(#!`4&!P`1"!(3%"$),146(B,D%T$RQ8=QH;$S0S2T
M-C<8>&'!4H*2LD1%1PH1``(!`@4"`P,'"@8#``````$"`Q$$`"$2!08Q!T$B
M$U%A(W$R0E*R%76!D='2,T,4-!8(H<&BPG0U<H(E_]H`#`,!``(1`Q$`/P#?
MXT8,&C!@T8,&C!@T8,&C!CB8Y2`)C"!2E`1,8WH4I0`1$QC#L4```]1_1KX#
M4T%:X#D*GIB&L#YOI_(:B*9*H)UW50/<;_4H:76[9D+`G0KE,TQU88E5(>A:
M$EG\&LJT4^*B`E-^G6QW/:;G9KE;2\(-QZ:.1XKZBAM#"@HRUH1[NIQK]KW6
MUWBT_C;*IMB[*"00&TDKJ6O532H/CB9]:_&PP:,&#1@P:,&#1@P:,&.ATZ;,
MFSAX\<(-&C1!9TZ=.54T&S9LW3,JNX<+JF(DB@BD43'.80*4H"(B`:_2JSL$
M0%G)H`!4DGH`!F2?`8^,RJI9B`H%23T`]^-:_GQ[G=DY/Y%B?;K]M^5^K[]E
MB45I.3,[P!W"E>J-;<"5M:T*7,-"&!RUBXH[A27GDQ!JV;)'19J*KJE42Z,X
M)VTM>-;:_<+N,ABL;1?4AM6`+.X^89%/BS:0D?4D@O0"AYBY[W8;EF\)VP[:
MR-/N=VXCN+N+-((Z_%T-E4A0=4@-%!\I)S#[^.N$:EQNP;BO!5&2[55Q92(*
MGQ9Q3!)1\,4T*F^F7)`WV?3DB95VOZC]ZL;4'WW>+KD&\W6]WQ)NKJ=Y&J:T
MU&H6OL444>X#'1.Q;1;[!LUMLMH2;>VA6,$]6TBA8^]C5C[R<31K4XVN#1@P
M:,&.)CE(4YSF`A$RB8YSB!2%*4O48QC"(`!2A\1'T#7P&I(P8JSD3D[!PZTA
M`8Y:)7:QLFSEP_D@<IM:=7&[8IC.9&:G%5$&GA,B%$RJG=3;)E`>M<NPAKTB
MCDFE6&%6>9V`50"68GH`!F2?8!C\R.D4;2RLJQ*"68D``#,DDY``=2<*)Y!>
M_OA'C_,2M9JQH3D]8D(B/0#\KY8D?58"W)1R2$ZQF[PLT=Q#^/:S;=8=HY!X
MH"2A!*H)1#:V<4[#<QWPK<;R!MFWL-59165A4?-B!!%16A<C,=,0'G7]QG!N
M(Z[3;V.Y;L%!"1&D1K49RT(.8Z*#^A9L38_=<]\65DHAG+,\&<5`>$:SXQ@2
MM7Q@5@H<XBU<'2='NF9I84$1_#"K\M!00[GB@/I79(^U/9-%<J;WE&FHJ5DG
MKD1U`2W&8(:@)`--9&</M+OO-_<%/I23[JX:'\Q35''2@\M#Y[AA\I2M?F"F
M-D_@?[;W'C@%3EHO%\2M8<@SS%LTO&7+0BT7N5G*@8JWRULHBF5"NU=%V`J(
MQK39/JV.L==4.[KG'G?<7D'/KSU=S?T]N1R8H$KZ:>\_7>F6L^_2%&6.J^W?
M;+C?;?;VMMG0O?RT,T[T,DAI^94KF$&7M).>&`Z0<47!HP8-&#$29+S51L7(
M=$Y("\G%2`+&LQ70ZFG9U/1'J0`X%9(*&$`!182`(#]D##Z:,&$Z\X_<1J>$
MX!1UG.S.Z\K)MCN*CQSQZZ:N<FW!,?ZNXM+ER9-O48$YNGNO)7MAT[^.R7/L
M`T/A/;+DW.)EDLH_1VG51KB0$1BG4(*5D;W+D#2I&)QW![I<4[<V!N-YF#WS
M#X<"4,CG+P^B!6K$]!^2NNA;\E>XK[H9K#7,)XANJ.!8)TR.\QCB5HX8T)B<
M[@2ME;_=Y5U%JY1M*1`!4R3IPMV@()VS%`@@`]7;3Q[MGV?MDDO9XAN\E1Z\
MQ5IY*#]VG[M?_'2"31G)&.*MYY;W>[\3/;[+!+%QZ-B&C@)6(*:#XA)!E('4
M&IS%`,73QU[3F,<18\/<LFXWYE67+U>5;6(MCFL)8W88)KZD5^(2CWE2E<JN
M96<8)O2E,+QZL?NCM^!$/N15IN[^Z;INHLK#[L79Y*IH2X<W;!A0LKA`BM2M
M%`H,_/\`2Q4^.=@^-[#M0OKX7\W(HB7#M`/1#`5"^F2=0)H*GWT6OF-_L'\M
MVCIK$2UYKUBP'8$.S$QF3*C674=07*Q!%)LQO5&C/+:54CM)$%.J+[S44Q$Q
MF)2@(A+N9=J)YIGW'B\\E[,[$R0R.#,,@2RNS`R9D@CJ,J$XM?'>=R;3%!M7
M+K?^#4H/2F1-,++4@:D4?"^6@'BP&&XT'E*=JTB$\J-H\T3+E*$!E*FKI3M'
ML28"!?(\J,,Y12.'Q4!$3'2'T411V$`B%W:7=A<-:7T4D-TAHR.I5A\H-#_E
MBL6]Q;W<*W%JZ26["H92&4_(1EBX47*QDVQ;R</(,Y2.=D!1L^8.4G358@AO
MNFLB8Z9MOTAON`^@ZQ\>V/0T8,4AY"Y\G*Q%R3N'M%,H>.X]=2-G<HR$\U>R
M+642ZR.:]'5YN1::1L740X(M4FKAVN!!43%,@&.&=MNV7^[WJ;?MD3S7DA\J
MJ,\LR?<`,R3D,8.Y;E8[19O?[E*L5H@S9O\``#VL>@`S)POZH-\R9V))SV%(
MJ7QAB]NA)/[9R@R>V[EWGH]DBJO+.<=0*ZRWRI11LW4%)PBHJY*.P*/T!W(%
M1M=BXEPXK_4;KN/*FH$M(R&ABD+443L,F-:5!.0KY"2#B>R[_P`CY2A?CR/M
MVP*"7NI5^*Z@:O@QGIE](U'OZC&OSQPX56CF1;)[E'F.0RLC09>Y.I/'D2MQ
MJY`YRC,JU&(EGK,R,M9\7.(5&-ATG+3QUB,I8SYXZ*X'9,/O%.A>;]R['A-O
M'QG:HHCNXA59-$L,:VQ*@@Z7IJ8@U&H!5%-5:Z1R1PSMI<=RMWDYIR][L;*9
MRL$8AED,P5B*LR`Z4&6I\];5-5%*M>O;+#N$:X1J[PQQ_B3$:N#UJGJ>UCRK
MKREC?$!+NIQKN7R>S8E[KA0G>64,;H#]83&]!BVU2[WS6Y,9GW"6(FDDKWEL
MRQK\ZC5S^B**#F:&E*8Z8BX_L6WV7I6=I;*$%0@LI(\JTU%30UH"2Q%6H:#H
M,0?!<>;=FB7)=<AXPC\05<PM3Q-!JGMN<L7T9+L1,1PN9P$+8D'"*+@%-TW2
MKI9;<0[9$TR@&F;<.;[9Q^U7:]JFFO=Q5:/-)=6U%8#+2#I%`:@QCH.K>)PU
MXO:W=RSM"([8H&5EM)*&HZ*0:T(\S'V&@ZY6U:XPI-=CT0:81Q!'1\*4KH'3
M[VF.9*GB@R((I23^1>9%*)UFZ0"8SA8XF`=S;AMI$?E^Y32F62\OO48U.F^M
M%`^0#H*]`.E/'&[M^.[7;*B""*JK05LINE*$9DUK7QQ`V.+A<6N:HBE\2K]%
MY13RFHZ<RF,6&(KM0L5,%FJ:KEZSFJSE>YVN4*0$VZAS/]X\8M/H*DY$1#H+
MOG/&M^MTV?EMG-)+&"@O`R/.E`='S:"0!CYCJS&8KTQ]L^&\BV8G=N*7,,<D
MQ!:VDC:.(KF::6),;5R`IE7J!EA@6+LXS=6OB5`3:3W';-+EVT;N</Y$.LXQ
MY=G[M7QVY:59GPBW'YBL.S5)Z8IE.H"H/UC;`*IO7")+2UDW?8+J'<]BC"ZI
M8R`Z5KE)'74M*9GIF*5S.&S9N7K=W:[/OEO)M^_L3IB>I209D&*2E&%`<NOR
MX8-_F(D>S_6\7^5\K^2[?4TQX?YF^?O\H\GY5O\`37R?U\WI['G?<=_;[>D.
MHPYX6;R.CV4@K%-GK1N\;N^;6/&;ILY2(L@Z:NCVINX:N$E`,19!P@J8ARB&
MQBF$!]!U1>WD\MM]]7%NQ2X39)RK#)E(:/-3X'Y,(?<"&.:RVY)0&0[Q:@@Y
M@AF8$$>((P]![#Q[V&=P*J":40\BW$0JT;$*W338.&IF9T&Y4R@1!,C8PE*!
M0V*'P^&I^DKQRB93\16#`G/,&N=>N?MZX>'BCDA,##X3*5(&61%*?FQI7XJS
M.IP7N.9.#^>J[&,[%A.T6-]BB?M^;N5=#99'I-GLBC^FPE:@<.S#JK-5'T9)
MA(-W!T6X.BJ*H&_$HF*?K??N))W%@L>;;`ZFWO8D2Z"Q6[/$\<='?7*%:JL`
MA7(``."0:XXLXEOT7!=^NNVW**0SVURPLY9Y;M4EC=P8E`@=4HQ?573D"$S*
MD">\>1]2M,P?*^7+WAZ7=RC=P>-Q[>\Q<_40I[=-VHJU!PHPITE((&8I(%41
M2,]$$3B*AQ$X^F@Y!-?V%E_3/&+:>.U234\HCLVUL*'R,'44U5)/3H%H,5_;
MH;69S+N%S:ZE%`6FOR6'75^U72HJ0HZZ3YO?+.0.3E"I+*%?5Y#%F7RR9D%E
MF^-^6W/0Q&,4;<%7;J6LTE"Q:+L"D^[;=1E/7<P$+MO$KG<H+=Y8):K=I44-
MI:4U@_-8BM!7J14CV'#C#Q>6;T9X!;RV,C`L5NK]3Z9^E'6=E8D?-!H.AJ1C
MX,8\?^6/-::=R]71MV+,*38)LW+FSY)RW,X_-%)KBL8L9'7JXV.:OD@(D#J5
M2*1J<Y2@91$H``+EW?37FGUEB&GZD:)^?0HKASVW9[+:2YLO5'J4KKEDDZ=*
M>HS4]N7B3A\'%'A9BCB=".2U5-Q9+U--DV]FR%.(H%F9%$A@4"-C&J/4W@($
MBH`8&J(F,H8`,LHJ8I3!AT&-IB#_`'"$&_UCPQ<BDCY0<CJ^@5?MI]\&X^*H
M=(%NGN@B*I"F$H#TB8`$0W`-5;MA&SP[Z2"81L\E?JUU+IJ/;DQ7V9XG7/60
M7>RY@2_>:D>VGIO6GY=-?R8KO_0_O`_:&I%^IBD?IQCO(,=G<$(?$.<>-1#^
M$'-F$/X]4;@?['?/P*X^U'A$YW_*;=^,VGVFP]H?74_(J*8>,:T/OI80Q9E3
M)F))"X24E3+9!XUGE:G<JC'LWUG6?_.7:\?%2K-5]%&D:\28:MC`H=RDI'"=
M15N;K,=-2W]K^YL/`=DOH[D?Q"RW$96W+$%@11G0FJK05#$BC5`()TD2/N=V
MJVWN0L7KN]IN4%&AN8P-:L-1(?*I7II\U0:TIG5?%[YOY[88HQ+BK.?)*ZL\
M?/3%IK*ZV%C+ME;FDB];)2,K>+!3X127N$;5$%T_+,(N3HMRE%8JZP]9U"TX
M[OG<O?KZ\XI80Q1`M*8E=42-3T52["K-T`44+'(*,;N??]D[:<=L+/E^XEF"
MI")I!G(R@`D^V@IUJS#,`G(/XX<>W+QD@JS4\LR=EK_)>0FV+6>KUG;*LY'%
M()J@0R+JN0S9P]93GCJ%,7OR"C@>K?9%$Y=BI-Y97>W73V-]%)#=Q&C(ZE64
M^P@@$8=K&^LMRM([[;Y8YK*50R.C!E8'H01EAM***3=))!!)-!!!,B***)"I
MI(I)E`B:229`*1--,A0`I0````V#6-C+QV:,&%I^X.'5<>%Q?^+DG`%_Z@9A
M_OU8>UG_`%W(/PL_[L3+N!_VFQ_\\_8Q7?MCV?@/^(G;^)?C\P^'Q^/\6HQ3
M[&*A^MC%<_&$ZL"8?B;G!C81V^']9LVJ+P/]COGX%<?:CPB<[_E-N_&;3[;8
M>L[<I,FKEXN8"(-&ZSE8XCL!$D$S*J&$?T`4A!'2!AXQJ.Y'K=JY(66]YVR[
MDNO8RG[?+/G%(@,V5/-=9HTQ0E&RGTN-<RQ`T][38>&:MC)-VQDW"W6H"BZO
M08?MM_%-NVY[Z*^WV*2?:`X!6%X]>JM!J1G5BO4Z1\X>XX5^0;XVW@16TD*3
M@C7ZJRA2C?5E12JN*]6\M:`E>H^.MK0_)7'*?$?)*>4[JBR(:$CH?'W(SC-F
MFL-'L6F1!B^QVPS?7JO:*S9&S<5>P6,G"&7(0.T8X*BGJZ26D_$+Q>7\8$"V
M"U>GH31LT3#]Z8V96B!"FF@%6)/08D'(-JMN6;2=FWM9;JUD8:5ANH+BAJP!
M#2D21R+J%7#@,2J]<5[J]AYV>S#?).=Q%2,[Y#X;JBC+6VH9JQ9+U"N1YU3(
MHR0R$I7']TJ%*M!3]LJ,W$OU&+L!_%H'$`3TX3P\)[U;>J;K+:6W,>B/!,LC
MT-2HHP1Y%`KK1EJI^:1F<19)>X?8/=#<;6E]N'!9I"9([B(C1YA5O(S+$Y\V
MEPVEQ0%>F-J'A5S[X]<ZZ&%LP]9@1LD:V;'NN,+"HU97RD.UB%`Y)&+(L?YC
M#J+[E;R3056;CX`<J@&3)R_S/@G(.#WW\)N\=;9B?3F0$Q2#W,1DU.J&C#WB
MAQUKP/N-QCN)M@W#8)@9E`]6%B!+$?8R^RO1A53[:Y8NSI,P]X6I[@O]\^%?
M^I6O?RLM6'M9_P!;R'\+/^_$R[@?]IL?_/;[&*_?T/[S/VAJ,_JXJ'Z<87GS
M]>O_`.N#&W]ILVJ)P/\`8[Y^!7'VH\(G._Y3;OQFT^VV'K/6:$@S=L'1.XU?
M-EVCE/<0ZV[E(Z*Q-P]0ZDSB&I^1J%/`X>!EGC7DQW?GF!KQ9.,N1<T\V:3D
MVE6J5A**EBIE'YKI-DQ\J524J#]ICBW4>_R$4S;UPB22;2.1\<Z1>E,I%`4(
M#+MEQ_'NMJ\&W_#2NJ0B`MH!RUJZ:G/R$L:$YYX6=VM_X0BZ2?<5]1PNF(&=
M15JDLA1]*FM#T`6@6E!CQ,YT/`^=680U[Y/\5'=T(Z%6&E^3/$:4X\9.CWNQ
MBE:NK0A*XP%VCNJ(F3/$G(93<4^D=QU1^-;]R#C$DMYM]K>KMLC!'2.X$L)`
M^H&JV9%02S`CK4`83;V.RO)`!>;>]PFJOKVIC;2S9!F4H,F"T8**D56ASQ#,
M2AE+CF@ZJ-V0L.3L9V%L=M`Y!XG<T[._J\D@H`HR$`[HN5!M&,WC`T>8=XZ2
M;IG!,QP%15'I-ILNK7;>611[ML)2UWF(J9([FT",IH-+B2,*U:BJNIZ**D-4
M8QH]ON?5>Q">IM<OJ(1!?:E6,TJWIRAPVMM0*"NGV"IU4HSUP'ROQZF*YRQ]
MO^I\S:?<X)^>SK1[JI8]N<8I$R2BK]U+4B\8`FIRJ2=3*V#H?04I$HMEVX]`
M`82]@7/C?<2QW[U.&=PSMTL,BF/66,?F2BZ94F`996;S(\;DU).0`..<N7]J
M-[X5,O->UB;K!?1L6DA*)**$U^&T-0RBI!1DH`*>YG;^U?[Q=-YKD:X7S&TC
M,=<FXM@H*35%0K2I9:3C2*_,I"FI.5CN8JR,2(&4?PJHF.0`,JV.JD50B$A[
MH]HKOA9.\[06N.-R-[R\%<P)#2A0]%DK[`]"06M_9[OAM_<!!L>]A+3F$:YQ
MYJLP`S:.OTJ>9H^H&:U`-+.^X+_?#A9_J8KG_:W'^4-+W;261;C=HE8B)MEN
M:CP.G12OR5-/E.'WGBJ9MH8@:ANB9_+')7%?/Z']YG[0U+_U<47].,+SY^O7
M_P#7!C;^TV;5$X'^QWS\"N/M1X1.=_RFW?C-I]ML/@T@8>,4.YM<*(7E'`QM
MDK4DG3,W4A,%J1<TQ5;INTVZPO4*_/.&8>:FQ!Z'=:NDNI>/<&%0@&*91,Y@
MPEB+Y$YJX_3-@Q/R=O/,"/NS"303;EB+)B+)T+)1SYP5%-PO5.0U?EJ[+U],
M@B=N\CIIJBL@)BF`#$$=,.W;A;OHLKB"R1=-!,XE0J0&(9FB;54FBUTTZ5H*
MG"YN6US*DUU;W%X0V9B71,#D00B2@]:UT:BI(%%'C+5KJ>-IN$"5RAC[##UG
M(MO,;6+D![>V2<..5F;OI4*[;\@.+TW/T11PNFKN60:@5,I3"=/</B[V6XW]
MI,DVT7$R2G3E;7:3UH"`/2GHU`NKRYUR'2FE&NXH((_3OHK=;=GH1/9RP5.2
MLWJVVJ/S?68>WZ/6M]&MUAXV6Z)C:;EV8LF$+$I*%@6?$7G1$WAQ4)`ZZ*K5
M.0HV=X%NV3>-$``%$7[1-%9(1,8W6!MJ+<VUESC;9+V6WCAY-'I!%S:,BR(*
M/E)$P`J*C4`66M*@4.,.);K;;E#9/(\)>L@MKORU-49O2FHJE6"E8P0ST(`&
M*]<\.$ELA9-]S1PHAR]JF>ZA+1639$+OQ_JT;"3:D"*$DI>8S(G&EO+XX:6I
MH*!7KE9V1HVE&R:IU%"*"85F/M_S^WG4<#Y"NWOMCAX%*S,6J:TB,<X#%2"4
M6A)5M*TJ,H7W1[7SVUV.XO$A>IO,#1SL'A4H_I#49EDC9@&8KJ;4`I)4T6N'
M2Y6S67D;ASVN<XD;I-ULH9)QC;I)JB)2HLYU_%199YB@!3*%[+.;\A(OVA^R
MF'J.I9QOCLFQ\BY/81D-#865S"*FA9&;RL,O!5J105)Q==QY$G)=DXOO(4J;
MZ>*8CZK>BVM:>YF(Z^&.?2;L_J__`$WI_P";YA^K\-0W]7%J_3C#\^`';KP_
MI_SS8V#?_9W;..W\6J+P/]AOGX'<?:CPB<[_`)3;OQBT^V</;U/\/&#1@Q7;
MD;Q?Q1R?IYJOD>&`7[--8]9N$85)O:*J]4#?R(J0,F<3M5#@'?:+`=LX*&QR
M;@4Q3!C7@OF)L[>WWD=M]<2F7K+A61,,;!6?$N8<D8QCG;8JIW+4C(L!.FKU
M9MS<PF[D?*,G;5V7J!,QR?>$V%IN<]G$T,:0/"S5(DC1\^F1(U#\AI[NN-9?
M;3;7\BS2//'.HH&CE=*"H/0'2>@ZJ<9])*Q/*O&T@Z%/D#9(^7;NXI-WD[CE
MQ6Y=R\%((%,!3&EL2GJF?(99J<Q#%441*J9%3T!3J'JI?'-^CV^^AW"Q>$F,
M`E([B>VH/*E&23U$=JG5UH2#G08G>YV#11/:7T5[)&T@TM)##.'9#ZJ@R1Z)
M-'E*YJ3U)J!3"H,E<I9W'6*"\9,)K2JF>;]8I3$S=CC>\<H\<6*M,Y9\R@SP
MUXPE;K!*XUE'MG(]4AVC,A$7C9,!652$"IBIT38\)M+O>/ZJWG3'LUO''=%6
M2VD21PFK6)U`D"J*.3D&:@\IU4Y\[@<^GLK3^AN.R)+R"_98%_AVN(F@20^>
M-XVJ6+B0#,U)J:THHV%,DX4/QUPE[66$G"B*S_&&2<75.66;["@O.MHN--8%
MFXEW`4%9LRYBC^DH@.H-Q[=AOG)N3;XC,+6>QNW"FM2'=5CJ,Z$!L_!03T&+
MK?[$O'>/\7V0^::TN((BV6;+`^L_^S"N/6_\3]Z/[:U#_P!3%J_6Q'?(-TW;
M-X1=RNBW;-^;^.W+APLH1)%!%`UH46665.8J:2*2)3&,8P@!2@(B.P:I/;V*
M6X^^K:!2\\FR7`51F2=4>0P@<^=8[+;W<@(-XM"2>@&HX>^FJDL0BJ2A%4E"
M$4343,4Z:B:@`9-1,Y1$IR'*.X"`B`AJ=^[QP]8[-&#!HP8KOR;RQQLQ5BJP
MR?*6VX_K6+7[59A+MLA+-CLITHEZACHJ%437D9^4Z@`R2+%%9R4X`8@`8`$-
MQLG']ZY)>C;MBMI;F\/T4%0/>S?-4>]B!C4;WOVS<;L&W/?;F*UL4ZLYI7V!
M1\YV/@J@L?`'&A[R7Y&X^O>:)JI\!J;D=U59-R[95"1N-=;6#(!C+-%!EC4&
M&2;24O%Q**74=D]>[RS1-/NB*9R%5#J_M[V7M^)N.0\PN(S<JI^"K@0*":#U
M7-"YZ>046IH2P)!XI[H]_9>87"<8[>V?\2AZ3M&S2ZV!'P5&:$=237I^9IGL
M0<5<-AFV;S!R`GDIGD_"&6E<24*PN3O21*3U@K]3WI60='=(6?([3NF2`G=,
MI&(&47+W%#&401N\'=V'>H7XAQ1G79E;1/+IT^KH.4<8R9801YM04N0!0*,Z
M3V*[*2<;9>;\M83\BG0-$K'5Z.JM68L*F0@BGU3JZ^4AY_N!.F@WKA6R\IOY
MW^9*LNRLN^EY9FHJ-6XN@;=7>%N"YRDZ]NGK$`WW$`T@]M(0$WJ^DJL,>T3)
MJ.2ZI"@"D]-1IY16IQ8>>,#<[/"*&5MS4@>)`CDJ0.N517Y1B#NHOB?K%_Q1
MW^(?#YWMO_!OJ54/^G%'J/\`5BS_`"(P%-2["1CV6/J;D+%+]ZI-3-&+&+I6
M0\XL"P+V89@CD;`M.I>2H#=RQ<$.@D<R?CF3$X&W&T;QN6Q7R[CM4K0W:Y5%
M""#U5E-0RGQ!'^.-7NFU;?O5DVW[G$);1B"5-1F#4$$4((]H/NZ$XIQC.SYU
MX['$N!;!)9GQDP5-\TXX9*>F)DJIM$14.Y0QW.=!2SR+3J$"(-4B+AL`'C3"
M'<T_#=^)<R'H[_%'M6^E<KJ%:6\C"N4L*CR:JCS+XBI.=,(DNV\JXC\;8I'W
M+8U.=M)G-&M1E#)U>@!`#4I[#UQ?.@<_^,]PHUCNEEO\1B-2BQ[B0R#7<K/F
MM0EZ@FS$$W1G(2"J:$F@5T()$%J910YS$(*95#E3UJ=T[;<MV^\BM(+9KQ;@
MJ(I+>LL;Z@"!4"JFAJ=87+.I&>-Q9\_XM<6DEU<W4=H8$+2I.1&\87KJ#'P.
M7E)J>F$"\W/_`-&2_>E<?\&:HD<I%G3-SG/)$4HH5=-$QB+.\?8^54!11+I(
M8R3Z8,4HE$#>"(;&U<.#_P!NZK2_YU+6H!%M"W0D=)9?=4`I%X_3\,<T\_\`
M[I8D>3:.WELT]U72+F1:K4==$5/-4=&<Y>*5Z*<I_%KDSSNE2YNY$\K<)1AG
MKAFL[6S]R<I$'D=W`K&,=Q]-4TJDXVI3,K<GW"+QI&H%$P=+<Q0'52W#E_%>
M#1G8^.[=<272JVE+6V9H@PI^TD%"<SF5]1O:>E9'M_;/N)W-*[_R_<HX[>20
M46XF8,_M$:!652.E*`@GIUQ?"B86Q!!F?XVXF4FN4ZU-JU(165,^-.>HJ(W"
MFMDB+2@N9!M3:S"Q\,_<*`*R32.`%^DB221R")CIEWNN^SPQ[OR]IIE$JR06
M<=DPT2$'2AI(S2^4C-C0'S'H"+_Q_@7'.+1JG'[6V2]2/XLWWB4F?1GZIU1`
MPJK`FE%%:>X8E2,QV64:QV2>-&-\OU"P8:E9"?MF5;!F5MD.O3#RN-6[B+>U
M6S3,)6B_-G2[%=1./23,LX36Z!;"!M]2OE''-DL[S^I.:W<7Q$4I9VJ+%<2Y
M$4D`)",I(URYUTFN9RHVS\FY!NMM]W\5MG>4U]2[N6+01MD&,=%`D&K40@\3
M6AKABG%[$LQFE.L9SBT+%D7*-E9Q\[,9IR^=-S%T>925-W6-`@B@X8%=0;M(
MR;=R8KE8G0!D468;;(>]<\W#<=M^X=KAAV_CX_<PC-Q4D>K(:LY\3TJU3XTP
MW[1PZTLKU=YW6:6_W\?OI3DAITBC'E11G3*H!PU7\EIKL[?4];\KY)Y/D_EY
M`=/YE^;U?F%XW7V?,^3_`(3L?J=7XC^=]=(N''%A=&#%?\UXDQ=98"<N5K`M
M5=5J)?V!_=XGH9R$<PA6BTB\?2`D`$I!%FV;&.(J@*A2D^P<H^NO6WMYKNXC
MM;<:IY'5%7Q+,0%'Y2<><TT5M"]S.=,,:%F/L514G\@&-+Y[C+DM[O.47V:Y
M=M,TWB'1+,I36F3@J;9W)KP<<X[B+@S-%5BYR)D15AVS.7[YR9I$"J1L+@.@
MJ2G9J[_QOL9Q>/8KB1[SE;1B1H59C5WJ*DFJPQ"A`%*N%J%-:XX0EXYS3^XK
ME<VZO_\`/X+!,\<<F@+J532@I1IGI6K&H6I6HZ8O?B3BDQX`M+/?*9'90R/3
M))F#<F8<(VK'T;;T5.SVT(R]1F2,;7)>CIN?B=/\''=X=R*+Z4]SY9:]X(8-
MOL[N/;[U)*M;S!Z$4))C9'3U,Q3ZP'LZ8I6S=MX.TEQ->):S36#1E5N+<KZA
MH:TFUQR&,/722M`.E<1LQD<Q<GK2ZKEC4SE>';ABJ[I-3AW/'RQ)$.J[6(D>
M[24+C%,D<UB&PBHL\<M$^Z`?SB!3=6FM=KVCAFWI>E[>UBC)]260S"5C0U]/
MXGF9AD*'IX$XV5MO-_NNXQ#9S=3;IH\B1FWD1-8!.J1H%":2,V;4Z@Z:U+8O
M'A[A=`).JM'WN(@LT9$KL>=E'T''==K5;H5>5743%Q(9"N],B*_]5OEUB`9V
M1F9NS4$O0H\5*`$U'.4]W)GE:WX8)+:!C5IG)>1J"@"B35Z8&?2ASQ0-E[<"
M>?[TY@R7-X:$0KE&OCYRH7U37P^9[B,AGG)+-^/L.QA\=LI"'RYG15L-9JN+
M<?MDDL38D=2R81[=!XTA"H-9>R(*NBE;Q+0H&4=@'EB(>JD6GGGNIVN+EVDG
M<DLS$DDDU-2<_;BIPPPV\*P6ZJD*"BJH``'N`R&&X\2,62V%>-V(,:3Y@&P5
MNHMAGR`8#`VG)ARZGI9B!RB)#_+W\HHAU%^R;M[AZ#KRQZ8L7HP8-&#$$<HZ
MQ9+MQJY`4^G=P;7:,+Y-@:X1'J[RTW*TR991C=+I^T"CEXL1,!#U`3;ZV_'[
ME++?;.\DTZ(KF-CJ^:-+@@GV@',^X8TW(K1K_8;VQ6M9K65,B0:,A!`*Y@D&
ME1G[,13[>452HS@OQ2CZ)%LXNLA@G'9_EK8$U")3#FMLEK85Z)"D!:35LZKW
MS3&`#'<BH)@`VX!L.:W5_>\LW"ZW)P]X]RY+`$*5KY-(;,)HTZ1X+3&!PFUL
MK+B6WVFWJ5LX[5%4$!3D,RP&08M4M[R?'&;7GC?"R+YQ9\;21\<V]1-8JIHU
M(/IN8(L!@6:3$*4HMA:N@,)52D(*1P$>M)3?2R"58,I(8&H(Z@^T'P.&CJ*'
MIA=^9,A8"XW^?6;?::C5Q=-&#ZSX:XZ0T6G;;G;U&H*33FV/V:;6+KL,>2Z@
M11?N"@DF(=EJ0-AUEWFX7^X,'OYYIV'0R.ST\,M1-/\`/&+:V5E8JR64,4*L
MQ8A%5:L>I.D"I.*.RO)[D[RK=K83XKXW>XVHKPP-GU?QT=<T\\9*G.D#S)&4
MG`,2L&JB2H@J`*,TC$W*(K!L&L/&5AG/"/VUZUQ[>QV4,JNX^\YA2)Y,2W;D
M,M5:`Y7*85EHCR4R*S5D*"@D-(K$("0[]@A1^],8,-0T8,&C!@T8,&C!BI=L
MO.#.#F/[#*6>RDKE+FK;8[-4Z,U1([E0F[.[4GK'7J-#HJ$7<,'UC>N7X)B"
M;5@=Z<#*)H]`%]9YY[F3U9V+R4`J34T`H,_&@R^3&/;6MO9Q>C;+HBU$T'0%
MC4T'@*]`,AX`#+"F;5RBYP\]I.1J/&2D3N-<4]]6/D+`P>!$JN$#]1#%M.2U
MR(-F!SH"(GCH;=QTB)3"L&O+&1B;L$>SM28,[:?Y"W1W?I8Q@<N:?4E7D)5A
M<&,510LK/J]NS3W<$3`<4_E_4([CU;Z,&&]43'E%QA7FE4QY4X&FUUD``A$U
MZ-;1K7K`H%%=<&Y"G=.E`#[:RHG5./J8PCHP8S+1@P:,&#1@P:,&,8NMO@<?
MU"SWFT/"1]=J,%*6*:>'$OW$;$,UGSLY`,8@'5%)$0(7<!.<0*'J.C!A-N$N
M)]JYOY!<<N.6))1M19]P#G$>&%'+IL0:0FIW(+YR9-1%:+KR[8"*BW1!-Q++
M'.Y6.5(Y"*&##HX*!A*Q$1\!7(B-@8.*;)LXR(B&3>.C6#5(.E-NT9M4TFZ"
M1`_04H!HP8];1@P:,&#1@P:,&#1@P:,&*^\IOH'\B[G^:GF?EOY5-^M_!VZ_
MIOZZK/S3S-__`$_C;^?MZ^#W=O7;1@Q/+/P_#:?+_&\#QD/!\/M>'X?:+XWB
C=C[GQNST]OH^ST[;>FC!CZ=&#!HP8-&#!HP8-&#!HP8__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
